The physical and psychological health of x-linked carriers of chronic granulomatous disease in the United Kingdom by Battersby, Alexandra
The Physical and Psychological Health of 
X-linked Carriers of Chronic 
Granulomatous Disease in the United 
Kingdom 
Volume 1 of 1 
Alexandra Battersby  
N000027753 
Institute of Cellular Medicine 
Thesis for: Doctor of Philosophy 





Chronic Granulomatous Disease (CGD) is a rare primary immunodeficiency in 
which there is a defect in one of the subunits of NADPH oxidase resulting in 
recurrent, severe infection, inflammation and autoimmunity. In the UK, 70% of 
cases are inherited in an X-linked (XL) manner, with the remainder being 
autosomal recessive (AR). Patients with CGD have an absent, or significantly 
reduced, neutrophil oxidative burst (NOB). XL-CGD carriers have a dual 
population of cells, those that function normally and produce an oxidative burst, 
and those that do not. XL-CGD carriers have been reported to have higher rates 
of discoid lupus, but there is little literature about other significant medical 
problems. Anecdotally, XL-CGD carriers suffer from more significant medical 
problems akin to that seen in CGD patients.  
Methods 
XL-CGD carriers were identified from the UK CGD Registry and through 
consultants caring for patients at the main centres in the UK; Great North 
Children’s Hospital, Newcastle upon Tyne, Great Ormond Street Hospital and the 
Royal Free Hospital, London. A control group of carriers of Muscular Dystrophy 
(MD) were recruited from the Great North Children’s Hospital.  
XL-CGD carriers completed questionnaires about their medical and psychological 
health. Blood samples were taken for neutrophil oxidative burst, autoantibody 
panel and cytokine measurement. MD carriers completed psychological health 
questionnaires.  
Questionnaires were compared with population data, where available, and 
published works about comparable groups. Psychological health questionnaires 
were compared to the recruited MD carrier control group.  
Results 
81 XL-CGD carriers were recruited from 62 families, 2 were deceased.  
 iii 
The mean NOB at enrolment was 47% with the majority of XL-CGD carriers 
falling in the range of 21-60%.  
Photosensitivity was reported in 74% of the recruited XL-CGD carriers and 40% 
reported a DLE-type malar rash. 26% of XL-CGD carriers met 4 or more of the 
ARA SLE criteria, whilst a further 30% met 3 or more criteria. 23% suffered 
recurrent or significant infection. 53% suffered from gastrointestinal symptoms 
and 59% suffered joint symptoms. Other autoimmune phenomena including 
Raynaud’s phenomenon were reported.   
66% XL-CGD carriers suffered greater than normal levels of anxiety and 27% 
suffered depression. The XL-CGD carriers had significantly higher anxiety scores 
than parents of children with Cystic Fibrosis and had similar anxiety scores to 
published data about patients with SLE.  
50% XL-CGD carriers suffered excessive fatigue. IL-8 levels were significantly 
higher in XL-CGD carriers compared to healthy controls. IL-8 levels were 
significantly higher in XL-CGD carriers reporting excessive fatigue than XL-CGD 
carriers who did not report significant fatigue.  
Quality of Life (QoL) Scores were reduced in all domains and significantly worse 
than UK population data. The XL-CGD carriers had poorer QoL than CGD patients 
in the social function, vitality and bodily pain domains.  
Conclusions 
This is the first study to have evaluated the health of XL-CGD carriers, and has 
demonstrated that XL-CGD carriers experience similar problems to CGD patients, 
with infection, inflammation and autoimmunity all demonstrated in this study. 
Excessive fatigue was reported in approximately half of the XL-CGD carriers and 
was associated with higher levels of IL-8.  
The aetiology for the symptoms seen in the XL-CGD carriers in this study is 
unclear. There was a lack of consistent correlation with degree of residual NOB 
function, with only recurrent skin abscesses, diarrhoea and abdominal pain 
being significantly associated with lower values. The raised IL-8 in the fatigued 
XL-CGD carriers supports the hypothesis of an inflammatory process but further 
work is required to investigate this. The lack of association with degree of 
 iv 
residual NOB function means identifying XL-CGD carriers at risk of medical 
symptoms is not possible simply by assessing their NOB function.  
Psychological health has also been affected with the high rates of anxiety in the 
XL-CGD carrier population and significantly reduced QoL scores in comparison to 
UK population data. This has not been previously demonstrated. The 
psychological health problems are likely to be multifactorial in aetiology.  
This study has clearly demonstrated that XL-CGD carriers must now be 
considered as potential patients and should be pro-actively assessed and 
managed. It is not yet clear what the optimal medical management is, and this 
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Chapter 1: Introduction  
This chapter will present an overview of chronic granulomatous disease (CGD).  
1.1 Definition 
Chronic granulomatous disease (CGD) is a rare primary immunodeficiency (PID), 
in which phagocytes are unable to generate reactive oxygen species (ROS) due to 
a defect in one of the subunits of nicotinamide adenine dinucleotide phosphate-
oxidase (NADPH) oxidase.  This defect results in a failure to kill bacteria and 
fungi. Patients suffer recurrent, life threatening infection and systemic 
inflammation.  
1. 2 History of CGD 
CGD was first described in the 1950s as a syndrome of recurrent suppurative 
lymphadenitis, abscesses and pulmonary infiltrates in boys, with death almost 
universal by the age of 7 years. The high early mortality led to the description 
‘Fatal Granulomatous Disease of Childhood’ [1, 2].   
The mechanism for this disease and its link to early mortality was unknown until 
the 1960s, when it was discovered that phagocytes of affected boys had reduced 
bactericidal activity and a reduced oxidative burst [3]. Further information about 
the mechanism of this disease was gained, with recognition of the failure of 
phagocytes to reduce nitro-blue tetrazolium (NBT) during phagocytosis, 
providing an assessment of phagocyte function. A carrier state was also 
demonstrated in female relatives with impaired, but not absent NBT reduction 
[4].  
Recognition of CGD as an X-linked (XL) disease, with female carriers 
demonstrating a dual population of cells due to lyonisation was the earliest 
understanding of inheritance of the disease in 1967[5]. Lyonisation is the 
process of random inactivation of one X chromosome in females. Thompson et al 
[6] as early as 1970 observed that the female relatives of patients seemed to 
suffer from skin complaints, including recurrent boils. Further studies 
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demonstrated that XL was not the only mode of inheritance, and an autosomal 
recessive form was recognised [7]. 
Further understanding about CGD has been gained from information about 
clinical features and outcomes that has been collected through disease registries 
both internationally [8-10] and in the UK [11]. The information gained through 
these registries has greatly advanced understanding of the condition and 
contributed to the knowledge of the disease and clinical course. The improved 
understanding has aided advances, which has improved survival and these 
advances will be discussed later.  
1.3 NADPH Oxidase 
NADPH oxidase is a complex enzyme involved in the oxidation of NADPH, found 
in phagocytes as its predominant role is in killing of microorganisms. In this 
process, NADPH is oxidised resulting in the production of NADP, a hydrogen ion 
and a superoxide. This is shown by the equation: 
NADPH + 2O2 → 2O2-- + NADP + H+ 
The resultant superoxide is converted into a reactive species such as H2O2 or 
HOCl. 
1.3.1 Structure of NADPH Oxidase  
NADPH Oxidase comprises 6 different subunits. Knowledge of the components of 
NADPH oxidase and their role continues to develop.   
There are two membrane bound subunits, three cytosolic components and a low 
molecular weight G protein.  The membrane bound components are gp91phox and 
p22phox and together comprise cytochrome b558. The 3 cytosolic components are 
p47phox, p61phox and p40phox. The final components are the low molecular weight 
G proteins, rac1 and rac2, which are required for activation. 
1.3.2 NADPH Oxidase Activation 
In order for NADPH-oxidase to be active, the cytosolic and membrane bound 
components must be brought together. This is a controlled process where the 
cytosolic components migrate towards the membrane bound cytochrome b558 
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and bind to them. p47PHOX is responsible for carrying the cytosolic proteins to the 
membrane bound subunits.  
Activation of NADPH oxidase may occur by either a receptor-dependant or 
receptor independent mechanism. Receptor dependant stimuli are short lived, 
up to 5 minutes, for example by complement fragment C5a or immune 
complexes, whilst receptor-independent stimuli continue for as long as the 
stimulus remains, for example phorbol myristate acetate (PMA). The process of 
NADPH oxidase activation is shown in the diagram in Figure 1-1. 
Figure 1-1: NADPH Oxidase Activation [12]  
 
1.3.3 Residual NADPH Oxidase Function  
There is considerable heterogenecity of disease severity in CGD, which, in part, 
may be related to degree of residual NADPH oxidase function. Evidence for this 
comes from case reports. For example, a recent report describes a boy who at 9.4 
years old was diagnosed with XL-CGD due to recurrent pneumonia but no other 
clinical features of CGD. He was proven to have XL-CGD despite residual NADPH 
oxidase function [13]. 
Kuhns et al [14] studied 287 patients with CGD with 154 distinct mutations. 
Better survival was associated with greater residual NADPH oxidase function 
and ROS production. Additionally, alongside improved mortality, less severe 
disease was associated with greater ROS production. The specific mutation was 
shown to correlate with the degree of ROS production and a reduction in 
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infectious burden. There was no association found between the degree of ROS 
production and the presence of colitis.  
1.3.4 Mechanism of Hyperinflammation in CGD 
The inflammatory complications in CGD are due to an aberrant response to 
inflammatory stimuli. The exact inflammatory pathology is poorly understood, 
but there are several hypotheses, which will now be considered. 
One of the earliest and simplest potential mechanisms is the failure of clearance 
of phagocytosed material. CGD phagocytes accumulate microbial material or 
cellular debris, including apoptosed neutrophils, but due to the lack of functional 
NADPH oxidase are unable to clear this material, resulting in persistent cell 
activation and inflammation [15].  
Inflammasomes have been indicated in chronic inflammatory disease and 
Meissner et al [16] evaluated their role in CGD patients. CGD patients had 
significantly raised IL1β released from monocytes in those who were 
symptomatic. The levels of IL1β release were particularly significant in those 
suffering from colitis, but were seen in all symptomatic CGD patients when 
compared with healthy controls. This study supports the role of capase-1-
mediated inflammation as an aetiology of the inflammatory complications of CGD 
and confirms the findings in the mouse model. 
Experimental work on CGD mice and human cells has yielded further 
information about IL1 dependant mechanisms in the hyperinflammation seen in 
CGD and have demonstrated a more complex understanding. Autophagy is the 
process of self-degradation [17] and is important in the removal of intra-cellular 
pathogens, and has been shown to be defective in CGD patients as it is thought 
that ROS production is a necessary component [18].  In a recent publication, de 
Luca et al [19] demonstrated that the defective autophagy, seen in both mice and 
human CGD patients, was associated with increased release of IL1. This release 
of IL1 has been previously studied in mice where autophagy was defective and 
severe colitis was seen [20]suggesting this has clinical relevance and is 
important in the inflammatory complications of CGD. Furthermore, de Luca et al 
demonstrated that this could be used as a therapeutic target. Defective 
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autophagy was repaired by the use of anikinra. Anikinra is an IL1 receptor 
antagonist. By blocking IL1, the amount of IL1 secreted was reduced and there 
was clinical improvement.  
A study of tryptophan catabolism in a CGD p47phox knock out mouse model[21] 
suggested that Indoleamine2,3-dioxygenase (IDO) has an important role in the 
exaggerated inflammation typical of CGD. The CGD mice were infected with 
Aspergillus fumigatus and the resultant inflammatory lung injury was not only 
more damaging than the initial infection, but also found to be due to inefficient 
tryptophan catabolism as a result of blocked IDO function.    
1.4 Genetics 
There are two modes of inheritance of CGD; autosomal recessive (AR) and X-
linked (XL). In the UK, Europe and the United States XL disease is the most 
common form, accounting for approximately 70% of cases [8, 11]. In areas with 
higher consanguinity rates, AR disease is more common. For example in Turkey 
and in India up to 60% of cases are AR[22, 23].  
The gene causing XL-CGD is CYBB, and is located at chromosome Xp21.1. This 
gene codes for the gp91phox protein, which is integral to NADPH oxidase function. 
The gp91phox protein consists of 570 amino acids. Missense mutations in amino 
acids 1 to 309 have been shown to be associated with higher residual superoxide 
production when compared with mutations in the later amino acids [14]. 
Accurate molecular diagnosis of patients has enabled over 681 different 
mutations to be identified within the gene at this location and shown to be, 
causing X-linked CGD [24]. Splice-site, insertion, deletion, missense and 
nonsense mutations are all described. The most frequently occurring mutations 
are deletions accounting for 35.6% of cases [24].  
AR disease is the result of a defect in one of p47phox, p67phox, p22phox or p40phox 
protein subunits, with defects in p47phox being the most common. Defects of 
p40phox have very rarely been described in isolation as causing CGD but a recent 
report confirmed findings from mice [25] that p40phox defects may cause CGD in 
humans [26]. Table 1-1 shows the different CGD subtypes, their mode of 
inheritance and relative frequency[27].  
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Table 1-1: CGD Subtypes and Inheritance [27] 
Subunit Inheritance Gene Frequency 
gp91phox XL   CYBB 70% 
p47phox AR  NCF1   25% 
p67phox AR NCF2 2% 
p22phox AR CYBA 3% 
p40phox AR NCF4 Rare 
AR-CGD has been described as having a less severe phenotype than XL-CGD.  
However, this is likely to be an over simplification. The role of residual NADPH 
oxidase has already been discussed and it is likely that this, along with the 
specific mutation, accounts for the differing phenotypes rather than simply the 
mode of inheritance.  This furthers the argument for ensuring an accurate 
genetic diagnosis in all patients.  
1.5 Clinical Features of CGD 
The clinical features of CGD are recurrent infection, inflammatory complications 
and a predisposition to autoimmunity [28].  
1.5.1 Infection 
Patients suffer recurrent, severe bacterial and fungal infection, with particular 
susceptibility to catalase positive organisms due to their impaired oxidative 
burst. The most common bacterial organisms affecting CGD patients include 
Staphylococcus Aureus and Burkholderia Cepacia [8]. Fungal infections pose a 
significant problem and represent a leading cause of death [8], with Aspergillus 
species of particular importance [10, 28]. All species of Aspergillus are prevalent 
in CGD, but Aspergillus Niduluns shows a predilectation for, and particular 
virulence in[29], CGD patients even when compared with other PIDs [30].  
Children with CGD may present with infection at virtually any site, but the most 
frequent presentations are pneumonia, abscesses and lymphadenitis [8, 10, 11]. 
Hepatic abscesses, particularly due to Staphylococcus Aureus [10, 31], are a 
common presentation in CGD and may be multiple and persistent. Less common, 
but reported, presentations include brain abscesses and osteomyelitis[8, 10].  
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An increased susceptibility to mycobacterial infection has been seen in both XL 
and AR CGD patients [32, 33]. Similarly, an increase in localised reactions to BCG 
(Bacille Calmette-Guérin) vaccination has been demonstrated. In a Chinese study 
of 17 XL-CGD patients, 7 patients suffered prolonged scarring or abscess 
formation following the administration of BCG vaccine [23]. This finding was 
confirmed in the large European study[10], where 8% of the 429 patients were 
found to have localised skin infection or lymphadenitis following BCG 
vaccination.  
1.5.2 Inflammation 
Clinical manifestations of CGD are not limited to recurrent infection. Patients 
with CGD suffer from abnormal inflammatory responses, which can affect 
virtually all organ systems and may occur independently of the infective 
manifestations. Well recognised complications include chorioretinitis [11, 34], 
colitis and granulomas in multiple sites [8, 10].  
Granuloma formation is the hallmark of CGD resulting from an abnormal 
inflammatory response. Granulomas are often formed when infection has failed 
to be cleared. They contain inflammatory cells and are usually sterile. 
Granulomas may be found at any site and can subsequently result in secondary 
complications such as obstructive symptoms, depending upon their location.  
Gastrointestinal manifestations are some of the most frequently seen non-
infectious manifestations occurring in up to half of all patients [15, 35]. Colitis is 
a particularly common feature of CGD [8, 10, 15, 35] and was present in 37% of 
CGD patients in a comprehensive UK study in 2000 [11]. It has been particularly 
associated with XL disease and a family history of CGD colitis [11, 36, 37].  
Median age of presentation of CGD colitis is 5 years, although it may present 
throughout life[37]. 
Symptoms of CGD colitis include diarrhoea, rectal bleeding, nausea, vomiting and 
abdominal pain[15]. In a study of 46 CGD patients with gastrointestinal 
involvement, abdominal pain was universal but diarrhoea, constipation, nausea, 
vomiting and bloody stool were all commonly described [37].  Growth and height 
attainment are significantly impacted by gastrointestinal involvement [37] and 
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failure to thrive is frequently present prior to the development of typical 
gastrointestinal symptoms, associated with anaemia [6, 15].  
There is considerable clinical and histopathological overlap between CGD colitis 
and inflammatory bowel disease (IBD), particularly Crohn’s disease, [15, 38, 39] 
and CGD presentation may mimic IBD. It is not uncommon for a diagnosis of CGD 
to be delayed if colitis is the presenting feature, as patients may be managed as 
IBD patients before the diagnosis of CGD is made [39].  
The classical findings on gut biopsies of CGD patients exhibiting symptoms of 
colitis are a high number of eosinophils, decreased neutrophils and lipid-laden 
macrophages, along with granulomas [15, 35, 37] similar to findings in Crohn’s 
disease. Histopathological findings in CGD colitis include microgranulomas, 
pigmented macrophages, tissue eosinophilia and acute and chronic inflammation 
[40]. A study of 7 patients with known CGD and gastrointestinal symptoms found 
that paucity of neutrophils with a predominantly eosinophilic infiltrate, without 
an associated rise in peripheral blood eosinophils, were the most specific 
features of CGD colitis [15]. Alongside this finding was the presence of large 
pigment-containing macrophages. Granulomas were not present in all patients.   
Patient’s without colitis symptoms are rarely biopsied, but it is possible that they 
have subclinical manifestations due to mucosal damage [41], as patients with 
CGD, irrespective of the presence of symptoms, have been found to have higher 
levels autoantibodies more typically associated with IBD than a control group 
[41]. 
Complications of gastrointestinal involvement may include obstruction at any 
point along the gastrointestinal tract, but frequently pyloric outlet obstruction. 
Fistulae and strictures are also common and initial presentation may be with 
appendicitis, in which granuloma may be demonstrated within the diseased 
organ when the appendix is removed [8]. 
Inflammation outside of the gastrointestinal tract is also seen. Within the urinary 
tract, inflammation is common, with inflammatory cystitis the most common 
manifestation [42]. Granulomas may be present within the bladder wall, or 
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throughout the urinary tract, and secondary obstruction may result in 
hydronephrosis [8, 43].  
Pulmonary disease, manifesting as infection or inflammation, was the most 
common site of disease in the European registry [10]. Chronic respiratory 
disease was common in the UK registry, with 77% of those undergoing 
computerised tomographic imaging of the chest having significant 
abnormalities[11]. Typical features may include diffuse infiltrate, 
reticulonodular opacities and focal consolidation[28].  
Chorioretinitis as a manifestation of CGD has been reported since the 1970s [44]. 
It affects a significant number of patients but is only very rarely associated with 
loss of vision [45]. 
1.5.3 Autoimmunity 
Autoimmune phenomena are also described in CGD patients[46]. Juvenile 
idiopathic arthritis, cutaneous lupus erythematosus (LE) and IgA nephropathy 
are all reported in the CGD population [46]. Systemic lupus erythematosus 
(SLE)[47, 48], discoid lupus erythematosus (DLE)[10] and glomuerulonephritis 
[48] are also described. The pathogenesis of this is not well understood.  
However, it is likely these are not simply manifestations of disease, but, in fact, 
represent an increased risk of developing autoimmunity in CGD patients through 
disordered immune regulation, which may be related to abnormal apoptosis [49] 
and immune complexes. This will be discussed in greater depth in chapter 2.  
1.5.4 Malignancy 
There have been case reports of an increased risk of malignancy in CGD patients 
with Hodgkins lymphoma [50] and glioblastoma [51]reported. Weel et al[52] 
report 3 CGD patients each suffering from different malignancies 
(rhabdomyosarcoma, melanoma and retinoblastoma). 
These case reports have not been corroborated by the large scale registries[8, 
10] and the small number of different malignancies makes it difficult to be 
certain of a disease-related association.  
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1.6 Investigations and Diagnosis 
Suspicion of a diagnosis of CGD is based upon a clinical history of recurrent 
infection, particularly with catalase positive organisms or fungi, and 
inflammation. Clinical suspicion is confirmed by the demonstration of abnormal 
NADPH oxidase activity or protein expression and subsequent identification of 
the specific mutation. In families where there have been previous cases of CGD, 
diagnosis may be made before the onset of symptoms.  
Diagnosis of carriers of XL disease may be made by family history. For example, 
female offspring of affected males will be obligate carriers and carrier status may 
be suspected in the female relatives of diagnosed patients. Confirmation of 
carrier status may be made using the same techniques used for diagnosis of 
patients.  
This section will outline the techniques used for diagnosis of patients and 
carriers of CGD.  
1.6.1 NADPH Oxidase Activity 
The diagnostic feature of CGD is demonstration of abnormal NADPH oxidase 
activity and an inability of phagocytes to produce reactive oxygen species (ROS). 
Neutrophils are routinely used to demonstrate the diagnosis. As NADPH oxidase 
is inactive in resting phagocytes, the neutrophils must be activated by a stimulus 
in order to assess NADPH oxidase activity. Phorbol-12-Myristate-13 Acetate 
(PMA) has become the standard agent but alternatives are available. The 
neutrophils are stimulated to produce ROS such as hydrogen peroxide [53].  
NADPH oxidase activity may be assessed in a number of ways: through oxygen 
consumption, superoxide generation or hydrogen peroxide production.  
Oxygen Consumption 
Measurement of oxygen consumption is rarely used in clinical practice as it is 
time consuming and expensive. However, it does provide a quantitative 
assessment of oxygen consumption by use of an oxygen electrode[54]. 
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Superoxide Generation  
Superoxide generation may be measured by the ability of phagocytes to reduce a 
known reagent. The most commonly used agent is nitroblue tetrazolium (NBT) 
in the NBT reduction test.  
Nitroblue Tetrazolium (NBT) reduction test  
The NBT reduction test is the traditional test used to confirm the diagnosis of 
CGD. NBT is a yellow dye that is reduced to blue formazan by the superoxide 
produced as a result of the respiratory burst. Neutrophils are stimulated as 
described above and NBT added.  The reaction takes place intracellularly and the 
result is read manually. CGD phagocytes, which have phagocytosed NBT, remain 
yellow as they do not reduce the NBT (as no superoxide is generated) and 
normal phagocytes show the blue insoluble, precipitate of formazan. XL-CGD 
carriers demonstrate both colours, as the two populations of cells are present.  
Interpretation of results in this test is subjective and detection of XL-CGD 
carriers can be difficult as the two populations may not be well defined or 
distinct [55]. However, an experienced technician will be able to quantify the 
percentage of functioning neutrophils. Figure 1-2 shows a normal and abnormal 
NBT.  
Figure 1-2: Normal and Abnormal NBT Reduction Test Slides[56]  
 
Alternatives to NBT include ferricytochrome c or lucigenin, but these are rarely 
used in clinical practice.  
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Hydrogen Peroxide Generation 
Hydrogen peroxide (H2O2) generation may be used to assess the oxidative burst 
by using flow cytometry and H2O2 detecting agents.  
Flow Cytometry (DHR) 
A flow cytometric method may be used to demonstrate the absence or reduction 
in the oxidative burst in CGD patients and carriers.  Neutrophils are isolated and 
stimulated in the same manner as for the NBT reduction test. An H2O2 detecting 
agent such as dihydrorhodamine-1,2,3 (DHR) is added and freely enters the cells. 
DHR is oxidased by the ROI to rhodamine-1,2,3 which emits a fluorescent signal, 
which is detected by the flow cytometer.  
In healthy controls, all phagocytes produce an oxidative burst, shown as a peak 
as seen in Figure 1-3.   
In patients with CGD, the oxidative burst is absent in the majority of X-linked 
patients or substantially reduced, and no peak is produced upon stimulation as 
shown in Figure 1-4. 
Figure 1-3: Unstimulated and Stimulated DHR in normal control (images courtesy of Dawn 
Barge, Immunology, Newcastle upon Tyne Foundation Trust) 
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Figure 1-4: Unstimulated and Stimulated DHR in CGD Patient (images courtesy of Dawn Barge, 
Immunology, Newcastle upon Tyne Foundation Trust) 
 
Carriers of XL-CGD demonstrate two populations of phagocytes, as some 
phagocytes produce an oxidative burst when stimulated, whilst those in which 
the mutated X-chromosome is active i.e. gp91phox negative, do not. Most carriers 
will exhibit between 20-80% normal burst activity. The DHR of an XL-CGD 
carrier is shown in Figure 1-5. 
Figure 1-5: Unstimulated and Stimulated DHR in XL-CGD Carrier (images courtesy of Dawn Barge, 
Immunology, Newcastle upon Tyne Foundation Trust) 
 
This is a very sensitive and reliable method of assessment and can be performed 
on a small amount of blood collected with EDTA.  It requires less subjective 
assessment than the NBT reduction test.  
The use of DHR and flow cytometry is also dependant on myeloperoxidase 
oxidase (MPO). MPO deficiency would result in an abnormal result and is more 
common than CGD but of less clinical significance.  G6PD deficiency will also 
result in an abnormal result by DHR flow cytometry. DHR has also been shown to 
be inaccurate during acute illness [57].  
Alternatives to DHR have been shown to be less reliable. DHR provides the best 
distinction between normal and abnormal (CGD) phagocytes. When compared 
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with two other fluorescent probes (2’7’-dichlorofluorescin and 5,6-carboxy-2’7’-
dichlorofluorescein diacetate) DHR demonstrated a higher intensity fluorescence 
and the greatest separation of fluorescent signals between normal and abnormal 
phagocytes [58]. Another alternative is Amplex Red which, although also 
sensitive and reliable, does not provide the quantitative value provided by DHR 
[54]. 
Practical Considerations 
When assessing NADPH oxidase activity, there are several practical 
considerations to ensure accuracy as erroneous results can occur throughout the 
process. Samples of blood should be processed within 48 hours, and ideally 24 
hours, of venepuncture in order to avoid inaccurate results. Samples should be 
transported in either an EDTA or heparin medium and kept at room 
temperature. Samples that are not fresh, are likely to contain degraded 
neutrophils due to apoptosis. Degraded or apoptotic neutrophils do not produce 
an oxidative burst and will result in a false reduction in measured NADPH 
oxidase activity, thereby giving an inaccurate result. This may be particularly 
important when determining carrier status. A control sample should be taken, 
transported under the same conditions as the test sample, and processed 
alongside the test sample.  
1.6.2 NADPH Component Expression 
Analysis of the individual components of NADPH oxidase may also be used in the 
diagnosis of CGD. By using FACS analysis of intact neutrophils and 7D5, a 
monoclonal antibody against gp91phox it is possible to determine the presence or 
absence of gp91phox. This is the standard first investigation of component 
expression and if normal is followed by immunoblot analysis with antibodies 
against all NADPH oxidase subunits. One difficulty with this investigation is with 
the membrane components of NADPH oxidase. As gp91phox and p22phox stabilise 
each other, if one is absent the other is not detectable. Therefore, if one of the 
cytosolic components is absent, it is possible to be certain that this is the correct 
diagnosis. However, if either gp91phox or p22phox are absent, the other will not be 
detectable and further investigation is required to confirm the diagnosis, 
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although a family history or the sex of the patient may suggest the more likely 
diagnosis.  
1.6.3 NADPH Component Activity 
In rare cases it may be possible to demonstrate the presence of all 5 subunits, but 
with absent or reduced enzymatic activity. In these cases, it is important to 
consider variants in which a genetic mutation results in the preservation of 
protein expression, but the absence of activity.  
1.6.4 Genetic Diagnosis 
Mutation analysis should be undertaken in all cases of CGD [54], as defining the 
mutation allows for certainty in diagnosis and more accurate genetic counselling. 
Precise genetic diagnosis may have implications within the clinical setting.  For 
patients undergoing haematopoietic stem cell transplantation (HSCT) from a 
family donor, the donor may be accurately screened to ensure they do not carry 
the defective gene. If gene therapy is to be used it is clearly imperative that there 
is a genetic diagnosis. In the research setting, the mutation can be used to 
correlate with clinical severity and specific problems. The precise mutation may 
also be used to determine association with degree of reduction in NADPH 
oxidase activity, information that can be transferred into the clinical setting. 
Gene Sequencing 
PCR amplification and sequencing may be used to analyse CYBB, CYBA, NCF2 and 
NCF4 genes, encoding gp91phox, p22phox, p67phox and p40phox proteins 
respectively. The analysis of NCF1, encoding p47phox, is more difficult owing to 
the presence of pseudo-NCF1 genes either side of the NCF1 locus.  
1.6.5 Carrier Specific Investigations 
The identification of carriers of CGD is important for genetic counselling and for 
identification of further family members at risk. It may also be important for the 
individual’s own medical health.  
Whilst the importance of testing for carrier status of AR and XL disease is the 
same, the techniques required are different. AR carriers should be tested on a 
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genetic level with knowledge of the specific family mutation. This is required, as 
in AR disease carriers, NADPH oxidase activity is virtually normal.  
XL-CGD carriers differ from AR-CGD carriers as they have variable NADPH 
oxidase activity owing to lyonisation. Lyonisation is a random process, occurring 
in early foetal development, which involves the inactivation of one X 
chromosome in all cells. For female carriers of XL-CGD this means, that in some 
cells the mutated X chromosome will be active whilst in others the wild type X 
chromosome will be active. As lyonisation is a random process, there may be an 
uneven split.  
XL-CGD carriers will normally demonstrate a dual population of cells on either 
NBT or by flow cytometry with DHR, correlating with the degree of residual 
NADPH oxidase activity. XL-CGD carrier status may also be confirmed by the 
specific mutation in the CYBB gene. However, up to one third of XL-CGD patients 
have a new germ line mutation [54] and therefore, the absence of an XL-CGD 
carrier mother does not exclude XL disease in the patient.  
X-Inactivation Measurement 
It is possible to quantify which X-chromosome is active in carriers by use of the 
human androgen-receptor gene (HUMARA) assay.  This assay measures the 
degree of methylation at the HUMARA locus [59]. This can be correlated with 
degree of reduced NAPDH oxidase activity found by either NBT or DHR.  
1.7 Management of CGD 
Treatment of CGD is based upon prophylaxis against bacterial and fungal 
infection, aggressive management of established infection and management of 
the inflammatory complications.  
Antibiotic prophylaxis is well established, with the most commonly used agent 
being co-trimoxazole [11, 60]. Antifungal prophylaxis is part of standard care 
and itraconazole is increasingly the agent of choice[60].  Management of acute 
infectious episodes should be aggressive. This involves prompt initiation of 
antibiotics, thorough investigation for causative organisms, particularly fungi, 
and use of adjuvant therapies. Examples of adjuvant therapies include 
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corticosteroids for the treatment of liver abscesses [61] and the use of IFNγ,  
common place in the United States of America, and granulocyte infusions[42].  
Corticosteroids form an important part of the treatment of inflammatory and 
granulomatous manifestations of disease. Corticosteroids remain first line and 
mainstay treatment for CGD related colitis [37]. The management of CGD colitis 
is similar to the treatment of other inflammatory bowel conditions, with agents 
such as sulfasalazine being used with good results and infliximab becoming 
increasingly important [15, 37].  
The use of infliximab may be considered in those patients with significant CGD 
colitis despite conventional management. However, whilst there has been 
success with the use of anti-TNF alpha therapy, serious and even fatal infections 
are reported [62]. In a case series of 5 CGD patients with inflammatory bowel 
disease treated with infliximab, all improved significantly, including resolution of 
fistulae, but all developed significant infection requiring the infliximab to be 
discontinued [53]. 
Haematopoietic stem cell transplantation (HSCT) remains the only curative 
treatment at present. There has been success with unrelated donor stem cell 
transplantation as well as matched sibling donor transplantation [63] and 
increasingly HSCT is being viewed as an early treatment option. A recent UK 
study demonstrated that, not only was HSCT successful in curing CGD patients, 
but that quality of life in paediatric CGD patients who had undergone HSCT was 
the same as normal population data [60, 64]. The continued success of HSCT in 
CGD patients has now led to HSCT being considered the treatment of choice. 
Gene therapy remains a salvage therapy at present for CGD, but a promising 
alternative therapy although currently remains predominantly in the research 
setting [65-68]. Conservative management remains an option for those who do 
not undergo HSCT. However, life expectancy for those managed conservatively 
remains significantly reduced with up to 50% dying before mid-adulthood [11].  
1.8 XL-CGD Carriers 
Female carriers of XL-CGD possess one copy of the mutated gene and have a 
mosaic pattern of wild type and mutated X chromosomes, producing a mixture of 
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gp91phox positive and gp91phox negative phagocytes. This is the result of 
lyonisation. Lyonisation is the random inactivation of one X chromosome and 
occurs early in the foetal development of haematopoietic precursor cells. In 
phagocytes where the X chromosome with the mutated gene is active there is no 
gp91phox expression whilst, where the wild type X chromosome, is active there is 
normal gp91phox expression in those phagocytes. As lyonisation is a random 
process, there is a wide variability of the proportion of phagocytes expressing 
the mutated gene.  
Phagocytes expressing gp91phox have normal NADPH oxidase activity, whilst 
those which are gp91phox negative, do not. XL-CGD carriers therefore, have 
overall reduced NADPH oxidase activity. The degree of NADPH oxidase activity 
depends upon the proportion of phagocytes expressing gp91phox and also the 
specific mutation [14]. It ranges from near normal to severely depleted. It is 
possible to quantify the degree of activity and most XL-CGD carriers fall within 
the range of 20-80% reduction [69, 70].  
The reduction in degree of NADPH activity has been considered to have no 
significant clinical consequences, with XL-CGD carriers considered healthy 
despite the link with discoid lupus erythematosus (DLE) [71-73].  Currently, 
most centres in the UK do not routinely offer carriers any clinical review or 
prophylactic treatment. Logically, however, carriers have a theoretically 
increased risk of infection and abnormal inflammatory response similar to 
patients with CGD, if a sufficient percentage of phagocytes are functionally 
deficient. Early observations found the mothers of boys with the newly described 
CGD, had rashes resembling lupus [6] and increasingly, manifestations beyond 
skin disease are being described in XL-CGD carriers, with symptoms similar to 
classical disease reported. There are numerous case reports of female carriers 
manifesting symptoms typical of CGD and the associated features [74-77].  The 
literature on this will be reviewed in the next chapter.  
The frequency and percentage of symptomatic XL-CGD carriers is unknown. The 
overriding hypothesis for symptoms in XL-CGD carriers is that whilst most XL-
CGD carriers have fairly equal distributions of the two populations of cells, some 
appear to have disproportionate levels of inactivation of the unaffected X-
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chromosome. This results in a reduction in the degree of NADPH activity to levels 
more akin to that of patients, making these carriers susceptible to the same 
spectrum of disease.  
The degree of skewing of X-chromosome inactivation and symptoms in XL-CGD 
carriers is not constant throughout life and the exact relationship to degree of 
symptoms has not been established. Some XL-CGD carriers appear to have had 
little difficulty with infection in early childhood, unlike the typical CGD patient 
[75, 76], whilst others who have significant manifestation at older ages have also 
suffered recurrent, although less severe, infection in childhood [74].  It is 
proposed that age-related skewing of lyonisation and a decrease in the 
percentage of functioning neutrophils may account for the increased 
susceptibility to opportunistic infection later in life [75], but this has not been 
corroborated.  
The ‘breakpoint’ at which female carriers become susceptible to infection and 
symptoms of CGD is uncertain, as symptoms have been described with a range of 
NOB reduction. It would seem likely that there is point at which functional 
phagocytes are unable to compensate for the defective population, and it is at 
this point that symptoms are seen.  
Testing for Carrier Status 
Testing for carrier status of a genetic disease has ethical and medical 
implications. The timing of offering and performing genetic testing is an 
important issue. For CGD, at present, the benefits for an individual in knowing 
their carrier status relate predominantly to decisions regarding reproduction 
and having an affected child. As carriers of XL-CGD are currently believed to be 
healthy there is little to support testing female relatives of index cases, except to 
confirm inheritance pattern and in screening for potential transplant donors.  
It is currently recommended that in children and young people, testing for 
carrier status of any genetic condition is deferred until an age at which they are 
able to make an informed decision themselves. Conventionally this is 18 years of 
age [78]. The benefits of testing versus the benefits of delaying testing are 
controversial.  
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Few studies have evaluated the opinions of adolescents themselves, but James et 
al [79] looked qualitatively at a small cohort of adolescent sisters of patients with 
CGD and also at their parents. There was discrepancy between the views of the 
parents and the adolescent girls. The adolescent girls agreed with the 
recommendation that testing should be deferred. They uniformly felt that they 
would want to know their carrier status before starting a family, but when 
offered hypothetical immediate testing none would have accepted this. The 
parental view differed as the majority felt that testing earlier would be beneficial 
for the family as a whole.  
There is currently not sufficient evidence to support testing for carrier status on 
medical grounds. Knowledge of carrier status will not alter the treatment 
received by an individual or their management. However, if it can be 
demonstrated that XL-CGD carriers are at increased risk of medical problems, 
there may be an advantage to earlier testing in order that they may receive 
appropriate investigation and treatment at an earlier stage. My study will 
provide evidence as to whether there is a benefit to testing for XL-CGD carrier 
status earlier than currently indicated.  
There are psychological aspects to both knowing and not knowing about carrier 
status. These may be affected by the relationship of the potential carrier to the 
index case. Those who have a greater understanding of the condition may have a 
very different viewpoint to a more distant relative who has not seen the full 
impact of the condition and treatment. This may affect psychological health and 
indeed quality of life.  
1.9 Outline of Thesis 
This chapter has outlined information about CGD including genetic inheritance, 
pathogenesis, diagnosis, clinical manifestations and treatment. Chapter two will 
review the pertinent literature to the study and provide further background 
information about XL-CGD carriers. Chapter three will outline the aims and 
hypothesis underpinning the study and chapter four will describe the methods 
employed in the study. The results will be presented in chapters five to eight and 
will be divided into clinical, psychological (including IQ), fatigue and quality of 
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life findings. Chapter nine will discuss the findings and chapter ten will draw 
together the final conclusions and make clinical recommendations.  
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Chapter 2: Literature Review  
2.1 Introduction (Manifestations of Disease in XL-CGD Carriers) 
There is little published literature about the health of XL-CGD carriers, and it is 
confined predominantly to case reports, case series or letters. However, within 
the literature about patients with CGD, references are made to their female 
relatives and the health of these XL-CGD carriers.  
This chapter will examine all the available literature about carriers of XL-CGD. It 
will also examine the literature surrounding the symptoms described in XL-CGD 
carriers and about XL carrier status in other diseases. 
2.1.1 Anecdotal Experience 
Unpublished anecdotal experience in the Great North Children’s Hospital 
(GNCH), Newcastle upon Tyne, highlighted that female relatives of XL-CGD 
patients were suffering from significant medical problems. Inflammatory bowel 
disease (IBD) and systemic lupus erythematosus (SLE) were seen in two 
separate families.  
2.1.2 Early Descriptions 
The earliest observation of symptomatic XL-CGD carriers was in 1969 when 
Thompson et al reported on 10 cases of CGD in 1969 and observed facial rash, 
resembling lupus, polyarthritis and Raynaud’s phenomenon occurring in 3 of the 
female relatives [6].  Since 1969 there have been more descriptions of 
symptomatic XL-CGD carriers and these will be discussed here.  
2.2 Infection in XL-CGD Carriers 
As previously discussed, CGD patients suffer recurrent infection with particular 
susceptibility to infection with catalase positive organisms.  Despite the reduced 
number of functioning neutrophils in XL-CGD carriers, recurrent infection has 
not been reported as a significant problem. There are a handful of cases 
described where infection has been the main, or an important, feature in an XL-
CGD carrier.   
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Johnston et al[80] described a girl presenting with recurrent infections classical 
of CGD, including recurrent infective abscesses, pneumonia and multiple 
isolations of Staphlyococcus Aureus, who was found to be a carrier of XL-CGD. 
Lewis et al [74] described a 16 year girl who presented with persisting 
pneumonia despite aggressive antibiotic therapy who was found to be an XL-CGD 
carrier. Aspergillus fumigatus was isolated from broncheoalveolar lavage and 
sputum specimens. She had been previously fit and well, but did have a history of 
recurrent abscesses suggesting an additional infective burden.  
Further to the case described by Lewis et al[74], recurrent skin abscesses 
requiring antibiotics and, at times, surgical drainage have been described in XL-
CGD carriers [70, 76, 77, 81] and have been shown to isolate CGD-associated 
organisms including Staphlyococcus Aureus [82]. Single episodes of infection 
have also been reported such as the case of persistent systemic salmonella 
infection in a 34 year old XL-CGD carrier[83]. As a single example of infection, 
this perhaps does not carry significant weight to the hypothesis of XL-CGD 
carriers being at risk of similar infective organisms to the patients. However, in 
the context of the case reports, there is a growing body of evidence that suggests 
XL-CGD carriers may be at greater risk of the infective manifestations of CGD.  
In summary, the literature about infection in XL-CGD carriers is limited 
predominantly to case reports and the small numbers reported make it difficult 
to draw conclusions. However, these reports are of interest as they lead us to 
question if there may be an infection risk associated with XL-CGD carrier status 
and if there are more cases, as yet unreported, indicating that further 
investigation is warranted.  
2.3 Inflammatory Manifestations of CGD in XL-CGD Carriers 
2.3.1 Skin Disease 
The most frequently reported problem in XL-CGD carriers is skin disease. An 
association with discoid lupus erythematosus (DLE) has been well described [69, 
72, 84, 85]. The presence of a persistent facial rash resembling DLE in 2 XL-CGD 
carriers was first described in 1970 [6] and these findings have been 
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corroborated subsequently, most recently in 2007 when Cale et al [69] found 
photosensitive skin rashes in 58% of their XL-CGD carrier cohort.  
The clinical and histopathological features of rashes seen in the XL-CGD carriers 
are consistent in the literature, but severity and clinical course are not. Virtually 
all cases describe the presence of photosensitive eruptions on sun-exposed 
surfaces with similar, if not identical, histological findings to DLE when biopsies 
were performed[84]. The most common site described is in the malar 
distribution and on the hands.  Age at onset of skin disease is not constant, with 
reports of early childhood appearances [81] featuring alongside later 
presentations [72]. Severity ranges from minor irritation, resolving in childhood, 
to treatment-resistant disease persisting into late adulthood.  
Photosensitivity alone is commonly described in XL-CGD carriers without the 
presence of classical DLE[84, 86]. Sillevis-Smitt et al described 10 of 16 XL-CGD 
carriers with relapsing skin eruptions, in whom 7 were provoked by sunlight, but 
not all had typical features of DLE [72]. Despite the link of DLE with XL-CGD 
carriers, DLE is unusual in patients with XL-CGD, although has been occasionally 
reported [87].  
Conversely, when XL-CGD carrier status was sought in patients presenting with 
DLE, no carriers were found [88]. This was, however, a small scale study of 19 
patients and the authors acknowledged that it remains important to look for XL-
CGD carrier status in women presenting with DLE, particularly in the presence of 
related symptoms such as recurrent or suppurative infection or a family history 
of early childhood death.  Their findings were corroborated in a further study of 
34 patients presenting with DLE, tested for XL-CGD carrier status by performing 
an NBT test. Again, no XL-CGD carriers were found, but the authors 
recommended screening for carrier status particularly in the presence of 
aphthous stomatitis [89]. 
Alongside photosensitivity and DLE manifestations, aphthous stomatitis is 
reported with even greater prevalence. Brandrup reported as early as 1981 that 
7 out of 9 X-linked carriers suffered recurrent aphthous-like stomatitis[84]. This 
was supported by a later survey in 1989 when 70% of 16 carriers reported 
recurrent aphthous stomatitis [72] higher than the 63% reporting recurrent skin 
 26 
eruptions. In both reports the symptoms have been severe. Case reports also 
corroborate these findings [70, 75].  
Photosensitivity may not always be immediately clinically apparent. Therefore, 
unless specific enquiry is made, the symptom will be missed. Subsequently, it is 
likely to be more prevalent than previously described.  
2.3.2 Gastrointestinal Disease 
Gastrointestinal manifestations have infrequently been described in XL-CGD 
carriers and there are three reports in the literature. Moltanyer et al [90] 
described a female carrier who presented at the age of 41 years with proven 
bronchocentric granulomatosis. Her background history revealed that, at age 13 
years, she had been diagnosed with ulcerative colitis and had a history of 
recurrent infection. On testing, she had 10% functioning neutrophils.  This 
combination of inflammatory bowel disease, recurrent infection, respiratory 
disease and reduced NADPH oxidase function is remarkable as it occurred in an 
XL-CGD carrier, but presented in a very similar manner to a CGD patient.  
The other gastrointestinal manifestations reported in the XL-CGD carrier 
population were intermittent diarrhoea in one of 19 XL-CGD carriers [69] and 
colonic polyposis in a single XL-CGD carrier reported primarily due to skin 
disease [85].  
Due to the overlap of histopathology, it is possible that there could be 
undiscovered XL-CGD carriers in the IBD population. A recent prospective study 
screened 120 paediatric patients with a diagnosis of IBD by performing a 
neutrophil oxidative burst.  They failed to find any CGD patients or XL-CGD 
carriers within the IBD cohort [91].  However, this study is limited as it included 
children of all ages. The majority of CGD patients are diagnosed by the age of 5 
years[11]. The mean age in Jaggi et al’s[91] study was 14.8 years, so it would be 
expected that any CGD patients would have already been diagnosed. The lack of 
XL-CGD carriers diagnosed may reflect the small scale of the study rather than a 
lack of association. No study to date has looked at XL-CGD carriers specifically for 
IBD or gastrointestinal symptoms. Anecdotal reports, including our own 
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experience at the GNCH, suggest there may be more cases than currently 
reported in the literature.  
Impaired neutrophil function, albeit with normal NBT reduction, has been found 
in Crohn’s patients when compared to healthy controls [92]. No patients or XL-
CGD carriers were found, but this finding highlights the close relationship 
between neutrophil dysfunction and inflammation, particularly within the 
gastrointestinal tract.  
Further to the reported overlap in histopathology and clinical symptoms of IBD 
and CGD colitis, Casanova and Abel [93] report the concept of CD as a primary 
immunodeficiency and specifically an immunodeficiency of macrophages thus 
there is an immunological overlap of CD and CGD. Evidence has accumulated that 
Crohns disease is the result of impaired clearance of bacteria and impaired 
inflammatory response resulting in excessive inflammation. Specifically, CD 
patients are unable to clear E. Coli when it is present at high levels and that 
whilst neutrophils are functionally normal in CD, there is a problem with 
neutrophil recruitment to the site of infection i.e the gut. The neutrophils, 
therefore, do not clear the bacteria. The failure of clearance of bacteria within the 
gut results in granuloma formation and the ongoing accumulation of 
macrophages and lymphocytes [94], which ultimately results in the prolonged 
release of cytokines and subsequently local damage and irritation.  Despite the 
finding that the macrophages in CD patients only secrete low levels of 
proinflammatory cytokines, the accumulation of large numbers of these cells 
results in ongoing chronic inflammation and damage.  
The proposed underlying mechanism in CD outlined above is also attributable to 
CGD, where there is impaired neutrophil function by the inability to generate 
superoxide. Thus, the CGD patients are unable to clear bacteria or foreign 
material from their gut and subsequently may suffer sustained inflammation as a 
result of accumulation of bacteria.  
The similarities in presentation of Moltanyer et al’s [90] XL-CGD carrier to boys 
with CGD, and the incomplete understanding of why some CGD patients suffer 
from severe colitis whilst others do not, leads us to consider whether there may 
be clinicopathological overlap between the gastrointestinal disease seen in the 
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patients and in the XL-CGD carrier case reported, and potentially other, XL-CGD 
carriers. It is possible that inflammatory bowel disease is more common in XL-
CGD carriers than hitherto suspected, but this has yet to be investigated.  
Despite the paucity of literature, the published reports raise the question of 
whether there may be a higher prevalence than expected of XL-CGD carriers in 
patients with IBD and whether XL-CGD carriers may be at greater risk of 
inflammatory gastrointestinal disease and manifestations similar to those seen 
in the CGD patients.  
2.3.3 Chorioretinitis 
As already discussed, chorioretinitis is a recognised inflammatory complication 
of CGD. Chorioretinitis in isolation, outside of CGD is rare, although can occur in 
other conditions such as toxoplasmosis. Although the lesions are usually non-
progressive, cases of retinal detachment have been described [95] and it is 
therefore, an important finding.  
In 1999, Goldblatt et al [34] examined the eyes of a cohort of CGD patients and 
also their XL-CGD carrier relatives and non carrier relatives.  Of 38 patients 
screened, almost 24% had chorioretinal lesions demonstrated. Interestingly, 
10% of the XL-CGD carrier cohort had discrete typical lesions, compared to none 
of the non-carrier, non-patient control group. Lesions were rarely associated 
with visual disturbances. The lesions seen in both the XL-CGD carriers and the 
CGD patients were similar to previous descriptions of affected CGD patients; 
well-circumscribed chorioretinal scars [34]. The use of family members as a 
control group adds weight to the finding that the lesions seen in the XL-CGD 
carrier family members were related to their carrier status as it controls for 
other genetic and environmental factors.  
The findings concur with an early case report by Brandrup et al [84] who 
described an historical case of chorioretinitis in an XL-CGD carriers. There are no 
other reports of visual symptoms or signs in XL-CGD carriers.  
Whilst the findings of chorioretinitis in XL-CGD carriers appear to have been 
incidental and not to have an adverse or significant effect on the individuals, the 
finding is nevertheless important. It highlights that there may be similar 
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pathological processes in the XL-CGD carrier population as seen in the CGD 
patients.  
2.3.4 Other Inflammatory Manifestations 
There are no descriptions of other inflammatory manifestations in XL-CGD 
carriers such as inflammatory cystitis or chronic respiratory disease.  
2.4 Autoimmunity in XL-CGD Carriers 
Autoimmune manifestations are recognised features of primary 
immunodeficiencies [96] and CGD is no exception. However, the association with 
autoimmunity is also described in XL-CGD carriers.  Case reports of CGD patients 
frequently comment that their XL-CGD carrier female relatives suffer from 
features of autoimmune disease [6, 46, 72].   
2.4.1 Symptoms of Autoimmune Disease in XL-CGD Carriers 
Reports about autoimmune manifestations in XL-CGD carriers have been 
published. Polyarthritis, recurrent aphthous ulcers and Raynaud’s phenomenon 
are all reported [6, 72, 73, 84, 90]. The prevalence of these features appears to be 
more than expected in a healthy population.   
Following these reports, Cale et al [69] performed a limited assessment of the 
physical health of 19 XL-CGD carriers to further investigate autoimmune 
manifestations. Aphthous stomatitis, photosensitivity and Raynauds 
phenomenon were demonstrated, with photosensitivity occurring in 58% [69]. 
37% of X-linked carriers reported that they suffered from joint pain, with no 
other cause identified and nearly half of the cohort suffered from excessive 
fatigue [69].   This was the largest cohort of XL-CGD carriers studied to date, but 
direct questioning and examination about symptoms of other autoimmune 
conditions or other manifestations of CGD was not undertaken, although any 
information volunteered was recorded. It confirmed the smaller scale findings of 
Sillevis Smitt’s study where 70% of the XL-CGD carriers surveyed suffered 
recurrent apthous ulcers and 63% had recurrent skin eruptions [72].   
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Autoimmune features were also described in the case reports and series 
describing XL-CGD carriers with skin disease as the predominant feature. These 
reported arthralgia [82], polyarthritis [6, 70] and Raynaud’s phenomenon [6, 72] 
highlighting that XL-CGD carriers may be affected by more problems than simple 
skin disease.  
Case reports of CGD patients also frequently comment that female relatives, 
known to be carriers, suffer autoimmune phenomena [6, 97]. Autoimmune 
diseases are more prevalent in females, but the association with X-linked carriers 
of CGD appears to go beyond simply gender predisposition. 
2.4.2 SLE and ‘Lupus Like’ Disease in XL-CGD Carriers  
Winklestein et al’s [8] registry of CGD patients observed that, within families of 
boys with X-linked CGD, there was a higher incidence of autoimmune conditions 
and most notably systemic lupus erythematosus and its variants.  The 
autoimmune phenomena described in the previous section may all be part of 
SLE, but the descriptions in the literature refer to ‘lupus-like’ disease due to 
absence of associated autoantibodies in serum [6]. 
2.4.3 Autoimmunity and Primary Immunodeficiency 
Autoimmune manifestations are a feature of primary immunodeficiencies as a 
result of immune dysregulation.  The interplay between autoimmunity and PID 
has generated much interest and X-linked PIDs are of particular significance.  
Autoimmune features are frequently seen in conditions where there is random 
X-chromosome inactivation. For example, CGD, X-Linked lymphoproliferative 
syndrome (XLP) and X-linked Hyperimmunoglobulin M syndrome (XLHM) have 
clear associations with autoimmunity which are less prevalent where there is 
non-random X-inactivation for example in X-linked Severe Combined 
Immunodeficiency (SCID) [98]. 
CGD patients are particularly at risk of autoimmunity [97] and features of 
autoimmune disease are recognised within CGD patients.   
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2.4.4 Autoantibodies 
There is little published about routine autoantibody screening being performed 
in XL-CGD carriers, even in those who are symptomatic.  
Early work on the presence of autoantibodies in primary immunodeficiency 
identified a higher than expected rate of autoantibodies in both patients and 
female carriers of XL-CGD. Amman et al, in 1979[99], demonstrated that even in 
the absence of clinical features of autoimmune disease, over 50% of patients had 
autoantibodies present, of which Rheumatoid factor and anti-poly (Au) were the 
most commonly found.  XL-CGD carriers, who were relatives of the patients, 
demonstrated similar findings: 50% had positive autoantibodies with 
rheumatoid factor, ANA and anti-poly (Au) frequently found. The cohort was 
small, with 11 patients and 8 XL-CGD carriers, but the findings interesting. 
Within the XL-CGD carrier population, clinical symptoms of autoimmune disease 
were present and correlated with the positive autoantibodies. Three out of eight 
XL-CGD carriers clinically had DLE whilst one had SLE.   
These early results were supported by a study twenty years later. Martin-Villa et 
al [98] looked at 5 families each with at least one XL-CGD patient per family.  
Patients, carriers and non-carrier relatives were all studied for the presence of 
autoimmune disease and autoantibodies. The findings showed that the XL-CGD 
carriers and the CGD patients had significantly higher rates of autoantibodies 
including ANA and anti-smooth muscle autoantibody, present than their non-
carrier relatives.  Of the eight patients, six had autoantibodies present and 11 of 
the 13 carriers also had autoantibodies present, whilst only two of the 13 non-
carrier relatives demonstrated presence of autoantibodies.  Unusually, two CGD 
patients had evidence of DLE and one XL-CGD carrier also had DLE whilst there 
were no autoimmune features in the non-carrier family members [98]. The 
patients with DLE had autoantibodies present.  
The early work described has not been replicated in a larger, more recent study. 
Cale et al’s [9] prospective study of XL-CGD carriers investigated the presence of 
autoimmune features and autoantibodies in 19 XL-CGD carriers. Only five of 
these XL-CGD carriers had autoantibodies present and all five had a positive 
ANA, although in three the values were only weakly positive. One XL-CGD carrier 
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also had a weakly positive DS-DNA antibody present.  All of the women with 
autoantibodies present had clinical features of autoimmunity (four 
photosensitive rash, one joint pain and recurrent aphthous ulcers without rash). 
However, overall within this cohort there were features of autoimmunity and 
lupus like symptoms in over 50% of carriers, but autoantibodies only found in 
25%.  
An earlier case report supported this finding. Cordona-Guijarro in 2000 reported 
an individual XL-CGD carrier who manifested features of lupus, but in whom 
extensive autoantibody testing was negative [100]. 
On balance, therefore, it would seem the literature does not support 
autoantibodies as a reliable method for screening for symptoms of autoimmune 
disease in XL-CGD carriers and the classical patterns seen in autoimmune disease 
may not be present in XL-CGD carriers. The exact relationship between 
autoantibodies, autoimmune diseases and XL-CGD carriers has yet to be 
elucidated.  
It is possible that autoantibodies are present in more XL-CGD carriers, but that 
they are not detected by conventional techniques, and with more sophisticated 
and advanced methods, autoantibodies would be detected more frequently. If 
this is the case, there may be a closer correlation with the presence of symptoms 
than is currently recognised.  
Mechanism 
There is no consensus over the mechanism for autoantibody production in XL-
CGD carriers. A review of the literature reveals several leading hypotheses.  
A popular hypothesis is that there is failure to clear debris, which may act as 
antigenic stimulant, because of abnormal apoptosis of affected phagocytes, 
particularly macrophages. This results in persistent antigenic stimulation, which 
leads to autoantibody production. It can be theorised that this may correlate 
with the degree of reduction in neutrophil function in carriers i.e. that those with 
greater number of functioning neutrophils are more likely to be able to clear 
debris and organisms [98]. 
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A further hypothesis is that the defect may lie more specifically with the inability 
for affected phagocytes to produce superoxide[98]. 
Finally the interaction of gp91phox with B cells may account for autoantibody 
development, as there has been demonstrated an interaction between p47phox 
and this may be transferable[101] .  
2.5 Possible Causation 
2.5.1 Residual NADPH Function 
Historical understanding of CGD severity and survival is that XL-CGD is the most 
severe manifestation, with AR-CGD presenting later and with a milder clinical 
course [8, 10]. Increasingly it is realised that this is too simplistic an 
understanding and does not account for the differences seen.  
Kuhns et al [14] reviewed 287 patients from 244 kindreds, of whom 195 patients 
(169 kindreds) had XL disease. They found that whilst NADPH oxidase function 
was impaired in all CGD patients, the degree of residual ROI production was 
variable.  From the residual ROI production, four discrete quartiles were 
identified, without accounting for the clinical phenotype. The authors were able 
to conclude that residual ROI production was associated with survival. Even 
small degrees (1% of normal) of residual ROI production improved survival with 
the best survival seen in patients with the greatest residual production. The 
specific gene mutation was not as important to survival as the degree of ROI 
production. Although survival was accounted for by ROI production, there was 
no association found between residual ROI production and the presence or 
severity of inflammatory gastrointestinal manifestations.  
Further evidence for the clinical implications of residual NADPH oxidase function 
can be found in case reports. In 2007, a case resembling juvenile sarcoid was 
reported in a male. He presented with a classical picture of juvenile sarcoid, 
including a raised ACE, but went on to develop a hepatic abscess. Upon DHR 
testing, residual NADPH oxidase activity was apparent and [102] genetic testing 
confirmed the presence of a mutation in the CYBB gene. 
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In 2012 Gutierrez et al[13] reported a 9.4 year old male who presented with 
recurrent pneumonia.  He had no other manifestations of CGD and was well 
grown. Investigations revealed a dual population of cells upon DHR with only 
34% negative for ROI production, thus showing preserved residual NADPH 
oxidase function. Genetic testing confirmed the presence of a known CGD 
mutation in the CYBB gene.  This is an unusual case both in the mild phenotype 
presented, as he suffered only isolated lung disease, and in the dual population of 
cells more akin to a female carrier than a typical XL-CGD patient. However, it 
further supports the evidence about the importance of residual NADPH oxidase 
function.   
2.5.2 Correlation with Neutrophil Oxidative Burst 
As not all XL-CGD carriers demonstrate significant problems, interest has been 
directed towards how to identify those who may be affected. Quantification of 
the oxidative burst by either DHR or NBT shows significant variation amongst 
carriers, ranging from 20-80%[69]. Reports from published studies are 
conflicting.  Some studies suggest severity of symptoms and incidence of 
autoimmune manifestations was associated with lower NBT values [6, 72, 86] 
whilst patients in Cale et al’s study showed symptoms at both ends of the NBT 
range [69].  It is difficult to draw significant conclusions about the relationship 
between symptoms and oxidative burst value due to the small number of XL-CGD 
carriers studied and the discrepancy between timing of oxidative burst 
measurement and onset of symptoms.  
Furthermore, little is known about whether neutrophil oxidative burst is 
consistent throughout life in carriers, or whether there is variation with age and 
how this may affect the development of symptoms.  
2.6 X-Inactivation and Skewing  
Females have two X-chromosomes; one paternally derived and one maternally 
derived. Only one X-chromosome remains active in a cell with one X-
chromosome being ‘switched off’. The process by which this occurs is called 
lyonisation or X-inactivation and occurs in all women early in foetal 
development.  Lyonisation is considered a random process. It is anticipated that 
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the split between maternally derived and paternally derived active 
chromosomes would be approximately 50/50, but, as it is a random process, the 
split may be anywhere between 0 and 100%. Where there is no mutated gene 
present on the X chromosome, which chromosome is selected to be active is less 
significant. However, when considering XL conditions such as CGD in female 
carriers, which X-chromosome (wild type or mutated) becomes inactivated is of 
particular functional importance for relevant cells in which the gene product is 
expressed.  
Where the distribution of maternally to paternally derived X-chromosome is not 
equally distributed, it is referred to as skewing. Skewing is considered to be 
significant when there is a disparity between activation of parentally-derived X 
chromosomes and where ratios are approaching 80:20[103].  
In a study of 1005 females, with no known XL genetic mutation, less than 12% of 
women had extreme skewing i.e. a ratio of 80:20 or more [104]. Almost all 
women had near equal distribution. Measuring this ratio at one point in time is 
useful, but the ratio may not be constant throughout life. It has been 
hypothesised that the degree of skewing may be related to age and that extreme 
skewing becomes more likely with increasing age[105]. In the same study, it was 
shown that there was a greater percentage of extreme skewing in older women 
compared to newborn cord blood (19.5% > 80:20 in adult women compared to 
5.6 % in the newborn group [104]). Extreme lyonisation (>95:5 %) occurred in 
less than 1% of the newborn population.  
It is possible that the ratio varies not only from individual to individual and with 
age, but also between tissue types. In muscular dystrophy the degree of skewing 
has not always been equal when muscle and peripheral blood measurements 
were made simultaneously [106]. Gale et al[107] found differences in X-
inactivation between t-lymphocytes and neutrophils in the same patients. In XL-
CGD carriers the ratio may differ between different tissue types explaining why 
there are symptoms in some systems and not others. However, there is no 
literature about this at present.  
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2.6.1 Assessment of Skewing  
As highlighted from the study results discussed earlier, it is possible to quantify 
the degree of X-inactivation skewing. In XL-CGD carriers, the degree of skewing 
may be inferred from the neutrophil oxidative burst result, as those neutrophils 
producing a respiratory burst express the normal X chromosome. Koker et al’s 
[59]study of one family found that the DHR correlated well with assessment of 
DNA methylation from leucocytes, although the correlation was less close when 
buccal swabs were compared.  
Simple measures using methylation can look for extreme degrees of lyonisation, 
but it is also possible to quantify the degree of skewing using the human 
androgen receptor (HUMARA) assay[108].  
2.6.2 Cause of Extreme Skewing 
The reason why some women demonstrate such extreme lyonisation is unclear. 
As discussed earlier, in the ‘normal population’, up to 14% women have skewed 
inactivation [109]. Potential causative factors will be discussed here.  
Age 
As outlined in the study of healthy controls discussed earlier, it has been 
suggested that there may be an increase in extreme skewing with increasing age. 
In one family of XL-CGD carriers, three generations of women were assessed[59]. 
The percentage of functioning neutrophils ranged from 36 to 81% and the 
highest levels were seen in the youngest generation[59].  
A large study of 333 healthy females found that there was an increase in the 
presence of excessive skewing associated with increasing age[110].  It was found 
when using a definition of 90:10 or greater, less than 2% of neonates 
demonstrated extreme skewing compared with 22.7% in the over 60 years age 
group.  
In a similar study, Hatakeyama et al [111] examined 350 females to assess the 
degree of skewing. They found that whilst there was an increase in the incidence 
of extreme skewing with increasing age, this was only at a modest level. There 
was little difference within 20-year age brackets.  A smaller study by Racchi et 
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al[112], failed to find significant correlation between increasing age and degree 
of skewing.  
The flaw with these studies in evaluating the relationship between age and 
degree of skewing is that none are longitudinal and so the natural history of 
skewing within an individual cannot be assessed.  
Inheritance of Extreme Skewing 
It has been hypothesised that X-Inactivation may be controlled by genetic 
factors[113]. Early work with mice found a region on the X-chromosome was 
responsible for controlling the inactivation process[114]. This was further 
supported by work in humans when a different gene (XIST gene), located in the 
same region of the X-chromosome, was found to control the X-inactivation 
process [113]. Naumova et al [109] add weight to the hypothesis of an 
inheritability of skewing in their study of 3 generations of 36 families. Their 
study found that in a family with extreme skewing in the grandmother (90:10 
ratio), all 7 of her grandchildren manifested the same degree of extreme 
skewing. The women were not carriers for any known genetic mutations and 
statistically the probability of this occurring by chance was insignificant. Further 
analysis suggested that the most convincing explanation was that the process 
was controlled by a specific locus on the X chromosome.  
Preferential Selection 
In some conditions, there may be preferential selection of the non-mutated 
chromosome as there is a growth or selective advantage.  
In a study of X-linked Dyskeratosis Congenita (DC), a rare cause of bone marrow 
failure, 16 carriers were reviewed. Vulliamy et al[115] found that all 16 XL 
carriers demonstrated extreme skewing, on peripheral blood, of greater than 
90% in favour of expressing the non-mutated chromosome. This supports the 
hypothesis that, in the case of XL DC, there is a selective disadvantage for the 
cells in which the mutated X chromosome is active and, therefore, cells in which 
the wild type X chromosome is active preferentially survive.  
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Conversely, in a study of a 72 year old female carrier of X-linked sideroblastic 
anaemia and her family[116], all of the female carriers demonstrated skewed 
inactivation in favour of the mutated X chromosome. The authors suggested this 
was the result of congenital skewing. The original patient only presented with 
symptoms at the age of 64, perhaps supporting a degree of age affected skewing. 
This, however, was a single family and only tentative conclusions may be drawn. 
It may also support the case for an inherited component of the X-inactivation 
process.  
This literature suggests that, in certain circumstances, X-inactivation is not a 
random process.  In XL-CGD there appears to be no selective survival advantage 
for phagocytes containing the mutated or wild-type gene, and it is assumed that 
the active X chromosome is selected randomly.  
2.6.3 Skewing in XL-CGD Carriers 
In CGD, cases of extreme skewing in female carriers have been reported.  Gono et 
al[117] described a Japanese female with a de novo mutation of CYBB with 
extreme skewing and a ratio of 93:7, with a corresponding DHR of 9.6% positive 
cells. She was diagnosed as a result of clinical features similar to CGD with 
refractory abscesses and recurrent stomatitis. A similar degree of skewing was 
seen in another female patient who presented with pneumonia caused by 
Aspergillus Fumigatus [74]. She presented at 16 years of age and had only 9.68% 
functioning neutrophils on DHR, which correlated with assessment from the 
HUMARA assay where the ratio was 96:4.Two further cases have been 
reported[82, 118] and both reported significant symptoms associated with the 
extreme skewing. In the case reported by Anderson-Cohen et al[118], the 
skewing was so extreme that, upon performing an NBT, only one population of 
neutrophils was demonstrated. However, further analysis revealed that this 
young woman was in fact a carrier of a de novo mutation in CYBB and had a 
skewing ratio of 99:1. She had significant symptoms with recurrent infection and 
abscesses.  
In Koker et al’s [59] study of three generations of XL-CGD carriers, the oldest 
carrier demonstrated a 35:65 ratio of skewing, but was not noted to be 
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symptomatic. All but one of the reported female XL-CGD carriers exhibiting 
extreme skewing suffered from significant symptoms. However, this may not 
reflect the XL-CGD carrier population as a whole, as these cases may not be 
representative of the XL-CGD carrier cohort. There may be asymptomatic women 
who have a similar degree of skewing, but who have not been investigated.  It is 
uncertain whether there is a correlation between the degree of reduction of NOB 
and the presence and severity of symptoms and their severity.  The association 
with increasing age is also unclear.  
2.7 Carriers of other X-Linked Disease 
Female carriers of other XL disorders have some degree of expression of the 
defective gene. Therefore, they may be at risk of manifesting symptoms. Whilst 
there is limited literature about XL-CGD female carriers, other XL conditions 
have been reported and information about XL carrier status may be extrapolated 
from these.  
Muscular Dystrophy (MD) is a well-studied example. MD is a genetic progressive 
muscle disorder caused by a defect in the dystrophin gene located on the X 
chromosome. Symptomatic carriers are reported in the literature. Carriers of 
Duchenne muscular dystrophy (DMD) exhibit manifestations of disease, ranging 
from subtle weakness elicited only by detailed neurological examination to 
clinical patterns identical to the disease itself [119].  More significant 
manifestations, such as sudden death due to cardiac abnormality, have been 
described in XL carriers of the rarer Emery-Dreifuss Muscular Dystrophy [120]. 
This occurrence, whilst unusual, is important as it shows carriers may suffer 
from disease manifestations, including the most significant manifestations.  
Female carriers of haemophilia A, in which there is a lack of functioning clotting 
factor VIII, have been found to have reduced factor VIII levels, when compared to 
non-carrier controls with considerable variability in the degree of 
reduction[121]. The reduction in factor levels does not appear to be clinically 
significant in the majority of cases, however, cases of severe haemophilia in 
manifesting carriers are described[122]. This further demonstrates that XL 
carriers may be affected by their carrier status. A similar finding has been 
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described in an XL carrier of Wiskott-Aldrich where the platelet count was 
reduced, although to a lesser degree than patients[123] with the disease.  
The molecular cause of symptoms in disease-manifesting carriers has been 
investigated. DMD XL carriers have variable degrees of dystrophin protein 
expression, but this does not correlate with clinical phenotype[124]. It has been 
assumed that the reason for manifestations within the DMD XL carrier cohort is 
skewed X-inactivation and extreme lyonisation, as outlined earlier. Small studies 
have added support to this argument. Yoshioka et al[125] found that 3 out of 
their 4 symptomatic carriers had greater than 70% skewing compared to only 
6% of the control group. However, as this was a small study, it is not possible to 
draw definitive conclusions. It has also been suggested that whilst measuring 
skewing in blood may correlate with other tissues, it may be important to 
consider measurement on the tissue of interest, in the case of MD, muscle cells 
[106]. 
In summary, there is literature to support the hypothesis that female carriers of 
XL disorders may suffer from similar clinical problems as the affected males, to 
varying degrees.  
2.8 Symptomology similarities between CGD, SLE and IBD 
The literature reviewed so far highlights that there may be some overlap 
between symptoms seen in XL-CGD carriers and other inflammatory conditions. 
In this section, I will review the pertinent literature about two such conditions; 
Systemic Lupus Erythematosus (SLE) and Inflammatory Bowel Disease (IBD).  
2.8.1 Systemic Lupus Erythematosus 
Many of the autoimmune features described in XL-CGD carriers are part of the 
spectrum of SLE.  This section will review some of the literature about symptoms 
and diagnosis of SLE, in order to be able to evaluate the overlap with the 
symptoms described in XL-CGD carriers.  
SLE is a multi-systemic autoimmune disease.   
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Risk Factors for Development of SLE 
The exact aetiology of SLE is uncertain, but several factors have been shown to 
be important in the development of this disease. A popular hypothesis is the 
exposure of susceptible individuals to trigger environmental factors leading to 
the development of disease [126-130].   
Epidemiological studies have shown a female predominance of SLE, with rates 
up to nine times more common in females [127]. Incidence and prevalence varies 
with sex and age. In England and Wales in 1982 the prevalence was 12.5 / 
100,000 women of all ages and 17.7 / 100,000 in women aged 15 to 64 years 
[128]. The prevalence in women aged 15 to 64 years was higher in a more recent 
UK study by Johnson et al where the prevalence was 27.7/100,000 [131].  
A significant ethnic variation has also been demonstrated. A higher incidence is 
seen in the African population and with individuals with African or Asian 
ancestry[127, 129]. Caucasians also have a predilection to milder disease 
compared with African patients [129].  
Genetics 
Genetic susceptibility has been shown with HLA-DQ and DR highly associated 
[132, 133] and recent insights demonstrate genetic variability may account for 
the different phenotypes seen in this heterogenous condition [132]. 
Due to the heterogenecity of the disease, risk factors and associations have 
frequently been sought.  
Environmental factors have been considered in the development of SLE. There 
have been mixed reports about the effect of cigarette smoking on the 
development of SLE. Some studies have found that smoking increases the risk of 
developing SLE and particularly the cutaneous manifestations[134], whilst other 
studies have found no link between cigarette exposure and SLE [130]. 
More unusual associations have also been evaluated to a greater and lesser 
extent. Burry et al’s study in the 1960s, attempting to explain the female 
predominance, found an association between the use of lipstick and SLE [126] 
but this has not been further supported. A further association was found when 
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an inverse relationship between alcohol consumption and the development of 
SLE symptoms was shown[135] in a cross-sectional study. However, it is likely 
that this represents a reduction of alcohol intake after diagnosis of SLE, rather 
than alcohol as a genuine protective factor.  
Infective triggers have also been hypothesised as a cause of SLE. The most 
compelling evidence is seen with EBV [133] which supports the genetically 
susceptible individual suffering a second hit hypothesis.  
Symptoms and Diagnosis  
Diagnosis of SLE is based upon clinical clusters of symptoms with accompanying 
biological markers. The American College of Rheumatology published case 
definition criteria in 1982 [136] which were subsequently updated in 1997. 
Table 2-1 shows the modified classification criteria. There is a wide spectrum of 
disease and diagnosis is generally accepted if more than 4 of the criteria are met. 
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Table 2-1: Modified 1997 ARA Criteria for SLE 
 Criteria Additional Description  
1 Malar rash Fixed erythema, flat or raised, over the malar 
eminences, tending to spare the nasolabial folds 
2 Discoid rash Erythematous raised patches with adherent keratotic 
scaling and follicular plugging 
3 Photosensitivity Skin rash as a result of unusual reaction to sunlight 
(history or observation) 
4 Oral ulceration  Oral or nasopharyngeal ulceration (usually painless) 
5 Arthritis Non-erosive arthritis involving two or more peripheral 






Convincing history of pleuritic pain or rub heard by 
physician or evidence of pleural effusion 
Pericarditis documented by ECG or rub or evidence of 
pericardial effusion 
7 Renal Disorder: 
Persistent proteinuria 
 
Cellular casts  
 
Proteinuria >0.5g/day or greater than +++ if 
quantification not performed 
Red cell, haemoglobin, granular, tubular or mixed casts 
8 Neurological disorder See Table 2-3 
9 Haematological disorder Haemolytic Anaemia with reticulosis 
Leucopenia <4000/mm3 total on 2 or more occasions 
Lymphopenia <1500/mm3 total on 2 or more occasions 
Thrombocytopenia <100,000/mm3 in the absence of 
offending drugs 
10 Immunological disorder Presence of Anti-DNA antibody, Anti-Sm antibody or 
abnormal serum level of IgG or IgM anticardiolipin 
antibodies 
A positive test for lupus anticoagulant 
A false positive serological test syphilis 
11 Antinuclear Antibody (ANA) Abnormal ANA titre by immunofluorescence or an 
equivalent assay at any time point in the absence o f 
drugs known to be associated with ‘drug induced lupus’ 
SLE is a heterogeneous disease and there is debate on going as to whether it 
remains a group of diseases or a single disease with a broad spectrum of 
manifestations[137]. Table 2-2 shows the prevalence of different symptoms in 
SLE patients in a large European cohort (1000 patients).  
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Table 2-2: Prevalence of SLE Symptoms in European Cohort 
 Euro-Lupus Cohort [129] 
Number (%) 
Malar Rash 311 (31.1) 
Discoid Lesion 78 (7.8) 
Photosensitivity 229 (22.9) 
Oral Ulcers 125 (12.5) 
Raynaud’s Phenomenon 163 (16.3) 
Arthritis 481 (48.1) 
Serositis 160 (16.0) 
Nephropathy 279 (27.9) 
Neurological Involvement 194 (19.4) 
Death 68 (6.8) 
Neuropsychiatric symptoms are also observed in SLE (NPSLE) and they are 
diverse and numerous. A summary of the features observed was published in 
1999 [138] and their findings are reproduced in Table 2-3. 
Table 2-3: Neuropsychiatric Features of SLE 
Central Nervous System 
 Aseptic Meningitis 
 Cerebrovascular disease 
 Demyelinating syndrome 
 Headache (including migraine and 
benign intracranial hypertension) 
 Movement Disorder (chorea) 
 Myelopathy 
 Seizure Disorder 
 Acute confusional state 
 Anxiety Disorder 
 Cognitive Dysfunction 
 Mood Disorder 
 Psychosis 
Peripheral Nervous System 
 Acute inflammatory 
demyelinating polyradiculopathy 
(Guillain-Barré Syndrome) 
 Autonomic disorder 
 Mononeuropathy 
 Myasthenia Gravis 
 Neuropathy, cranial 
 Plexopathy 
 Polyneuropathy 
Included in the manifestations of NPSLE are mood disorder and anxiety disorder 
which are neither specific to SLE, nor are they limited to SLE, highlighting the 
broad range of symptoms observed and difficulties differentiating between 
NPSLE and other psychological disease processes. The proportion of patients 
with SLE with NPSLE symptoms ranges from 20 to 50%[139].  
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Features outside of the core diagnostic criteria are also commonly seen in SLE. 
Fatigue has been reported as a predominant symptom in SLE. Up to 80% of SLE 
patients report fatigue as a significant complaint [127, 140, 141]. Fatigue is also 
reported as significant in patients in whom their lupus was otherwise considered 
quiescent [140], although there has been correlation demonstrated between 
degree of fatigue and level of disease activity.  
Gastrointestinal symptoms are also reported in SLE patients [142]. However, 
these symptoms are usually attributed to an infective cause or the result of an 
adverse drug reaction. A study of 105 female patients with SLE in 2013 
demonstrated that up to 50% of these women met the Rome Criteria for a 
diagnosis of IBS [143], which was associated with reduced HRQoL. 
Gastrointestinal symptoms do not form part of the diagnostic criteria for SLE, but 
appear to be prevalent in the SLE population and impact upon quality of 
life[144].  
There is considerable overlap with SLE and anti-phospholipid syndrome (APS), a 
syndrome in which individuals suffer thrombosis (arterial and venous) and may 
also suffer spontaneous abortion[145]. It is classically associated with the 
presence antiphospholipid antibodies.  Recurrent miscarriage is seen in patients 
with APS, both with and without associated SLE [146]. 
The presence of APS, alongside SLE, results in a significantly increased risk of 
morbidity and premature death[127]. In SLE there is also an apparent increase 
in cardiovascular risk, which is separate to classical risk factors for heart 
disease[127, 129] and accounts for some of the early mortality seen in SLE 
patients.  
Natural History of SLE  
The clinical course of SLE is one of relapsing and remitting nature with acute 
episodes of flare. Outcome is extremely variable with permanent remission to 
early death reported. Survival of patients with SLE is improving and a recent 
review highlighted that the survival rate has increased significantly over the past 
40 years, with a five year survival rate of 93% compared to the 50% seen in the 
1950s[129]. 
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Autoantibodies in SLE  
Autoantibodies form part of the diagnostic criteria of SLE (Table 2-1). They may 
be present before the onset of symptoms[129], but may also be positive in the 
healthy population [147, 148] highlighting their lack of specificity.  The positive 
predictive value (PPV) of ANA at a titre of 1:640 was 6% in one retrospective 
American study of 232 patients referred for a positive ANA result [149].  
Autoantibodies are not only important in the detection and assessment of SLE, 
they may also play a direct role in the pathogenesis of the disease. The 
pathogenesis of SLE has not been completely elucidated, but there is increasing 
evidence supporting the hypothesis that organ damage is mediated by immune 
complexes [150]. Lupus nephritis is one of the clearest examples of this with IgG-
complex deposition leading to early disease [150] 
The role of autoantibodies in the development of NPSLE has been demonstrated 
in murine models. When anti-ribosomal antibodies were injected into mice, the 
mice developed depressive symptoms [151]. When anti-dsDNA antibodies were 
injected directly into the mouse brain, these mice developed problems with 
cognition and associated emotional disturbances [152]. Both these studies 
support the pathogenic role of autoantibodies in the development of SLE 
symptoms.  
A Japanese study of 597 health hospital workers found up to 20% of healthy 
volunteers were reported to be Antinuclear Antibody (ANA) positive [153]. 
However, the difficulty when assessing healthy individuals is that the follow-up 
time is often insufficient. As it is known that ANA may be positive years before 
the onset of clinical symptoms, the follow-up on healthy controls recruited to 
studies would need to be many years (and ideally lifelong) in order to be certain 
they did not develop symptoms and this is seldom the case. Despite this 
difficulty, there still appears to be compelling evidence that there may be a high 
level of autoantibody positivity in individuals without apparent symptoms.  
Dellavance et al [154] in 2005 evaluated 10,000 samples which were positive for 
anti-DFS70 ANA (dense, fine speckled antigen) and found that whilst they were 
common in those with autoimmune disease, particularly thyroiditis, they were in 
fact more common in those without any features of autoimmune disease. There 
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was a four-year follow-up of healthy individuals in this study. A more recent 
study by Mariz et al [155] confirmed this finding when they found that the dense 
fine speckled pattern was seen in 33% of ANA positive healthy individuals 
compared to none of the ANA positive individuals with autoimmune diseases.  
Measurement of Autoantibodies 
There are a number of techniques that may be used to detect the presence of 
autoantibodies. Immunofluorescence (IF), ELISA, and immunoblot are three of 
the most commonly used. The ARA still recommends the use of IF as the 
screening tool for ANA positivity [156]. 
 The degree of positivity is usually quoted as a titre. The level at which a titre is 
decided as positive is laboratory-dependant. 
An American study in 2013 [149] evaluated 227 patients who had been referred 
to a rheumatology service with a positive ANA result. The positive predictive 
value (PPV) of a positive ANA for a diagnosis of a defined ANA associate disease 
when the tire was 1:40 was less than 10%. When the titre accepted as positive 
was increased to 1:640 the PPV rose to 26.9%. No patients with a positive ANA at 
less than 1:640 had an ANA associated disease at the time of the study, 
suggesting that the clinical significance of a positive ANA at lower titres is at best 
uncertain, and at worst unhelpful.  
2.8.2 Inflammatory Bowel Disease 
Inflammatory Bowel Disease (IBD) is a term encompassing Crohn’s disease (CD) 
and ulcerative colitis (UC). CD has an incidence in the UK population of 
approximately 4 per 100,000, whilst UC is more common with an incidence of 10 
per 100,000 [157]. Onset of IBD is usually in late adolescence or early adulthood 
(around 15 to 30 years). Presenting symptoms are similar to CGD colitis with 
abdominal pain, diarrhoea and rectal bleeding all prominent.  
Extra-gastrointestinal manifestations are also described. Arthritis, particularly 
ankylosing spondylitis and large joint involvement [158] has been seen and 
fatigue is described in both active disease and in patients in remission [159]. 
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Ocular manifestations such as uveitis[158] are also part of the disease, 
demonstrating IBD may affect multiple systems.  
Histological findings in CD and UC differ. In CD there is transmural inflammation 
with granuloma. This may affect any part of the intestine and the inflammation 
may not be continuous with classical skip lesions leaving some areas spared. UC 
may affect any part of the colon, but typically favours the rectum and the 
inflammation is continuous but limited to the mucosa. The presence of 
granuloma in CD has led to difficulties in distinguishing CD and CGD-related 
colitis. As already considered histopathologically and clinically IBD and CGD-
colitis may appear very similar.  
Genetics 
The exact aetiology of IBD has not been completely elucidated but the overriding 
hypothesis is that there is abnormal immune response to normal gut 
commensals in those with a genetic predisposition, which results in chronic 
inflammation [160].  
IBD appears to have a polygenetic basis and genetic susceptibility has been 
demonstrated in family studies, which have led to the discovery of predisposing 
gene loci.  Recent advances in genetic techniques have identified new loci 
associated with IBD.  Genes associated with UC and CD have been identified in 
the interleukin-23-Th17 pathway (such as STAT3, IL23R and IL12B), the innate 
immune responses (such as NOD2) and also in other regions (such as MHC) 
[161]. Further loci continue to be identified. Further to this, genes have been 
identified which put the affected individual at greater risk for having a 
complicated disease course including the development of fistulae and stenosis. 
Any of the NOD2 variant alleles and also JAK2 have been shown to confer this 
risk [162].  
Neutrophils and IBD 
An association of CD and leucocytes was described as early as the 1970s [163].  
Impaired neutrophil function, albeit with normal NBT reduction, has been found 
in Crohn’s patients when compared to healthy controls [92]. No patients or XL-
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CGD carriers were found, but this finding highlights the close relationship 
between neutrophil dysfunction and inflammation, particularly within the 
gastrointestinal tract.  
Neutrophil dysfunction has also been associated with IBD in glycogen storage 
disorders [164, 165] further highlighting the, as yet, incomplete understanding 
of the interplay between neutrophils and gut disease.  
NADPH Oxidase and IBD 
The NADPH Oxidase complex’s role in CGD has already been described. Given the 
similarities between CGD colitis and IBD, the role of NADPH oxidase has been 
evaluated in CD patients. An early study of 43 patients found there was 
diminished H2O2 production, although preserved O2- production, in untreated CD 
patients compared with a control group [166]. There was a significant negative 
correlation between H2O2 production and assessment of disease activity and 
H2O2 was normalised in treated CD patients. This highlights the potential similar 
pathogenesis in IBD and CGD colitis, as failure to clear foreign matter results in 
granuloma production.  
A more recent study by Muise et al [167] further evaluated the link between the 
NADPH oxidase complex and IBD. The aim of this study was to establish if the 
NADPH oxidase components are important in the development of IBD. The 
authors were able to draw several important conclusions. Firstly, they identified 
novel mutations in NCF2, which encodes p67phox, which were associated with 
very early onset IBD but without evidence of immunodeficiency. NCF2 is known 
to cause autosomal recessive CGD. Secondly, they found mutations in NCF4, 
which encodes p40phox and is a very rare cause of AR-CGD, were strongly 
associated with ileal CD, but again without evidence of immunodeficiency. 
Finally, they identified a novel mutation in RAC2, associated with CD. RAC2 plays 
an important role in NADPH oxidase activation.   
In summary, associations between defects in the NADPH oxidase complex and 
the development of IBD have been proven, thus highlighting the overlapping 
nature of IBD and CGD, and perhaps offer a potential reason why XL-CGD 
carriers may be at similar risk of bowel disease.  
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Microbiota 
Whilst an infectious cause of gastrointestinal involvement in CGD has not been 
proven[37], disturbance of the gastrointestinal normal flora has been 
hypothesised to be involved in the pathogenesis of IBD. Subsequently, evaluation 
of the microbiota has been considered to be a potentially non-invasive insight 
into affected individuals. The normal flora of the GI tract in paediatric patients 
with IBD was examined in a large cohort [168]. Significant differences were 
found in the microbiota of the gastrointestinal tract in patients with IBD when 
compared to age-matched controls. The value of this is in both diagnostic utility 
and potentially aiding understanding of the pathogenesis of gastrointestinal 
disease. This has not been evaluated in CGD patients, but the clinical and 
pathological overlap suggests that there may be similar findings.  
2.9 Fatigue 
Fatigue is a commonly used term in both medical and non-medical settings. It is 
an instantly recognisable feeling, yet defining fatigue in a clinical or research 
setting proves difficult. This is due to the complex range of mental and physical 
symptoms it includes.  
Fatigue encompasses a broad range of symptoms. It may be used to describe a 
sensation of mental or physical tiredness, a lack of motivation to participate in 
activities or lack of energy to complete activities of daily living or simply the 
feeling of being ‘washed out’. It may also be used to describe abnormalities of 
sleep including insomnia, failing to be refreshed from sleep or disturbed sleep.  
The need to define fatigue is important in both clinical and research settings.   
Van Langenberg defined fatigue as ‘a persistent, overwhelming sense of 
tiredness, weakness or exhaustion resulting in a decreased capacity for physical 
and/or mental work’[169]. However fatigue is formally defined, the importance 
is to distinguish abnormal fatigue from everyday, transient tiredness that affects 
all individuals. The features differentiating abnormal fatigue are the 
overpowering nature causing it to impact upon daily activities, including, but not 
exclusively, ability to work or perform simple tasks. The other crucial difference 
is the persistent nature.  
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Although fatigue may be difficult to define and considered by some as an 
indistinct entity, its importance to patients should not be underestimated as it 
represents a significant problem to some individuals. Fatigue is often described 
by patients as debilitating, distressing, and even overwhelming. In the 1980s, a 
study in IBD patients showed they considered fatigue to be as significant a 
symptom as abdominal pain and diarrhoea [170]. Studies in other autoimmune 
disorders such as Rheumatoid Arthritis (RA) [171] and ANCA-associated 
vasculitis [172] have corroborated these findings. Not only has it been identified 
as a significant symptom, fatigue has been shown to impact upon health related 
quality of life (HR-QoL)[171, 173] reinforcing its significance to the patient.  
There is controversy over whether fatigue should be viewed as a unique entity or 
whether is solely a response to an underlying symptom such as pain or 
psychological co-morbidity. Fatigue is perhaps best conceptualised as a 
multidimensional model with physical, cognitive and affective components all 
contributing to the sensation experienced. Individual components may be 
affected differently in different individuals. This model of fatigue is progressively 
being more accepted. Figure 2-1 illustrates how the three components interlink.  
Figure 2-1: Conceptualisation of the Multidimensional Model of Fatigue 
A small qualitative study by Glaus et al [174] demonstrated that fatigue was 













highlighting that fatigue is more complex than simply present or absent; there is 
a qualitative aspect to the sensation.  
Physical factors contributing to the development of fatigue may include pain, 
anaemia and symptoms of a specific disease process. Pain can be used to 
illustrate the multidimensional model. Pain may contribute directly to the 
sensation of fatigue but also through disturbance in sleep, anxiety or low mood 
associated with not being able to function at the desired level. If pain is the only 
symptom, then removal of pain through effective analgesic agents or treatment 
of the cause should resolve the fatigue. Where pain improves, but fatigue 
persists, this evidences the presence of fatigue as an independent symptom, 
which may be affected by other factors, but exists independent of them. The 
same is true of other physical symptoms including anaemia where the associated 
feeling of lethargy may improve with treatment or may persist despite 
biochemical makers showing resolution of anaemia and confirming the presence 
of fatigue. In a study of IBD patients, fatigue was present in 40% of patients who 
were defined as being in clinical remission [175] strengthening the argument 
that fatigue may exist in the absence of physical symptoms.  
Cognitive consequences of fatigue include inability to concentrate and poor 
working memory. In addition, psychological factors may contribute to fatigue. 
Biological symptoms of severe depression include disturbed sleep. Therefore, 
reports of fatigue may be directly due to depression or mental health complaints. 
Equally low mood and a lack of motivation may be part of fatigue in the absence 
of overt depressive symptoms and they may not correlate.   Symptoms may be 
interlinked, but the origin of the symptoms remains important in order to 
identify and ultimately treat the cause. Fatigue may lead to depressive symptoms 
rather than all fatigue being the result of psychological co-morbidity.  
2.9.1 Assessment of Fatigue 
As already discussed, definitions of fatigue often lack specificity and the desired 
scientific certainty. Subsequently assessment of fatigue provides a significant 
challenge. Ideally, assessment of fatigue would include both subjective and 
objective components. Formal assessment must attempt to overcome the 
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imprecision of definition.  Self-assessment of fatigue as with all symptom 
assessment is likely to be affected by recall bias, whilst physician assessment is 
likely to be an underassessment.  
The simplest assessment method is by asking the patient directly about their 
degree of fatigue. The disadvantage of this is the lack of reproducible 
quantification.  Hence, to reliably and consistently assess and quantify fatigue, 
standardised questionnaires have been derived.  
Initial attempts to assess fatigue were unidimensional with scales such as the 
Fatigue Severity Scale (FSS) being introduced to assess fatigue in conditions 
including SLE [176], chronic hepatitis C [177] and immune-related 
polyneuropathies[178]. The appreciation of the multidimensional nature of 
fatigue as shown in Figure 2-1 has led to the realisation that when assessing 
fatigue it is necessary to incorporate all dimensions; physical, cognitive and 
affective. Fatigue has also formed part of questionnaires about quality of life 
including in the SF-36.  
Multidimensional assessment scales were developed to reflect this change in 
understanding and to address the qualitative as well as quantitative aspects of 
fatigue. These scales began to dominate in the late 1990s and early part of this 
century [179] and validation of them in both generic terms and in disease 
specific situations is on-going.   
Disease specific tools have also been developed. The disadvantage with this is 
that they are not generalizable and subsequent comparisons with other patient 
groups are not possible. They also focus on disease specific aspects, which may 
not be the sole contributing factor to any fatigue. Therefore, they may be an 
inaccurate overall representation of the fatigue suffered.  
The large number of questionnaires to assess fatigue implies a lack of consensus 
over how to define fatigue and subsequently how to assess it. This uncertainty 
was highlighted in a systematic review in 2007. Hjollund et al found there were 
252 different patient self report scales for fatigue published between 1975 and 
2004 [179]. Of these 252 different scales, 150 had only been used once, making 
judgements about reproducibility and reliability virtually impossible.  
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Correlation of fatigue assessments with assessment of other symptoms including 
psychological features may help to establish the predominant feature. If an 
alternative diagnosis such as depression is present, this must be considered 
when interpreting any assessment as outcome and treatments will be different.   
2.9.2 Fatigue and the General Population 
Evaluation of fatigue as a symptom in the general population reveals that it is a 
relatively commonly reported problem. In one study in the UK, 10.6% of women 
reported excessive fatigue [180] lasting over a month. A community based UK 
study of 15,283 responders (31,651 contacted) revealed even higher rates of 
fatigue with 18% reporting excessive fatigue lasting longer than 6 months [181]. 
Despite the large size of that study, there was only a 50% questionnaire return 
rate making it difficult to interpret the findings. However, this confirmed other 
reports[180] that women were more like to report suffering from fatigue than 
men. A greater number of women suffered from psychological disorders, but the 
authors were not able to establish the exact nature of this relationship and 
suspect that the two overlap rather than have a strict causative link.  
It has also been shown that age plays an important role in fatigue levels with a 
linear relationship being reported[182]; as age increases so do fatigue levels.  
2.9.3 Fatigue in Chronic Illness  
As demonstrated by the large of number of fatigue assessment tools, interest in 
fatigue in the context of chronic illness has dramatically increased over the past 
twenty years. Whilst there is very little literature about XL-CGD carriers and 
fatigue, there is a large body of literature about chronic illness and fatigue. This is 
perhaps in part due to the weight the symptom is given by patient groups. 
Fatigue is often reported to be of greater significance than other symptoms 
including pain and has been shown to have a negative effect on quality of life 
[171, 172]. Some of this literature will be reviewed in this section.  
Fatigue is repeatedly described as a significant and prominent feature of 
autoimmune disease and chronic inflammatory conditions, particularly in 
rheumatoid arthritis (RA) [171], sarcoidosis [182], IBD[170, 173, 183, 184], 
multiple sclerosis [185] and primary biliary cirrhosis [186].  
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Fatigue is reported in approximately half of IBD patients[183] of whom many 
suffer from chronic fatigue [173, 175, 184] and at greater rates than the general 
population [173]. 
The presence of fatigue in chronic conditions is important for several reasons. 
Firstly, fatigue is defined by patients as a significant problem and often, 
surprisingly, is the most severe problem they suffer. In one study of 116 patients 
with PBC, 85% reported suffering from fatigue and in half of these patients it was 
reported to be the worst or one of the worst symptoms they suffered [186] 
clearly highlighting the impact of the symptom. This is a similar rate to that 
reported in sarcoid where rates exceeding 70% are reported[182].  
Secondly, fatigue has been found to adversely affect health related QoL (HRQoL). 
A reduction in all domains of HRQoL was shown in IBD patients suffering from 
chronic fatigue [173, 184]. This was also found in a study of PBC patients where 
fatigue impacted upon QoL[186]. Fatigue has also been shown to be an 
independent factor in HRQoL of IBD patients [175] and in sarcoid patients[187]. 
Finally, it is currently not well treated and represents a domain to which 
treatments should be targeted.  
2.9.4 Factors Affecting Fatigue 
There appears to be a lack of consensus about the most important factors 
affecting fatigue in chronic illness and it is likely that the aetiology of fatigue is 
multifactorial. It would seem logical to suspect that disease activity may impact 
upon fatigue levels.  
Disease Activity 
Disease activity may be important in the presence of fatigue, but it maybe 
difficult to distinguish definite clinical activity with subclinical disease in many 
situations.  
A large study of 425 IBD patients found that fatigue levels were significantly 
higher in patients with active disease compared with those in clinical remission 
[183]. This finding has been corroborated with two smaller studies in 2011 
showing higher rates of chronic fatigue in patients with active disease [173, 184].  
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Surrogate markers of disease activity may also be used in an attempt to correlate 
with fatigue levels. For example, Michielsen et al[187] found that sarcoid 
patients using corticosteroids had higher levels of fatigue than those who did not 
perhaps reflecting those with more active disease.  
Whilst disease activity has been shown to correlate with fatigue levels, there 
remains uncertainty about the nature of the link. In IBD patients, fatigue was still 
present at high levels in patients deemed to be in remission [175] with 40% 
reporting high fatigue. This was a large study of 707 patients, suggesting other 
factors may play an important role or that there may be a cumulative or delayed 
effect. The lack of correlation with disease activity was also supported by a study 
of 116 patients with primary biliary cirrhosis (PBC) where there was no 
association with disease severity and fatigue levels [186]. However, this study 
differs from studies of other diseases, as it was predominantly women (89%), 
which may have impacted upon the fatigue levels reported.  
Reversible causes such as anaemia may be assumed to impact on fatigue levels, 
but this was not the case in Bager et al’s [183] study of IBD patients where there 
was no correlation with overall fatigue and anaemia except in a very small subset 
of patients. Conversely Romberg-Camps found that anaemia did impact on both 
fatigue and HRQoL[175].  
Psychological Co-Morbidity 
Many studies have not measured or looked for depression when examining 
fatigue, which makes it difficult to examine the link between them. Huet et 
al[186] were surprised to discover that when they screened 116 patients with 
PBC, 85% of whom reported fatigue, 50% met the criteria for a diagnosis of 
depression. They were unable to evaluate the direction of the association.  
Two studies in rheumatoid arthritis found that there was significant correlation 
between fatigue and depressive symptoms [188, 189]. However, again it is 
difficult to be certain of the direction of the association. 
Psychological co-morbidity does not appear to account for all fatigue described 
in chronic illness. Basu et al[172] studied patients with ANCA-associated 
vasculitis and found that whilst there was greater fatigue in those suffering with 
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mood disorder, this did not account for all those suffering with fatigue thus 
suggesting an alternative mechanism.  
Demographic Factors 
Age has been shown to be an important determinant in fatigue levels, 
irrespective of disease, with younger patients (defined as less than 60 years) 
suffering greater fatigue. This was demonstrated in IBD [183].  
 Age also appears to be an important factor in the reporting of fatigue in sarcoid 
patients. A Dutch study [182] demonstrated that the greatest differences 
between the general population and patient cohort were seen in young patients 
(less than 60 years), who reported the highest levels of fatigue.  Age has not 
always been found to be a significant finding particularly in smaller studies 
[184]. 
Being female has been associated with greater fatigue both in patient groups 
including IBD [175, 183], sarcoidosis [182, 187] and in the general 
population[180, 181]. However, gender has not always been found to be a 
significant contributor when assessing fatigue[184]. 
Employment status has also been shown to impact upon fatigue levels, with 
those who are unemployed reporting higher rates of fatigue that those in any 
type of employment[182]. This relationship may be bidirectional.  
In summary, fatigue appears to be a relatively common problem both in the 
general population and more so in chronic disease. The literature about fatigue 
in chronic illness highlights that it is a highly prevalent and important symptom. 
Fatigue also appears to adversely impact upon self reported HRQoL in 
individuals with chronic illness. There is some evidence to suggest fatigue may 
be associated with disease activity, although this is not always the case and 
assessment of disease activity may sometimes be difficult. Fatigue appears to be 
more prevalent in younger patients and in women.  
2.9.5 Inflammation and Fatigue 
As evidence accumulates to support the presence of fatigue as an independent 
symptom, interest is increasing in causation. The presence of fatigue in chronic 
 58 
inflammatory conditions, as discussed in the previous sections, suggests an 
intrinsic inflammatory mechanism. Evidence from clinical observation supports 
this.  
In chronic inflammatory conditions where fatigue has been studied, it has been 
found that there are higher levels of fatigue when disease is active as opposed to 
clinical remission, for example in IBD[173] and that disease severity correlates 
with fatigue levels [175]. This may suggest that greater levels of inflammation 
lead to greater fatigue.  
However, fatigue has also been found in 40% of [183] patients with IBD when 
they are in clinical remission. Van Langenberg puts forward a popular hypothesis 
in his review of fatigue in IBD that this may be due to on-going subclinical 
inflammation[169] as clinical remission in IBD does not always correlate exactly 
with microscopic resolution. The patient may report no gastrointestinal 
symptoms, but mucosal healing of the gut may not be complete despite apparent 
resolution of symptoms.  This may explain the persistence of fatigue even when 
other symptoms have improved as there may be on going inflammation.  
Further clinical evidence supporting an inflammatory process causing fatigue 
can be found from the use of anti-TNF agents in patients with rheumatoid 
arthritis and Crohn’s disease. When patients with rheumatoid arthritis were 
treated with the anti-TNF agent adalimumab, fatigue improved[190]. It is 
possible that this improvement is the result of the anti-inflammatory effect of 
adalimumab.  
Pro-inflammatory cytokines have been studied with regards to causation of 
fatigue and appear to support an inflammatory mechanism in the development 
of fatigue. Cancer patients have reported fatigue as a significant symptom[174]  
and research into this cohort of patients has been undertaken. Raaf et al [191] 
found that patients with advanced cancer had significantly higher fatigue scores 
in both physical and mental domains. Physical fatigue was associated with 
significantly higher levels of the pro-inflammatory cytokines IL-6, IL-1ra and 
neoplerin. However, this was not replicated with mental fatigue, where only IL-
1a was significantly associated with greater fatigue, perhaps suggesting slightly 
differing mechanisms. 
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IL-6 has been implicated in sleep regulation and fatigue as well as chronic or low 
grade inflammation and also plays a crucial role in the interaction between the 
immune system and central nervous system[192]. Further to this blockade of IL-
6 by tocilizumab has been shown to reduce fatigue in patients with rheumatoid 
arthritis[192, 193], although improvement in other symptoms including pain, 
may account for some of the improvement seen in fatigue.  
Conditions outside of rheumatoid arthritis have also found a correlation between 
IL-6 and fatigue levels. In Primary Sjogrens Syndrome, where patients report 
fatigue as an important symptom[194], levels of IL-6 have been found to be 
raised in tears, saliva and blood of patients[195], although these have not always 
correlated directly with fatigue scores [196]. 
Bower[197] reviewed their own and other data about fatigue in cancer patients, 
and specifically those undergoing radiotherapy. They found that cancer patients 
who suffered from fatigue had higher serum levels of the pro-inflammatory 
cytokines IL-1 and IL-6 during radiotherapy treatment and that this was 
correlated with the degree of fatigue reported by patients. Further work by 
Bower et al[198] did not corroborate this finding, as there was no association 
between IL-1, IL-6 and fatigue in post radiation cancer patients. However, they 
did find an associated rise in CRP and IL-1 receptor antagonist suggesting that 
there was a role for systemic inflammation.  
IL-8 is a pro-inflammatory cytokine. One of the major functions of IL-8 is as a 
chemoattractant with a particularly strong propensity for neutrophils[199].  IL-8 
has been implicated in fatigue.  Sorenson et al [200] studied patients with 
chronic fatigue syndrome (CFS) and compared them to healthy controls and 
fatigued controls who did not meet the criteria for CFS. IL-8 was significantly 
raised in both fatigued groups compared to the healthy controls. In the CFS 
group, IL-8 levels were higher than those in the fatigued, non-CFS group, 
correlating with higher levels of reported fatigue.  
Whilst the findings may not be consistent, there is a consistent message that 
there is an inflammatory aetiology to the fatigue suffered by patients with 
chronic disease and cancer. Pro-inflammatory cytokines appear to play an 
important role.  
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2.9.6 Fatigue and XL-CGD Carriers 
Cale et al [69] commented in their study of 19 XL-CGD carriers that excessive 
fatigue was reported, but there was no quantification of this or further 
information available.  
In summary, female carriers of XL-CGD may be at risk of fatigue for many of the 
reasons discussed in this section. Potentially, XL-CGD carriers are at risk of 
fatigue for a number of reasons: a potential inflammatory process, manifestation 
of SLE or associated with being a carer for children with a chronic disease in 
some cases. There is little research into the presence or causation of fatigue in 
XL-CGD carriers and this requires further investigation. 
2.10 Psychological Health 
There are many factors that may impact upon the psychological health of XL-CGD 
carriers, but there is no published literature specifically about this group. Factors 
that may impact upon the psychological health of XL-CGD carriers include being 
a caregiver for a child with chronic illness, genetic guilt, the presence of anxiety 
and depressive symptoms and potential ill health themselves.  Whilst there is no 
literature specifically about XL-CGD carriers in this area, there is literature from 
other conditions, which may be extrapolated to be relevant to XL-CGD carriers. 
This literature will be reviewed in this section.  
2.10.1 Caring for a Child with a Chronic Condition  
There is no literature about the impact of having a child with CGD on parents. 
However, there is a growing body of literature about the psychological effects of 
care giving. Since many XL-CGD carriers are confirmed following the diagnosis of 
CGD in their relative and often a son, many known XL-CGD carriers are caring for 
at least one child with a chronic illness. Subsequently, one contributing factor to 
the psychological health and quality of life (QoL) of XL-CGD carriers may be the 
impact of care giving.  
Children with a PID have higher rates of psychosocial difficulties including 
emotional and behavioural problems [64, 201]. What is less clear is the impact 
their diagnosis has on their parents and specifically mothers.  
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It can be anticipated that caring for a child with a chronic illness increases levels 
of stress.  It is less clear what the impact on other markers of psychological 
health including the presence of anxiety and depression may be. Barlow et 
al[202] demonstrated that having a child with a chronic condition impacted 
upon the psychological health of the family and this has been shown to impact 
upon the health outcomes of the child[203]. 
Studies examining the impact on parents of a child with PID have focussed on 
those in which the patients have undergone HSCT. McdDowell et al [204] 
performed a qualitative study examining parental stress and perceptions at 1 
year post-HSCT. The themes highlighted showed that caring for a child with a life 
threatening illness unsurprisingly increased perceived stress. These feelings of 
isolation and uncertainty seemed to persist after transplant. However, the 
parents did not appear to have clinical levels of psychological distress including 
mood. This was a small study of only four couples. There may have been an 
element of selection bias with those recruited being the ones who were 
motivated to respond to the invitation, as they felt they had suffered distress. It 
was not designed to provide generalisable answers, but simply to draw out 
themes. No formal assessment of levels of anxiety and depression were made 
and degree of distress was not quantified, but it does suggest that caring for a 
child with a life limiting condition, particularly during HSCT, may impact upon 
psychological health.  
A Dutch study [205] evaluated parental stress following HSCT for malignant 
disease and primary immunodeficiency. They found that, whilst mothers were 
more prone to general stresses even five years after their child’s HSCT, they did 
not report higher stress scores when compared with reference groups. The 
parents were described as resilient and mothers of children with non-malignant 
disease suffered less stress than the malignant disease group. This perhaps 
conflicts with the McDowell study [204] where the higher levels of stress had 
persisted and it may suggest factors outside of HSCT may play an important role.   
Manne et al [206]showed that maternal age may also contribute to the degree of 
distress, with younger mothers suffering from higher rates of distress compared 
with older mothers.  
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These studies have focussed on HSCT, which is an acute event requiring intense 
medical treatment and prolonged hospital stay. Not all children with CGD will 
have undergone HSCT and it is important to evaluate the stresses of caregiving in 
everyday life, rather than solely during the acute period of HSCT. As previously 
stated, there is little about parental stress in PID outside of HSCT. To further 
evaluate the impact of caring for a child with a chronic illness, information from 
conditions outside of PID will now be examined.  
Caregivers in muscular dystrophy (MD) have also been studied. A recent study 
from the US looked at 1238 women caring for someone with MD (either 
Duchenne MD or Becker MD)[207]. The authors found that, despite high levels of 
resilience in nearly 90% of the women, the rates of significant psychological 
distress were considerably higher in the caregivers than would be found in the 
general population. However, they also identified protective factors, i.e. factors 
associated with lower stress levels, including good family support and a higher 
income, which perhaps suggests that, whilst psychological distress is common, it 
is not inevitable in carers of children with chronic conditions. This was a large 
study, but the authors acknowledged that ethnic minorities may have been under 
represented due to the method of recruitment and that subsequently 
psychological distress may be under reported. However, the principles remain 
true and to extrapolate data for the UK, where there are far fewer Hispanic 
residents, is still possible.  
Genetic guilt may account for some of the psychological distress seen in the 
carers of genetic disorders. If this were the main cause, one would expect to see 
lower levels of distress in conditions where there is not such definitive 
inheritance. This does not appear to be true. A study published in 2013 of 
paediatric IBD patients and their parents found that there were high levels of 
caregiver stress [208]. The highest levels were seen where the disease was most 
active. Disease severity was also important in the MD study where, once children 
became non-ambulant, distress seemed to increase [207]. This again highlights 
the many factors that may contribute to distress in caregivers. It is not only 
severity of disease that influences the degree of distress for caregivers. Pain has 
been shown to be one of the most difficult aspects of care for caregivers when 
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Sickle Cell Disease (SCD) was studied[209]. A small scale study of SCD and HIV 
caregivers corroborated the findings in other disease with high rates of 
depressed mood in the caregivers of the SCD and HIV patients. The rates were 
higher than in parents of healthy children who recruited as controls. 
Interestingly, this study identified that the amount of time perceived to be spent 
caring also impacted on psychological distress, but that time spent caring did not 
equate to severity of disease. Nereo et al [210] also highlighted that stress levels 
are not constant and, in their study of MD caregivers, were highest at time of 
diagnosis. This may suggest that caregivers adjust to a diagnosis and that the 
stresses may decrease as time goes on making time since diagnosis an important 
factor.  
Caregiving is not restricted to looking after children. Studies have also evaluated 
caregivers caring for adult patients. One such study evaluated 100 caregivers of 
patients with brain tumours. All patients and caregivers were over 18 years of 
age. This study demonstrated that the carers had reduced quality of life and 
particularly in the mental health domain. They also suffered from greater levels 
of anxiety and depression than would be expected for the general 
population[211]. The authors suggested that one possible cause for the higher 
anxiety levels relates to fears about supporting the family alone and performing 
unfamiliar domestic tasks. This reflects that the majority (66%) of participants 
were a spouse or partner. This may therefore not be reflective for mothers and it 
is therefore, difficult to extrapolate too much from adult based studies.  
Assessment and quantification of the stresses of having a child with a chronic 
illness will be discussed in the next chapter.  
In summary, overall the literature about caregiving suggests that caring for 
someone with a chronic illness increases general stress levels. However, 
psychological health and well being is not solely dependent on this, with other 
factors playing an important role. Psychological distress has important 
implications for the carer, the patient and the family as a whole. 
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2.10.2 Anxiety and Depression  
Anxiety and depression are two distinct but overlapping entities. They include a 
range of biological and psychological symptoms, including low mood, sleep and 
appetite disturbance and difficulties in functioning in daily activities.  
The aetiology is uncertain but there are known to be contributing and protective 
factors. Female gender, a family history and significant loss at a young age are all 
known to predispose individuals to psychological ill health[212]. Support 
networks including family may be protective.  
Chronic illness is associated with higher rates of anxiety, depression and 
psychological distress. For example, in SLE mood disturbance forms part of the 
diagnostic criteria [139] and in conditions such as RA and IBD there are high 
rates of depression [213, 214]. CGD patients specifically have been demonstrated 
to have more emotional and behavioural problems than the general UK 
population [64]. 
The exact pathophysiological origin of depressive symptoms and diseases 
remains uncertain. Why some individuals appear to be more vulnerable suggests 
that there are factors out with external forces that are of importance.  
A biological explanation has long been looked for. Increasingly a role for an 
immune modulated or inflammatory cause has been hypothesised.   
Evidence from animal models supports the possibility for an inflammatory cause. 
When inflammatory agents are injected in to mice, sickness behaviour is induced 
which resembles depression with the mice demonstrating the core biological 
symptoms including anhedonia, poor appetite and sleep disturbance [151, 215]. 
Van Gool et al[216] reported that when human subjects were given IFNα, 45% 
reported depressive symptoms.  
Further support for an inflammatory or immune modulated cause of depression 
is found by the observation that an increase in production of pro-inflammatory 
cytokines is associated with depression, in particular levels of IL1β, IFNγ and 
TNFα[217].  
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The presence of depression in association with chronic diseases has been argued 
to support many differing hypotheses for the cause of depression. The link in 
Crohn’s disease (CD) is well established with increase in disease activity and 
increased anxiety and depressive symptoms occurring simultaneously. Further 
to this, not only is depression associated with reduced remission rates in CD 
[218] but is there is a high rate of psychopathology in patients with CD prior to 
diagnosis.  
However, it may be that the symptoms in CD are the cause of depressive 
symptoms as they are inherently distressing. The association of depression and 
increased symptoms does not exclusively suggest an inflammatory cause of the 
psychological component. A small study by Guloksuz et al [217] attempted to 
examine the potential link between immune activation and depressive symptoms 
in CD patients. Their cohort of 15 patients were all treated with anti-TNFα 
therapy. There was an increase in immune activation, as defined by raised 
positive acute phase proteins and decreased negative acute phase proteins, in 
patients with a history of past or present depressive episodes even after 
correcting for level of disease activity. This suggests an association between 
inflammatory response and depressive symptoms albeit on a small scale.   
When anti-TNFα agents, such as infliximab, have been used to treat 
inflammatory conditions including RA and CD, improvements in depressive 
symptoms as well as medical symptoms were seen[190] and these studies are 
ongoing to evaluate anti-TNF agents in treatment resistant depression.  
Kishida et al [219] studied gp91phox knock out mice as a surrogate for XL-CGD 
patients and did not find them to suffer from anxiety or depressive symptoms. 
There have been no published studies about human patients with CGD and the 
presence of anxiety and depression.  
2.10.3 X-linked Carriers and Psychological Health  
Whilst there is no literature about the psychological health of XL-CGD carriers, it 
can be hypothesised that XL-CGD carriers may be at higher risk of symptoms of 
anxiety and depression due to a number of factors.  
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SLE 
Mood disturbance is one of the features of neuropsychiatric SLE (Table 2-3). As 
XL-CGD carriers have been reported to suffer other features of SLE, as discussed 
earlier, they may be at risk of the neuropsychiatric manifestations as well.  
A mouse study discovered that depressive symptoms might precede the onset of 
other SLE symptoms[215], which perhaps supports the hypothesis that 
depression is a fundamental part of SLE as opposed to a reactive process 
resulting from chronic illness. In the same study, the lupus mice did not exhibit 
anxiety, but depressive symptoms correlated with the presence and level of 
autoantibodies, specifically ANA titres and anti-ribsomal P antibodies. 
Depression was also more common in the female lupus mice than their male 
counterparts. The depressive symptoms presented early in the disease process 
and were at times the primary manifestation of disease.  Despite the correlation 
with autoantibodies, they were not diagnostic of NPSLE, but MRI was also not 
informative in the diagnosis of NPSLE. These results were supported by a further 
study by the same group.  
Chronic Illness 
XL-CGD carriers may also be at risk of psychological ill health due to their own 
medical problems. On going, potentially untreated medical problems may 
contribute to the development of depression and anxiety but this has yet to be 
demonstrated.  
Genetic Guilt 
The inheritance of a medical condition results in complex feelings within a 
family. For the carrier there may be feelings of guilt associated with the passing 
on of a gene whilst being unaffected themselves by the faulty gene. There may 
also be subconscious or conscious blame attributed by other family members 
and the affected individual.  Mode of inheritance may contribute to these 
feelings. CGD is in a unique position, as it may be inherited in either an autosomal 
recessive manner or in an X-linked manner. This allows for feelings about 
inheritance to be studied.   
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James et al[220] examined the different aspects of genetic guilt in their 2006 
study of CGD families. AR and XL families were included in the study allowing for 
comparisons to be made. The feelings of guilt and self blame were more strongly 
associated with XL disease than AR. Mothers of boys with XL disease blamed 
themselves for their son’s condition more than AR mothers. The fathers of boys 
with XL disease also blamed the mothers more than in AR disease. This feeling of 
guilt may affect psychological health.  
2.11 Quality of Life 
Quality of life (QoL) represents an overlap of medical and psychological health.  
Quality of life is difficult to define and attempts at definition tend to be nebulous 
or ill fitting. However, it is a concept with which the majority of the population of 
the developed world are inherently familiar.  
Aristotle made an early reference to the concept of quality of life, ‘Both the 
multitude and persons of refinement….conceive ‘the good life’ or ‘doing well’ to 
be the same thing as ‘being happy’. But what constitutes happiness is a matter of 
dispute…some say one thing and some say another, indeed very often the same 
man says different things at different times: when he feels sick he thinks health is 
happiness, when he is poor, wealth.” [221] 
Aristotle identifies the difficulties in assessing quality of life. Firstly the lack of 
universality of definition and secondly the speed at which an assessment of QoL 
may change.  
2.11.1 Measurement of QoL 
There are several methods available to formally assess QoL in a clinical or 
research setting.  
In its simplest form, assessment of QoL may involve asking the patient how they 
would rate their QoL.  However, different interpretations of a simple question 
mean that information gained from this method is limited and lacking in 
reproducibility and validity. Comparisons between different groups are difficult 
and even comparisons of the same patient at different time points may not be 
valid. As such, tools have been developed to overcome these difficulties.  
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Tools assessing QoL may be generic, disease specific or aspect specific.  
Generic tools for assessing QoL have been designed to be used by all irrespective 
of the medical condition or circumstances and may also be used for healthy 
individuals. The advantage of this is that it allows for direct comparisons to be 
made between groups irrespective of disease using the same tool.  
An example of a generic tool is the Medical Outcomes Study 36-Item Short Form 
(SF-36). The SF-36 was developed in 1993 by Ware et al [222] and was designed 
to evaluate general health status. The SF-36 has become one of the most widely 
used QoL tools in clinical research [221]. As with many generic tools, the SF-36 
assesses multiple health concepts. The 36 items are categorised to provide 
scores for each of these domains in addition to providing a score for summary 
measures. This allows for comparisons to be made, not only in overall QoL, but 
also within different domains that have been predefined.  
Another example of a generic tool is the EuroQoL, which provides an overall QoL 
assessment, but given its brevity requires an additional tool such as a disease 
specific tool for more in-depth assessment [223].  
A disadvantage of a generic tool is if the question about quality of life relates 
directly to disease specific symptoms or manifestations this is not addressed. As 
such, disease specific tools have been developed.  
Disease specific tools focus on the relevant factors for the disease and 
predominantly include symptoms. For example, a QoL tool for a gastrointestinal 
disease would pay particular attention to diarrhoea and urgency. The advantage 
of disease specific tools is that they may detect subtle or small changes with 
respect to the specific factors deemed to be important. The disadvantage is that 
while generic tools make few preconceptions about what may impact upon QoL, 
disease specific tools have pre-defined the symptoms or factors that are likely to 
impact upon QoL.  
There may be aspects of QoL which are of particular interest and they may 
require more detailed examination than a generic tool allows. For example, 
fatigue, pain and anxiety and depression may be relevant across diseases. These 
aspects of QoL are often of interest, independent of the disease process and 
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therefore require individual assessment. Examples of these surveys include the 
Hospital Anxiety and Depression Score (HADS)[224] and the MFSI [179].  
2.11.2 Importance of QoL Assessment 
In some situations, a crude assessment of alive or dead is sufficient to determine 
if a treatment or intervention is successful. However, increasingly more subtle 
changes are being required to determine the benefits of an intervention 
especially as survival improves. QoL is increasingly a primary endpoint in its 
own right. By assessing QoL, it enables researchers or clinicians to detect 
positive and negative aspects of treatments. 
Patient assessment of QoL does not always agree with physician interpretation. 
This makes formal assessment even more imperative. Additionally, by assessing 
QoL, particularly when using a generic model, important factors, which have not 
been previously considered by the clinical team may become apparent. Once 
uncovered, these factors may then be addressed.  
On a population level, with an ageing population, chronic disease is likely to 
become increasingly significant. In many situations, chronic disease may not be 
completely curable, and therefore, advances must be measured in a manner 
other than survival. QoL is a more comprehensive and accurate assessment than 
absence of symptoms.  
QoL may also provide information about social and emotional functioning rather 
than only physical symptoms. This may be beneficial when assessing the holistic 
aspects for a patient.  
QoL assessment provides important information in both the research and clinical 
setting. In this study of XL-CGD carriers, mortality is unlikely to be a useful 
endpoint, whereas QoL may uncover more subtle difficulties relating to physical 
and mental health.  
2.11.3 The Literature: What has been seen in other conditions? 
Evaluation of the QoL of patients with CGD showed that patients with CGD have 
poorer QoL than the general population[60]. The study also demonstrated that 
children undergoing curative treatment for CGD, namely HSCT, had near normal 
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QoL after treatment. There has been no study to evaluate the quality of life of XL-
CGD carriers, but if XL-CGD carriers manifest symptoms similar to that described 
in CGD, it is plausible that they may have reduced QoL and that the reductions 
may be in similar domains. QoL has been assessed in other PIDs with similar 
findings. Soresina et al [225] evaluated children and adolescents with X-liked 
Agammaglobulinaemia (XLA) and compared them to an age matched control 
group.  They found that overall global health related QoL was lower in the XLA 
group than the healthy controls, despite there being no difference in the 
perceptions of physical health. This highlights the discrepancy between physical 
health and overall QoL and indicates the many factors that may impact on QoL 
rating.  
There is a growing body of literature regarding QoL in parents and families of 
children with chronic illnesses. As with the psychological stresses of caregiving, 
it can be anticipated that there may be a reduction in QoL in parents and families 
where there is a child with a chronic illness. Cystic Fibrosis (CF) has been well 
studied and whilst there are differences with CGD, there are significant 
similarities in disease severity and medical involvement for conclusions to be 
transferrable. Driscoll et al [226] demonstrated high levels of anxiety and 
depression in female and male caregivers of children with CF. These high levels 
of anxiety and depressive symptoms correlated with reduced QoL. Interestingly, 
reduced QoL has not been demonstrated in the siblings of children with CF, who 
report well-preserved QoL [227]. Reduced QoL was also seen in a study of 266 
caregivers of children with special needs [228], thus corroborating the findings 
in CF parents.  
As outlined, the evidence suggests that caring for a child with chronic illness 
reduces QoL. However, the hypothesis of this study into XL-CGD carriers is that 
there are unmet medical needs for the carriers themselves. Therefore, it is 
important to consider the impact of a chronic condition, such as SLE, on the QoL 
of the individual.  
A recent study examining QoL and presence of anxiety and depressive symptoms 
in SLE patients demonstrated that QoL was reduced and there were higher rates 
of anxiety and depression, but only in patients that reported high levels of pain 
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[229]. In SLE patients that were classed as ‘low pain’, the rates did not 
significantly differ from the healthy controls. This implies that it is not simply the 
presence of a chronic condition which effects QoL, but that there are more subtle 
factors involved.  
2.12 Cognitive Function  
Potential difficulties with learning in CGD patients were noted by Pao et al [230] 
in 2004. They performed a retrospective review of 26 CGD patients referred to 
their unit. This was prompted by the observation that many CGD patients had IQ 
scores of less than 70. The mean IQ was 89 (lower than the UK average) and 23% 
had an IQ of less than 70 meeting the criteria for learning impairment. The 
number found to have significantly lower than average IQ was more than the 
quoted 1-3% of the general population. However, the study suffered from 
significant selection bias. In particular, all included patients had been referred 
due to concerns about behaviour or education, which may account for the high 
rates of deficits. Alternatively, it may be that the impairment is more discrete in 
the remainder of the population, or that there are problems with specific areas of 
cognition such as memory and learning.  
Cognitive function is the result of the interplay between multiple factors and 
chronic illness may predispose patients to a number of psychosocial difficulties 
including cognitive dysfunction. However, a reduction in IQ has not been 
demonstrated in all chronic illness. For example when children with Cystic 
Fibrosis (CF) were studied, there was no difference in IQ [231]. Therefore, Pao et 
al’s findings may suggest that the CGD disease process itself may be involved in 
cognitive dysfunction.  
A more recent study by Cole et al[232] recruited all known CGD patients from 
the UK and Ireland to a study including an IQ assessment. This found that there 
was no significant difference between CGD patients and UK norms. The study did 
not have the recruitment bias demonstrated in Pao’s original study, but the 
assessment was not as comprehensive. However, the assessment tool used was a 
validated tool for IQ assessment and would have detected gross differences such 
as those found by Pao et al.  
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Causation of Reduced IQ 
Pao et al [230] hypothesise that the reduction in IQ and cognitive function may 
be due to recurrent infection or due to the lack of functional NADPH oxidase and 
the resultant loss of superoxide within neuronal cells.  
An important part of mammalian learning is thought to involve long-term 
potentiation (LTP) in the hippocampus[233]. Superoxide is thought to be an 
important signalling molecule in this process [234] and that the removal of 
superoxide adversely affects this process[235]. Superoxide has also been 
demonstrated to be important in associative memory [234]. NADPH oxidase is 
potentially an important contributor to the production of this superoxide[219].  
The clinical observation of reduction in IQ in CGD patients has led to exploration 
about possible causation and CGD mice provide a useful model.  
Kishida et al’s [219] study of CGD (gp91phox and p47phox knock out) mice drew 
several important conclusions. The first was that NADPH oxidase is an important 
factor in hippocampal long-term potentiation (LTP). This appears logical as 
superoxide is known to be required for hippocampal synaptic plasticity and 
specifically for LTP and hippocampal dependant memory [236]. The second is 
that whilst the hippocampus in CGD mice has a grossly normal structure, the 
function is impaired as CGD mice have mild memory impairment in hippocampal 
learning. CGD mice were also found to have a mild deficit in spatial learning and 
interestingly, in gp91phox knockout mice but not p47phox knockout mice, there 
were significant impairments in both motor co-ordination and motor memory 
[219]. 
Therefore, there is a theoretical reason why CGD patients, and potentially XL-
CGD carriers, could have problems with learning despite the findings by Cole et 
al[232] that CGD patients did not suffer reduction in IQ.  
2.13 Conclusions and Summary  
The anecdotal observations and what has been described in the literature 
formed the basis for this study and the need to fully evaluate the health of XL-
CGD carriers.  
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Chapter 3: Objectives of the Study 
3.1 Hypotheses 
The main hypotheses for the study were:  
1. XL-CGD carriers suffer from medical problems similar to those suffered 
by CGD patients 
2. XL-CGD carriers suffer from problems similar to SLE 
3. XL-CGD carriers have an average of 50% normally functioning 
neutrophils as defined by neutrophil oxidative burst 
4. There is a correlation between the reduction of neutrophil oxidative burst 
and any medical problems suffered in XL-CGD carriers 
5. Psychological health in XL-CGD carriers is worse than the UK population 
and mothers are more significantly affected than other XL-CGD carrier 
relatives  
3.2 Objectives 
The objectives of the study were: 
1. To identify and define the type and prevalence of medical problems in XL-
CGD carriers in the UK 
2. To define the average and range of neutrophil oxidative burst value seen 
in XL-CGD carriers in the UK 
3. To establish if medical problems in XL-CGD carriers are associated with 
the degree of reduction in neutrophil oxidative burst  
4. To evaluate the psychological health of XL-CGD carriers in the UK 
5. To compare the psychological health of XL-CGD carriers in the UK with a 
control group of XL-carriers of MD 
6. To evaluate the quality of life in XL-CGD carriers and to compare this with 
population data 
7. To evaluate IQ in XL-CGD carriers  
 
 74 
Chapter 4: Methods 
4.1 Recruitment 
The inclusion criteria for the study were: 
 Resident in the United Kingdom 
 Female carrier of XL-CGD 
 Aware of own carrier status 
4.1.1 Identification of Participants and Recruitment  
XL-CGD families were identified from the UK CGD Registry and by consultants 
caring for families with CGD at the main treatment centres for CGD in the UK, the 
Great North Children’s Hospital (GNCH), Newcastle upon Tyne and Great 
Ormond Street Hospital (GOS) and the Royal Free Hospital, London. Other sites 
included in the study were Birmingham Heartlands Hospital and Manchester 
Children’s Hospital as families were identified at these sites and subsequently 
recruited. 
XL-CGD carriers were also identified and recruited through the CGD Society. The 
CGD Society is a charity set up to support families and patients with CGD. The 
project was advertised via the charity website and participants responded 
directly to this. The annual ‘Family Day’ and ‘Ladies’ Carrier Day’, hosted by the 
CGD Society, included presentations about the research project and XL-CGD 
carriers were recruited from here.  
All eligible families were contacted either in person at a clinic appointment or by 
post, with the exception of where the index case was deceased, when the clinical 
team made a decision as whether it was appropriate to contact the family or not. 
There were two families where the index case had died shortly before the study 
commenced and it was decided that it was insensitive to contact these families 
for research purposes. One index case died during the course of the study. His 
mother had already enrolled in the study, but was not followed up for missing 
data. Additional XL-CGD carriers, within a family, were identified at the initial 
interview with the recruited participants.  
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Families not attending clinic appointments were contacted by post to participate 
in the study.  
If an XL-CGD carrier was deceased, they were counted in the total number of 
carriers. Where the next of kin was available, consent was obtained to include 
the deceased carrier in the project and to access any medical records. 
Information about these XL-CGD carriers was limited. The researcher recorded 
information volunteered by the next of kin about the deceased XL-CGD carrier.  
There will be XL-CGD carriers in the general population who are not known 
about, as they have not had children or where the diagnosis in family members 
has not yet been made. These constitute the ‘unknown unknown’ and it is not 
possible to include these carriers in the study or to quantify them.  
4.1.2 Confirmation of Carrier Status 
Individuals were considered to be a carrier if they had an abnormal neutrophil 
oxidative burst demonstrating a dual population of neutrophils by either NBT or 
DHR and a family history of XL-CGD.  
Deceased carriers were included if they had been tested prior to death, or if they 
were an obligate carrier i.e. the daughter of an affected father.  
The exact genetic mutation was not tested in the XL-CGD carriers due to the 
expensive nature of the test.  It was assumed that the mutation in the XL-CGD 
carriers was the same as that found in the index case. It is highly unlikely that a 
different CGD causing mutation would occur in the same family. After discussion 
with the genetics department at the Royal Victoria Infirmary, Newcastle upon 
Tyne, it was felt that this was an acceptable assumption.   
As different mutations are associated with different amounts of residual NADPH 
oxidase function [14], knowledge of the mutation was important in order to 
correlate medical symptoms with this. Information regarding the specific 
mutation in the index cases was sought from the original registry data[11] and 
recorded where the information was available.  
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4.1.3 Recruitment of Controls 
A control group was recruited in order to compare the psychological aspects of 
the study and to ascertain whether any psychological problems identified were 
related to being a carrier of XL-CGD specifically or if they were associated with 
being the relative of a child with a chronic, XL inherited condition. Additionally, 
small-scale studies [220] suggest there are greater feelings of guilt and blame felt 
by mothers who are XL carriers, rather than mothers who are AR carriers, which 
may be important when considering psychological effects.  It was also important 
that the index cases had a significant disease, which was life limiting and 
required frequent trips to hospital. The control group carriers needed to be 
accessible to the researcher in order that they may be approached for inclusion. 
Muscular Dystrophy (MD) met the required characteristics for the control group. 
Muscular Dystrophy was chosen as the control group for several reasons. It 
shares some similarities with CGD; it is X-linked inheritance, it has a severe 
course, the children have frequent trips to hospital and is life limiting. BMD and 
DMD classically have different severity patterns. Including XL carriers of both 
BMD and DMD meant a range of disease severity in the index cases was 
represented, which is similar to the broad spectrum of disease severity seen in 
CGD patients. MD is more common than CGD with an incidence of 1 in 3,500 
newborn males for DMD and 1 in 17,000 for BMD [237], meaning that 
recruitment of a control group of similar number to the study population was 
potentially possible. 
The Great North Children’s Hospital, Newcastle upon Tyne, is a leading centre in 
the UK for the diagnosis and management of MD, which is therefore comparable 
with CGD and means that there is a similar geographical spread for the control 
group as the XL-CGD carrier group. For both conditions, the Great North 
Children’s Hospital receive referrals from the whole of the UK meaning that any 
potential regional differences should be similar for both XL-CGD and MD carrier 
groups. 
Carriers of XL-MD were recruited from the MD clinic at the Great North 
Children’s Hospital, Newcastle upon Tyne to form a control group. Carrier 
mothers, grandmothers and sisters presenting to this clinic with an MD index 
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case were approached for inclusion into the study.  XL carriers of either 
Duchenne (DMD) or Becker’s Muscular Dystrophy (BMD) were eligible for 
inclusion in the control group. All eligible carriers were approached, at a clinic 
appointment, for inclusion in the study.  
4.1.4 Exclusions 
Girls under the age of 16 years who did not know their carrier status were not 
included in the study. The testing of children for genetic disease is controversial. 
At present, the guidance remains that where there is no health benefit for the 
individual, children under the age of 16 years should not be tested for carrier 
status[78]. A study of the adolescent sisters of boys with CGD found that they 
concurred with this recommendation and favoured testing for carrier status later 
in life [79]. 
Carriers who were aware of their carrier status were eligible and included 
irrespective of their age.  
In families where the index case was deceased, the families were contacted if the 
consultant caring for the family deemed it appropriate or if there was continuing 
contact with the family.  
There were no other exclusions. 
4.1.5 Consent 
Written consent was obtained from all participants prior to enrolment in the 
study.  Participants under the age of 16 years were enrolled after consent from 
their parent or guardian and assent from themselves.  Next of kin consent was 
taken where the carrier was deceased.  Consent and assent forms are included in 
the appendices.  
4.2 Assessment of Health 
For each enrolled participant a family pedigree was constructed detailing cases, 
carriers and where carrier status was unknown. Information was recorded about 
family history of disease and the general health of first-degree relatives. Known 
medical conditions, regular medications and hospitals attended were recorded. 
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Smoking status (never, current or ex-smoker) and weekly exercise were 
recorded.  
4.3 Medical Health  
4.3.1 Respiratory Symptoms 
Participants were asked to complete the St George’s Respiratory Questionnaire 
(SGRQ) to assess respiratory status.  This is a questionnaire designed and 
validated for use in both fixed and reversible airways disease and has been used 
as a research tool for respiratory conditions [238-241]. It assesses the presence 
and impact of symptoms.  Participants answer a series of questions in the 
questionnaire relating to cough, shortness of breath and effect on their activities 
of daily living. Answers were inputted into the licensed scoring software. Once 
the data had been entered, a numerical score was generated for symptoms, 
impact and activity. An overall score was also generated. The higher the score for 
each domain, the more affected an individual is. UK population data were 
available for comparison and published norms available [242].   
4.3.2 Gastrointestinal Symptoms 
Participants were initially asked an open question about their medical health and 
if they suffered from any medical problems or conditions.  They were then 
specifically asked if they suffered from any gastrointestinal symptoms such as 
recurrent abdominal pain, diarrhoea or rectal bleeding.  
If the participant had undergone any gastrointestinal investigations the type and 
result were recorded. This information was corroborated with medical records 
either in primary or secondary care where possible.  
Children with CGD demonstrate poor growth, which maybe the presenting 
feature of their disease[8, 11] and may relate to gastrointestinal manifestations 
of disease such as colitis, or on going diarrhoea of another aetiology. 
Measurement of growth in children is used as a surrogate marker for health and 
height and weight may be plotted on per centile charts. In adults, BMI forms part 
of the standard assessment of nutritional status. BMI was categorised into the 6 
 79 
categories published in the NICE guidelines [243]. The categories are shown in 
Table 4-1.  
Table 4-1: BMI Category [243] 
Category BMI Range (kg/m2) 
Underweight < 18.5 
Healthy 18.5 – 24.9 
Overweight 25-29.9 
Obesity 1 30 – 34.9 
Obesity 2 35 – 39.9 
Obesity 3 > 40 
All patients were asked to complete the Inflammatory Bowel Disease Disability 
Index. This is an assessment tool which evaluates quality of life in relation to 
bowel symptoms and provides an assessment of severity of symptoms [244].  A 
numerical score is generated from the answers given. A higher score indicates a 
greater impact of gastrointestinal symptoms on quality of life. Details about 
bowel habit were also recorded from this.  Gastrointestinal symptoms are 
frequently not volunteered by patients in consultations. This questionnaire 
looked for ‘hidden symptoms’ that have potentially not been previously 
disclosed by individuals and assessed the severity of symptoms already known 
about.  
4.3.3 Autoimmune Features 
To evaluate the presence of symptoms related to SLE, such as photosensitive 
rashes, a questionnaire based on the American Rheumatology Association (ARA) 
clinical criteria for diagnosis of SLE [136] was used. The criteria were phrased as 
questions, which were asked by the researcher if the participant was recruited in 
person, or completed by the participant themselves if recruited by post.  
Information about other autoimmune features, which were volunteered, was 




Initial findings indicated that XL-CGD carriers were suffering from what they 
perceived to be excessive fatigue. Formal assessment of fatigue was 
subsequently undertaken using the Multidimensional Fatigue Symptom 
Inventory-Short Form (MFSI-SF) and the vitality component of the SF-36 QoL 
questionnaire. If participants volunteered (unprompted) that they felt they 
suffered from excessive fatigue during the medical history taking, this was also 
recorded.  
The MFSI-SF questionnaire comprises 30 statements. Participants rate each 
statement from 0 (not at all) to 4 (extremely). The questions are ordered so that 
positive and negative statements are intermingled. The 30 questions comprise 
five domains; general, physical, mental, emotional and vigour. Each domain has 6 
questions attributed to it.  
Adding the scores from the general, physical, emotional and mental domains, and 
subtracting the score for vigour calculated a total score. Each individual domain 
may receive a maximum score of 24, making the highest possible score 96.  
The MFSI-SF was derived from the Multidimensional Fatigue Symptom Inventory 
(MFSI). The MFSI was designed to assess five domains of fatigue; global, somatic, 
cognitive, affective and behavioural.  The MFSI has been found to have good 
reliability in test and retest and internal consistency [245]. It is not disease 
specific and can therefore be used in individuals with a disease and in healthy 
individuals.  Therefore, it is appropriate for use both in the XL-CGD carrier 
population and in the control group. The design is such that questions relating to 
a specific domain of fatigue are not consecutive so as to ensure that each 
question is considered on its merits in order to attempt to gain maximal 
accuracy. It does not rely on medical symptoms allowing an assessment of 
fatigue where the cause of fatigue is uncertain.  
One disadvantage of the MFSI is its relative length, with 83 questions, which may 
adversely affect how well it is completed, particularly in individuals suffering 
from cognitive fatigue. In order to rectify this, an abbreviated version was 
created, the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-
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SF). This 30-point questionnaire covers the same domains as the longer version, 
but takes approximately 5 minutes to complete, providing an advantage over 
longer, potentially more daunting questionnaires.   
The MFSI-SF does not assume the presence of fatigue and has been validated for 
use in a study of 304 cancer patients when compared with both another fatigue 
scale and specific fatigue components of the widely validated SF-36 Quality of life 
questionnaire [246]. Further validations have been made [247].  
The choice of the MFSI-SF to assess fatigue was based upon several factors. A 
multi-dimensional tool was preferable as the cause of any fatigue in the XL-CGD 
carrier group is uncertain. It is useful to have a detailed and broad assessment of 
the different aspects of fatigue for to conclusions to be drawn about which 
specific aspects are a concern.  The MFSI-SF satisfies this criterion by assessing 5 
domains. As this study required participants to complete a number of 
questionnaires it was important to keep the questionnaires brief where possible 
so that they were completed as accurately as possible, hence why the MFSI-SF 
was chosen over the full version.  
Where questionnaires were not returned participants were contacted in writing 
to in order to complete data collection.  
4.4 Medical Records 
Consent was obtained to access medical records.  Upon enrolment into the study, 
participants were asked at which hospitals they had been seen as a patient.  It 
was not possible to obtain medical records from all hospitals, but consultants 
caring for participants were contacted and clinic letters requested.  
Data were abstracted from the hospital records by a single researcher using a 
standardised proforma. Detailed information was obtained about hospital 
admissions and referrals. Information was recorded about reason for admission, 
treatments including surgery and outcomes.  The data abstraction proforma used 
was based upon the proforma used for collecting data about the patients 
enrolled in the original registry[11]. 
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4.4.1 Primary Care 
The General Practitioner (GP) of each participant was contacted by post. They 
were informed of enrolment of their patient into the study. They were also asked 
to provide a patient record summary and return it by post or fax. GP records 
were used to confirm information recorded from patients and confirm regular 
medications.  
Consent was also obtained from each participant to inform their GP if significant 
medical problems arose during the course of the study requiring referral or 
treatment.  
4.5 Psychological Health  
Assessment of psychological health was undertaken, in the same manner, in both 
the XL-CGD carriers and the control group of XL-MD carriers. The study design 
for the psychological component was discussed with the psychologists attached 
to the paediatric immunology team at the GNCH, Newcastle upon Tyne and GOS 
hospital, London.  
In order to assess psychological health, participants completed questionnaires 
about self-esteem, quality of life, presence of anxiety and depression symptoms. 
Participants who were mothers also completed the Pediatric Inventory for 
Parents (PIP).  
IQ was assessed in the XL-CGD carriers using the Wechsler Adult Intelligent Scale 
(WAIS). 
4.5.1 Symptoms of Anxiety and Depression 
Assessment of symptoms of anxiety and depression was made using the Hospital 
Anxiety and Depression Scale (HADS). The HADS is a questionnaire comprising 
14 questions; 7 looking for anxiety symptoms and 7 for depression. The 
individual answered each question using a four-point scale (0-3). There is a 
maximum score of 21 for anxiety and 21 for depression with higher scores 
showing more severe symptoms. The HADS is easy to use and can be completed 
quickly. The original design was for use in individuals with a chronic health 
condition, therefore in order for the scale to remain generic and universally 
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applicable, physical symptoms were excluded from the design. It may be used as 
a screening tool, or as an assessment of severity.  
The score generated after completion of the questionnaire, for both anxiety and 
depression may be categorised and compared to population data [248]. Cut-off 
values were available from population data and results were evaluated 
categorically and as a raw score. Categories are shown in Table 4-2 and are the 
same for anxiety and depression.  






The HADS alternates between positively and negatively phrased questions. The 
strength of this is that it ensures as far as is possible, that an individual considers 
each question on its own merits, rather than simply choosing the same option for 
each question. By asking about specific symptoms and their frequency rather 
than using a one dimensional ‘are you depressed’ question, respondents were 
more likely to be honest and a more accurate representation of the presence of 
anxiety and depression should be achieved. Furthermore, many people may not 
consider themselves depressed or anxious even with symptoms. The HADS 
provides an objective assessment of the subjective responses. The use of 
multiple questions means an average response can be obtained.  
The HADS was developed in 1983 as a screening tool for anxiety and depression. 
It was designed to be a cost effective tool for use in patients without known 
psychiatric disorders. The questions were formulated to exclude anxiety and 
depressive symptoms related to somatic disorders such as fatigue or headache. It 
does not attempt to explore the cause of the symptoms but merely screens for 
their presence. As the tool is a subjective assessment, it may be affected by how 
the individual perceives they should feel and relies on honesty upon completion.  
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In 1996 Herrmann [249] reviewed 200 papers studying 35,000 individuals using 
HADS. His conclusions were that the scale is acceptable to patients.  There is 
good internal consistency and validity and reliability are sound.  
Bjelland et al [250]updated this review in 2002. They included 71 studies in their 
review that met the required criteria. They confirmed Herrman’s[249] findings 
that the HADS was a reliable and screening tool for anxiety and depression. They 
were able to conclude that the HADS was valid not only in medical patients but 
also when used in the general population.   
Population data for the UK were available for comparison [248] along with 
published cut off values. Data from parents of children with CF were also used 
for comparison [226, 251]. Data was also compared to published work about 
patients with SLE [140, 229].  
The acceptability, simplicity and brevity of the HADS along with the validity and 
reliability were the reasons for its choice in this study to assess the presence of 
anxiety and depression in XL-CGD carriers. Whilst it does not provide a cause for 
any symptoms identified, it provides a quantification of the distress. This was 
then correlated with the other assessments of psychological health to explore 
which factors impact the most on psychological health.  
A copy of the HADs questionnaire can be found in the appendices.  
4.5.2 Self-Esteem 
An association between anxiety and low self-esteem has been described[252]. 
Self-esteem is an important part of psychological health. Self-esteem was 
assessed using the Rosenberg Self-Esteem Scale. This is a 10-point questionnaire 
and respondent rates their level of agreement with each statement from strongly 
agrees to strongly disagrees using a 4-point scale. The questions relate to how 
the respondent feels about their self worth. The normal range has been defined 
as a score of 15-25 [252, 253]. It has been validated in both adults [252, 253] and 
school aged children and adolescents [254]. 
Preserved self-esteem is an important part of psychological health assessment 
and may be affected by feelings of depression or guilt amongst other things.  
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A copy of the Rosenberg Self-Esteem Scale can be found in the appendices.  
4.5.3 Pediatric Inventory for Parents 
The majority of the carriers recruited to the study were mothers of children with 
CGD. Being a parent of a child with a chronic illness, who requires frequent trips 
to hospital or medical intervention, may contribute to psychological health. 
Assessment of the stresses of being a carer may be difficult to isolate from other 
factors that may impact on psychological health. In order to account for this, 
recruited mothers were asked to complete the Pediatric Inventory for Parents 
(PIP). 
The PIP is a 42-point questionnaire designed to assess the impact of having a 
child with a chronic illness. It assesses both the severity and frequency of 
problems associated with being the parent of a child with a chronic condition. 
Each statement asks the parent completing the form to rate ‘how much of a 
problem’ and ‘how often it is a problem’ on a 5 point scale where 1 is ‘no 
problem at all’ and 5 is ‘a significant problem’.  The questionnaire includes 
questions about difficulties specific to medical care such as giving medications 
and is therefore, more specific than a generic parenting stress survey. The 42 
statements cover four domains; medical care, communication with the health 
care team and the child, role functioning and emotional functions. These domains 
reflect the multidimensional nature of parental stress and that stresses may be 
additive. A numerical score is calculated for frequency and severity. These are 
added together to give an overall total. The maximum possible score is 420 and 
frequency and severity are equally weighted. The higher the score obtained, the 
more severe the stress experienced.  
The PIP was originally designed for use in parents of oncology cases [255], but 
has been used in other chronic illnesses [205]. The PIP assesses the degree of 
stress associated with having a child with a chronic illness and can then be 
correlated with results from the HAD and other questionnaires assessing 
psychological distress. Data were compared with published work from parents of 
children with an oncological diagnosis [255]. 
A copy of the PIP can be seen in the appendices.  
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4.6 Quality of Life 
Quality of life was assessed using the Short Form 36 version 2 (SF-36V2). If the 
index case had undergone HSCT, the SF-36 was delayed until a year had passed 
since the transplant. As outlined in chapter 2, HSCT is an intense period for 
family and patient alike and the stresses associated may be evident for a 
prolonged period after the transplant is completed [204]. It was, therefore, felt to 
be appropriate to delay the assessment of QoL until a period of time had passed 
in order to get a truer reflection of QoL in XL-CGD carriers. As this study was 
limited to 3 years, there was also a practical component to the decision. Phipps et 
al [256] suggest that the anxiety and distress associated with HSCT for parents is 
transient and lasts for up to six months. Therefore, on balance it was felt delaying 
QoL assessment for 1 year would be appropriate.  
The SF-36V2 is a standardised quality of life assessment tool, which comprises 
36 questions.  Component scores are generated for 8 separate domains: physical 
functioning (PF), physical role (PR), bodily pain (BP), general health (GH), 
vitality (VT), social functioning (SF), emotional role (RE) and mental health 
(MH). A score is also generated for mental component score (MCS) and physical 
component score (PCS). Each domain receives a numerical score with a 
minimum of 0 and a maximum of 100. The higher the score the better the 
function.  It was developed in 1993 to assess quality of life in a manner not 
specific to age, disease or treatment group [222].  
The SF36 was chosen, as it is a generic tool, which may be applied to healthy 
individuals and across all age groups. It provides a subjective assessment of 
general health and focuses on physical, social and emotional functioning. The 
SF36 is the most commonly used QoL tool in clinical research. Additionally, the 
SF-36 may be self-administered, allowing it to remain valid even when posted 
out to participants.  
Once the questionnaire was completed the responses were inputted into the 
licensed scoring software.  Each domain results in a total score and there are 
normal values which are age and sex matched available within the software to 
provide comparison for the values. However, one disadvantage is that the 
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software uses US norms as the comparison data. As all the participants in this 
study are from the UK, this may not be the most appropriate comparison. 
However, there are published data on UK norms for an additional comparison to 
be made[257]. Data are also available from published works about different 
groups of patients, including carers of patients with brain tumours[211] and SLE 
patients [229], to which comparisons were made. Data about adult CGD 
patients[258] were also compared to the XL-CGD carrier data. 
A copy of the SF36v2 can be found in the appendices.  
4.7 IQ Assessment 
As outlined in chapter 2, there is limited research to suggest that boys with CGD 
may have reduced IQ compared to the population[230] and the factors behind 
this are uncertain, although it has been hypothesised that it is related to their 
disease state. Therefore, it can be hypothesised that a similar reduction may be 
seen in XL-CGD carriers and therefore, IQ assessment was undertaken in the XL-
CGD carriers.  
IQ was assessed using a standardised assessment tool, the WAIS-IV. It involves 
10 subsections which when scored provide an assessment of overall IQ and 4 
different domains.  The different domains are Verbal Comprehension Index 
(VCI), Perceptual Reasoning Index (PRI), Working Memory Index (WMI) and 
Processing Speed Index (PSI). Together they provide an overall assessment of 
intellectual functioning. The test is validated for individuals aged between 16 
years and 90 years 11 months.   
IQ was assessed by an individual researcher who performed all but one of the IQ 
assessments. The other IQ assessment was performed by a clinical psychologist 
in the presence of the researcher. The researcher was trained in the use of the 
WAIS by an educational psychologist.   
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4.8 Blood Investigations 
4.8.1 Neutrophil Oxidative Burst 
Blood was taken at enrolment into the study from each carrier and a neutrophil 
oxidative burst performed.  Neutrophil oxidative burst was performed at the 
recruiting centre due to the time-dependant nature of the investigation. DHR was 
used at all sites.  
All sites followed their standard operating procedure.  The standard operating 
procedure (SOP) for the GNCH, Newcastle upon Tyne is shown in the appendices.  
Results are presented as per cent normal functioning neutrophils.  
4.8.2 Autoantibodies 
All serum samples for autoantibodies were sent to the Immunology Laboratory 
at the Royal Victoria Infirmary, Newcastle upon Tyne. A routine panel of 
autoantibodies was sent from each XL-CGD carrier at time of enrolment. 
Previous results were obtained from medical records if they had been tested.  
The panel included:  
 ANA pattern 
 Anti Gastric parietal cell antibody 
 Anti nuclear antibody 
 Anti mitochondrial antibody 
 Anti smooth muscle antibody 
All samples were tested in the same laboratory and the local values were used to 
determine if they were normal or abnormal. The SOP is shown in the appendices. 
A sample of serum has been stored in a freezer at -80 degrees. This sample was 
stored for use in future work on XL-CGD carriers.  
4.8.3 Cytokines 
Cytokine analysis was undertaken by a third year medical student and I received 
the raw data to analyse.  
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Serum from 52 of the recruited XL-CGD carriers was analysed alongside serum 
from 15 healthy controls and 20 Sjogren patients, 10 of who reported high 
fatigue and 10 who reported low fatigue. Using a cytometric bead array 
immunoassay, levels of IL1, IL5, IL8, IL10, IL17, IFN and IFN were assessed 
by a Biosciences LSRFortessaTM cell analyser. Data were compared for significant 
differences using STATA.  
4.9 Ethical Approval 
A favourable ethical opinion was obtained for the study from Newcastle and 
North Tyneside REC 1. All amendments to the design of the study were 
prospectively approved by the committee.  Local research and development 
approval was obtained from all hospitals involved.  
4.10 Statistical Analysis 
All data were analysed using STATA.  All data underwent testing for normality of 
distribution using skewness and kurtosis assessment and the null hypothesis 
that the data are normally distributed was rejected if the combined p-value was 
<0.05. 
Where data were normally distributed, mean values and standard deviations are 
presented. Where data were not normally distributed, median and interquartile 
ranges (IQR) are presented. Where data were normally distributed, parametric 
tests were used. Where data were skewed or not normally distributed, non-
parametric tests were used.  
The QoL questionnaires were inputted into the licensed software, which 
generated total scores for each domain. Each domain could score a maximum of 
100. Scores when the compared by the software with population data to produce 
norm based scores (NBS).  
Spearman’s correlation was used to assess factors associated with anxiety and 
depression scores. Data are presented with rho correlation coefficient and p-
values.  
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Where published data were available for comparison, means were compared 
using a one-sample t-test. For non-parametric data, the Mann-Whitney test was 
used.  The per cent or proportions affected were compared by a one-sample test 
of proportion. P-values are presented, a value of ≤ 0.05 was considered 
significant. 
In order to assess the impact of the age of a child with chronic illness, the index 
cases were categorised into age ranges to fit with developmental stage. The age 
categories were then used in comparisons for analysis of the psychological 
assessments.  A one-way ANOVA test was used to assess differences in PIP scores 
across the 5 different age categories.  A one-way ANOVA test was used to make 
comparisons across more than one group.  
 91 
Chapter 5: Clinical Results 
This chapter will present the results of the tests for normality of the data, 
information about recruitment and characteristics of the participants and the 
clinical manifestation of disease results. 
Data were tested for normality by skewness and kurtosis. A combined p value 
was produced and the hypothesis that data were normally distributed rejected if 
p<0.05. These results are shown in Table 5-1 and Table 5-2. 
Table 5-1: Skewness, kurtosis and test for normality of data 
 Skewness Kurtosis p-value 
Participant Age 0.45 4.38 0.03 
Index Case Age 2.27 6.98 <0.0001 
HSCT Age 1.01 2.93 0.07 
Neutrophil Oxidative Burst Values 
Enrolment NOB 0.011 2.13 0.17 
Historical NOB 0.35 2.28 0.53 
St George’s Respiratory Questionnaire 
Symptom Score 1.14 3.17 0.0063 
Activity Score 1.38 4.13 0.0008 
Impact Score 1.65 4.45 0.0001 




0.39 2.89 0.40 
BMI 0.53 2.87 0.16 
The data for participant age, index case age and SGRQ were not normally 
distributed.  NOB values, IBD disability index and BMI were normally distributed 
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Table 5-2: Skewness, kurtosis and test for normality for psychological assessments 
 Skewness Kurtosis p-value 
Psychology Assessments 
HAD-A 0.39 2.88 0.39 
HAD-D 0.64 2.69 0.11 
Rosenberg 0.005 1.73 0.0003 
PIP-Total -0.13 3.5 0.49 
PIP-F -0.98 3.76 0.35 
PIP-T -0.003 2.60 0.98 
Fatigue 
MF Total 0.27 2.03 0.043 
MF Gen 0.19 1.69 0.0001 
MF Physical  0.78 2.48 0.044 
MF Emotional 0.47 2.14 0.055 
MF Mental 0.76 3.38 0.044 
MF Vigor 0.45 3.29 0.22 
Quality of Life 
PF -1.56 4.23 0.0002 
RP -0.84 2.30 0.021 
BP -0.43 2.09 0.040 
GH - 0.10 1.78 0.001 
VT 0.17 2.10 0.084 
SF -0.60 2.29 0.067 
RE -0.68 2.38 0.057 
MH -0.35 2.89 0.46 
PCS -0.74 2.46 0.05 
MCS -0.69 3.64 0.04 
 
HAD-A, HAD-D, PIP-total and PIP-F were normally distributed whilst Rosenberg 
and PIP-S were not normally distributed. MF Vigor was normally distributed but 
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all other fatigue domains were not normally distributed. In the QoL assessment, 
the PF, RP, BP and GH domains were not normally distributed but all other 
domains were normally distributed.  
Table 5-3 shows that all of the cytokine data were skewed and not normally 
distributed.  
Table 5-3: Skewness, kurtosis and test for normality for cytokine data 
 Skewness Kurtosis p-Value 
IL1 4.99 26.49 <0.0001 
IL5 4.14 19.79 <0.0001 
IL8 6.30 43.25 <0.0001 
IL10 5.09 28.89 <0.0001 
IL17 5.02 26.93 <0.0001 
IFN 4.91 27.22 <0.0001 
IFN 1.71 9.21 <0.0001 
5.1 Recruitment of XL-CGD Carriers 
There were 94 XL-CGD families identified. 20 were excluded; 4 were not 
approached due to deceased index case, 11 were non-UK residents and 5 known 
to have a new mutation in the index case. All families were approached either in 
person at a clinic appointment or by post. One family declined to participate and 
11 families did not respond. There were two participants who were originally 
included, but were excluded after they were found to have a normal neutrophil 
oxidative burst and are not counted in the numbers or presented in this thesis.  
There were 81 XL-carriers recruited from 62 kindreds, who participated in the 
study. Of these, 19 were lost to follow up or did not return questionnaires 
despite reminders, 1 withdrew (due to death of index case). Complete data were 
available for 61 XL-carriers. Two XL-CGD carriers were deceased and therefore, 
only limited information was available.  
A summary of the recruitment of XL-CGD carriers is shown in Figure 5-1 and 
Figure 5-2.   
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Figure 5-1: Identification and Recruitment of XL-CGD Carriers 
 
Figure 5-2: Recruited Participant Flow Chart 
 
Demographics 
The baseline demographics for enrolled participants are shown in Table 5-4. 
There were 81 XL-CGD carriers from 62 families, with a median age of 41 years. 
Ethnicity of XL-CGD carriers was recorded at enrolment. 96.2% (76) of the XL-
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Table 5-4: Baseline Characteristics of recruited XL-CGD Carriers 
 XL-CGD Carriers  
Number of Carriers  81 
Number of Kindreds 62 
Median Age (Range) 41 (3-77) 
Number Alive (%) 79 (97.5%) 
Number Deceased (%) 2 (2.5%) 
Median Age Index 
Case (Range) 
12 (1-43) 
Number of Children 
per index case (Mean) 
1.7 
Number of Affected 
Children (Mean) 
0.84  
The age of the index case was recorded at the point of enrolment of the 
participant into the study.  Index case age was categorised based upon 
developmental stage. This breakdown is shown in Table 5-5, with the majority of 
index cases being aged between 7 and 18 years, at the time of enrolment.  
Table 5-5: Age Classification of Index Case 
Age of Index Case XL-CGD Carrier Group Participants 
Number (%) 
Infant (<2 years) 7 (8.9) 
Young Child (2-6 years) 8 (10.1) 
Middle Child (7-12 years) 20 (25.3) 
Adolescent (13-18 years) 169(24.0) 
Adult (>18 years) 17 (21.5) 
Deceased 8 (10.1) 
New Mutation  1 (1.2) 
Recruitment Location 
XL-CGD carriers were recruited in person from 5 centres; Newcastle upon Tyne, 
The Royal Free and GOS Hospitals London, Birmingham and Manchester and also 
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through the postal approach.  The breakdown of sites is shown in Figure 5-3, 
with the majority being recruited from the three main centres; Newcastle upon 
Tyne, the Royal Free and Great Ormond Street.  
In total, 81 GPs were written to for medical information about the recruited XL-
CGD carriers. 55 replied with information. 22 did not reply and in 3 cases there 
was no GP recorded and so they could not be contacted.  In 1 case the GP was 
incorrectly recorded.  
Figure 5-3: Recruitment Site of XL-CGD Carriers 
 
Relationship to Index Case 
Once an index case was identified, all known carriers within the family were 
invited to participate in the study. The relationship of the recruited XL-CGD 
carrier to the index case is shown in Figure 5-4. The majority of XL-CGD carriers 
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Figure 5-4: Relationship to Index Case of Recruited XL-CGD Carriers 
 
Mutations 
The exact mutation was known for 20 of the XL-CGD carriers. Due to the limited 
number the mutation was known in, no further analysis was undertaken about 
correlation of symptoms in XL-CGD carriers with the specific mutation.  
Transplant 
In 40 of the XL-CGD carriers, the index case had undergone HSCT. There was one 
index case that had undergone gene therapy and there was 1 XL-CGD carrier in 
which there was no index case as the XL-CGD carrier was the first identified in 
the kindred. The remainder were managed conservatively. The demographics of 
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Table 5-6: Baseline Characteristics of HSCT vs. No HSCT in index Case Cohorts 
 Index Case Underwent 
HSCT 
No HSCT 
Number of Carriers 40 40 
Mean Age Carrier (years) 39.0 45.5 




The control group of carriers of XL Muscular Dystrophy (MD) were all recruited 
from the GNCH, Newcastle upon Tyne.  
There were 58 families with XL MD (Duchenne or Becker) were identified at 
GNCH. Of these 22 were a new mutation in the index case (and so no carriers in 
the family) and 4 were non-UK and therefore, not eligible for recruitment to the 
control group. Additionally, 3 of the index cases were adopted or not living with 
biological parents and therefore, contacting carriers was not appropriate. 19 MD 
carriers were approached for recruitment. There were 7 MD carriers who agreed 
to participate and returned questionnaires, 4 MD carriers declined to participate. 
There were 8 MD carriers who agreed to participate but did not return 
completed questionnaires.  
All eligible carriers were approached in person. The demographics and a 
comparison with the XL-CGD carrier cohort are shown in Table 5-7.  
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Table 5-7: Baseline Characteristic Comparison of XL-CGD Carriers vs. MD Carrier Control Group 
 XL-CGD Carrier Group Control Group 
Number 81 7 
Mean Age (Range) 42.5 (3-77) 39.6 (36-48) 
Number Alive (%) 97.5 100 
Number Deceased (%) 2.5 0 
Median Age Index Case 
(Range) 
12 (1-43) 9.3 (2-13) 
Mean Number of 
Children per participant 
1.7 1.7 
Mean Number of Affected 
Children per participant 
0.84 1.3 
Ethnicity (% WB) 96.2 100 
% Index Cases Ambulant 100 50 
The relationship to the index case was recorded for the MD control group in the 
same manner as the XL-CGD carriers. This is shown in Table 5-8. All of the 
recruited controls were mothers of the MD patients.  
Table 5-8: Relationship to Index Case in XL-CGD Carrier and MD Carrier Control Groups 
 XL-CGD Carrier Cohort Control (MD) Group 
Mother 56 7 
Grandmother 6 0 
Sister 13 0 
Other 5 0 
As with the XL-CGD carrier cohort, the age of the index case was recorded and 
categorised for the control participants and this is shown in Table 5-9. 
 100 
Table 5-9: Classification of Index Case Age in XL-CGD carrier and MD carrier control group 
Age of Index Case XL-CGD Carrier Group MD-Carrier Control Group 
Infant (<2 years) 7 (8.9) 0 
Young Child (2-6 years) 8 (10.1) 1 
Middle Child (7-12 years) 20 (25.3) 4 
Adolescent (13-18 years) 169(24.0) 2 
Adult (>18 years) 17 (21.5) 0 
Deceased 8 (10.1) 0 
No Index Case 1 (1.2) 0 
5.2 Clinical Results 
This section will present the clinical findings in XL-CGD carriers. 
5.2.1 Information about Deceased Carriers 
Two of the XL-CGD carriers were deceased at the time of enrolment into the 
study as consent for inclusion was gained from their next of kin. The clinical 
information obtained about these XL-CGD carriers is shown in Table 5-10.  
Table 5-10: Clinical Information about deceased XL-CGD Carriers 
Carrier ID Information Available 
24 Died in late 30s 
Recorded cause of death ‘lupus’ 
28 Died age 30 years 
Recorded cause of death: Ischaemic Heart Disease at post mortem.  
Suffered from diarrhoea and abdominal pain. ‘Mild Lupus’ with joint pain and 
photosensitivity. Asthma. Recurrent skin abscesses particularly in groin. 
5.2.2 Neutrophil Oxidative Burst 
Neutrophil Oxidative Burst results were available for 54 of the XL-CGD carriers. 
Results are given as percentage of normal function. The mean value was 47.01 % 
with a standard deviation of 21.67. The absolute range was 7 – 94%. The 
majority of XL-CGD carriers fell in the range of 21 – 60% functioning, and this 
distribution is shown in Figure 5-5. 
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Figure 5-5: Distribution of NOB in XL-CGD Carriers 
 
Historical NOB results were available for 26 of the recruited XL-CGD carriers.  
Historical and enrolment NOB means were compared using a paired t-test and 
the results are shown in Table 5-11. Historical NOB values were significantly 
higher than those performed at enrolment.  
Table 5-11: Historical and Enrolment NOB in recruited XL-CGD Carriers 




P = 0.022 Mean 47.0 51.7 
SD 21.7 18.6 
Absolute Range 7-94 24-92 
Age against NOB 
The age of recruited participants was compared to the percent of normal NOB 
and a scatter graph of these variables is shown in Figure 5-6.  There was no 





































Figure 5-6: Age (years) against Per Cent Normal NOB in Recruited XL-CGD Carriers 
 
5.3 Infection  
Infection was considered significant if it was potentially life threatening e.g. 
pneumonia or meningitis or if it were recurrent. The infectious complications in 
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Table 5-12: Significant Infections in XL-CGD Carriers 
 Number of XL-CGD Carriers (%) 
Any Significant Infection 19 (23.5) 
Fungal 1 (1.2) 
Pneumonia 4 (4.9) 
Meningitis 2  (2.5) 
Recurrent Abscesses 14 (17.3) 
Sinus 2 (2.5) 
Lymphadenitis 4 (4.9) 
Recurrent UTI 6 (7.4) 
The neutrophil oxidative burst values in those affected and unaffected by 
significant infection were compared (Figure 5-7). There was no significant 
difference when the groups were compared by a two sample t-test (p=0.6).  
Figure 5-7: NOB Values in those affected and unaffected by recurrent or significant infection 
 
XL-CGD carriers were specifically asked about mycobacterial infection. 
Information was also volunteered by 3 XL-CGD carriers about reaction to BCG 


















Table 5-13: Mycobacterial Complications in XL-CGD Carriers 
 Number Of XL-CGD Carriers Affected 
(%) 
Definite TB Infection 0 (0) 
Possible TB Infection 1 (1) 
Discharging BCG Site 3 (4) 
Recurrent abscesses were considered separately and the neutrophil oxidative 
burst values were compared in those affected and unaffected by a two-sample t-
test and a significant difference was found (p=0.0088). The NOB was significantly 
lower in those affected by recurrent abscesses. These results are shown in Figure 
5-8. 




















5.4 Inflammatory Manifestations 
5.4.1 Gastrointestinal Symptoms 
Growth  
Height and weight measurements were available for 69 of the recruited XL-CGD 
Carriers. These measurements were used to calculate BMI. Classification of BMI 
was taken from the NICE assessment of BMI [259] and the results are shown in 
Table 5-14. A comparison of the proportion of XL-CGD categories in each 
category with the proportion of UK females in each category is shown in Table 
5-14.  There were significantly more XL-CGD carriers classified as underweight 
and significantly fewer in the overweight category. In all other categories there 
was no significant difference between the XL-CGD carriers and UK female 
population data.  






Female Population Data 
(2008-2010) (%)[259]  
 
p-value 
Underweight <18.5 5 (7.3) 1.2 0.0002 
Healthy 18.5-24.9 29 (42.0) 36.8 0.18 
Overweight  25-29.9 16 (23.2) 34.4 0.025 
Obesity 1 30-34.9 10 (14.5) 
24.0 0.5 
Obesity 2 35-39.9 7 (10.1) 
Obesity 3 >40 2 (2.9) 3.5 0.39 
Missing n/a 13 (16.3) n/a  
Gastrointestinal Symptoms 
All recruited XL-CGD carriers were asked about the presence of gastrointestinal 
(GI) symptoms. Gastrointestinal symptoms were present in 40 (53%) of the XL-
CGD carriers.  
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The type of gastrointestinal symptom suffered and the number of XL-CGD 
carriers affected is shown in Figure 5-9 with abdominal pain and diarrhoea the 
most frequently occurring. 
Figure 5-9: Gastrointestinal Symptom Type and Frequency in XL-CGD Carriers 
 
A comparison with the published data about GI symptom frequency in CGD 
patients is shown in Table 5-15 along with a one-sample test of proportion. 
Rectal bleeding and constipation were significantly more common in the XL-CGD 
carriers whilst abdominal pain was significantly less common. Diarrhoea 































Table 5-15: A Comparison of frequency of gastrointestinal symptoms in XL-CGD carriers compared 
to published data about CGD patients 




Number in Study 81 140  
Abdominal Pain 34% 46 % 0.018 
Diarrhoea 33% 33 % 0.51 
Rectal Bleeding 23% 6 % <0.0001 
Constipation 11% 4 % 0.001 
Gastrointestinal Investigations 
GI investigations undertaken in XL-CGD carriers were recorded. The distribution 
of the type of investigation is shown in Table 5-16 and the findings are shown in 
Table 5-17. The most common investigations were endoscopy and colonoscopy.   
Table 5-16: Gastrointestinal Investigations in XL-CGD Carriers 
 Number of XL-CGD Carriers 
Any Investigation 15 








Table 5-17: Results of Gastrointestinal Investigations and Results in XL-CGD carriers 
Carrier Investigation Investigation Finding 
3  Colonoscopy Colitis consistent with CGD colitis 
Endoscopy Hiatus hernia 
4 Colonoscopy Minor, non-specific inflammation (reported as not 
significant) 
11 Labelled white cell  






Hiatus hernia and gastritis 
Normal 
13 Gastroscopy Normal duodenal biopsy. Telangiectasia. Normal GI tract 
20 USS Normal 
21 Colonoscopy Crohn’s disease 
34 Body scan Diverticular Disease 






Crohn’s disease  
Patchy inflammatory abscesses with cryptitis and crypt 
abscesses. No convincing granulomas. Consistent with 
mild/moderate chronic inflammation 




Patchy inflammatory changes. Acute inflammation with 
cryptitis and crypt abscesses. Mild chronic inflammation in 
left colon. No convincing granulomas.  
The appearances are of patchy mild and moderate active 
chronic inflammation, in keeping with clinical history of 
Crohn’s disease.  
42 Sigmoidoscopy Normal  
53 Endoscopy Oesophagitis (Early Barrets) 
Episodes of gastrointestinal surgery were recorded where the information was 
available and the findings are shown in Table 5-18. 
Table 5-18: Surgical Interventions in XL-CGD carriers 
Surgery Type Number XL-CGD Carriers (%) 
Colectomy 1 (1.2) 
Appendicectomy 4 (5) 
The IBD Disability Index was completed by 61 XL-CGD carriers. The higher the 
score on the IBD Disability scale, the greater the effect the symptoms have upon 
quality of life. The mean score was 28.7 (+/-10.94) in the XL-CGD carrier cohort.  
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Scores in the symptomatic group were higher than those not suffering from any 
GI symptoms (p<0.01), which is expected. 
Gastrointestinal Diagnosis  
Not all XL-CGD carriers who suffered from GI symptoms had a formal diagnosis. 
In those where a diagnosis was available it was documented. These findings are 
shown in Table 5-19. The majority of XL-CGD carriers did not have a 
gastrointestinal diagnosis. Of those that did, irritable bowel syndrome was the 
most common diagnosis, affecting nearly 10% of the XL-CGD carrier cohort.  
Table 5-19: Gastrointestinal Diagnoses in XL-CGD carriers 
Diagnosis Number (%) 
Inflammatory Bowel Disease 2 (2.5) 
CGD Colitis 1 (1.2) 
Irritable Bowel Syndrome 8 (9.8) 
Other 2 (2.5) 
None 66 (81) 
Referred for Investigation 2 (2.5) 
Correlation with Neutrophil Oxidative Burst  
The neutrophil oxidative burst value in the affected and unaffected groups were 
compared using a paired t-test. The results are shown in Table 5-20. The NOB 
was significantly lower in those suffering from diarrhoea and also in those 
suffering from abdominal pain. This was not found in those suffering from rectal 
bleeding. The significance was not found when GI symptoms were considered 
overall, although it was approaching statistical significance. 
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Table 5-20: Neutrophil Oxidative Burst Value in Symptomatic and Asymptomatic XL-CGD carriers 
Symptom Average NOB in 
Affected Group 




Any GI Symptom 43.6 52.3 0.08 
Abdominal Pain 39.8 51.8 0.05 
Diarrhoea 36.5 53.5 0.009 
Rectal Bleeding 43.5 49.6 0.16 
The proportion of XL-CGD carriers with any positive autoantibody tested by 
immunofluorescence was also compared between the affected and unaffected 
groups and these results are shown in Table 5-21. The proportion of individuals 
with positive autoantibodies was not significantly different between the affected 
and unaffected groups.  
Table 5-21: Autoantibodies and GI Symptoms in XL-CGD Carriers 
 % Any Autoantibody 
Positive 
PR Test of Proportion  
GI Symptoms 22 
p  = 0.76 
No GI Symptoms 27 
Factors contributing to the development of gastrointestinal symptoms were 
considered and the correlation is shown in Table 5-22. Age, the presence of an 
index case with colitis, anxiety and depression scores, fatigue and joint 
symptoms were all significantly correlated with gastrointestinal symptoms.  
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Table 5-22: Correlation of Gastrointestinal Symptoms with Potential Contributing Factors 
 Correlation Coefficient p – value 
Age 0.37 0.0010 
Index Colitis 0.46 0.032 
Smoking 0.18 0.12 
Anxiety (HAD-A) 0.31 0.015 
Depression (HAD-D) 0.28 0.028 
Fatigue (MFTotal) 0.33 0.0098 
NOB -0.17 0.23 
Autoantibodies (IF) 0.10 0.48 
Joint Pains 0.99 <0.0001 
SLE Criteria -0.03 0.75 
Total PIP 0.16 0.34 
IBD Disability Score 0.53 <0.0001 
Ulcers 0.18 0.12 
Regression: GI Symptoms 
A logistic regression analysis was undertaken in relation to the presence of any 
gastrointestinal symptoms and the results from this are shown in Table 5-23. 
The presence of colitis in the index case, a higher anxiety and depression score 
and a higher number of SLE criteria met were all significantly associated with the 
presence of gastrointestinal symptoms.  
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Table 5-23: Regression Analysis of Gastrointestinal Symptoms in XL-CGD carriers 
 Odds Ratio 95% CI P-Value 
Age 1.01 0.985, 1.037 0.41 
Index Colitis 8.67 1.049, 71.56 0.045 
Smoking 1.69 0.8607, 3.305 0.13 
Anxiety (HAD-A) 1.19 1.026, 1.370 0.021 
Depression (HAD-D) 1.18 1.012, 1.372 0.034 
Fatigue (MFTotal) 1.03 1.006, 1.057 0.014 
NOB 0.98 0.95, 1.01 0.23 
Autoantibodies (IF) 1.60 0.442, 5.787 0.47 
Joint Pains 1.84 0.708, 4.79 0.21 
SLE Criteria 1.37 1.00, 1.88 0.05 
Total PIP 1.01 0.994, 1.016 0.33 
5.4.2 Respiratory Symptoms 
Specific respiratory diagnoses or complaints in the XL-CGD carriers and their 
frequency are shown in Table 5-24. The most common diagnosis was asthma.  
Table 5-24: Respiratory Diagnoses and Symptoms in XL-CGD Carriers 
Diagnosis/Symptom Number of Carriers (% Carriers) 
Asthma 10 
Bronchitis 1 
Pleural Inflammation 1 
Cough 3 
Other  1 
There were 59 XL-CGD carriers who completed the St George’s Respiratory 
Questionnaire (SGRQ). The data were not normally distributed. The median 
scores and ranges for each domain are shown in Table 5-25 along with published 
normal values. It can be seen that the scores are similar for all domains.  
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Table 5-25: Comparison of Results of SGRQ in XL-CGD carriers with published data 




Symptom Score 12.7 (0-39.8) 12 (9-15) 
Activity Score 12.17 (0-35.2) 9 (7-12) 
Impact Score 1.63 (0-13.6) 2 (1-3) 
Total Score 7.32  (1.6-21.8) 6 (5-7) 
5.4.3 Skin Disease 
Photosensitivity was seen in 74% of the XL-CGD carriers. Other dermatological 
conditions were seen in 56 of the XL-CGD carriers and the frequencies of these 
diagnoses are shown in Table 5-26. The most commonly seen was eczema 
followed by acne of adult onset. A history of poor wound healing was 
volunteered in the medical history by 2 XL-CGD carriers.  
Table 5-26: Skin Disease in XL-CGD carriers 
 Number of Carriers (%) 
Photosensitivity 57 (74%) 
DLE/malar rash 30 (40%) 
Eczema 11 (14%) 
Psoriasis 3 (4%) 
Adult acne 8 (10%) 
Erythema multiforme 2 (3%) 
Dermatitis 5 (7%) 
Allergic/hives 5 (7%) 
Rosacea 5 (7%) 
Malignant 1 (1%) 
Other 12 (16%) 
Poor wound healing 2 (3%) 
An association was sought between NOB value and the presence of the most 
prevalent skin disease.  These results are shown in Table 5-27. It can be seen that 
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there were no significant differences between NOB value in the affected and 
unaffected groups. 
Table 5-27: NOB Values in affected and unaffected groups of XL-CGD carriers with skin disease 
 Mean NOB in affected 
group 
Mean NOB in unaffected 
group 
p-value 
Photosensitivity 46.4 48.5 0.61 
DLE/Malar Rash 46.2 47.5 0.58 
Eczema 57.5 46.6 0.12 
5.5 Autoimmune Features 
SLE Symptoms 
The frequency of the different SLE symptoms in XL-CGD carriers is shown in 
Table 5-28 alongside published data from a European cohort of SLE patients 
[129]. There were significantly higher rates of mouth ulcers, photosensitivity and 
Raynaud’s phenomenon in the XL-CGD carrier cohort. The death rate was also 
significantly higher in the XL-CGD carrier cohort.   
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PR Test p-value 
Geographical Area Europe United Kingdom  
Number of Patients 
(%) 
1000 66  
Malar Rash 311 (31.1) 30 (39) 0.0681 
Photosensitivity 229 (22.9) 57 (74) <0.01 
Oral Ulcers 125 (12.5) 57 (76) <0.01 
Raynaud’s 
Phenomenon 
163 (16.3) 27 (35) <0.01 
Arthritis 481 (48.1) 48 (62) 0.01 
Serositis 160 (16.0) 3 (3.8) 0.003 
Nephropathy 279 (27.9) 3 (3.8) <0.001 
Neurological 
Involvement 
194 (19.4) 3 (3.8) <0.005 
Death 68 (6.8) 2 (3) <0.0001 
A diagnosis of SLE is made using the ARA criteria as previously described. 4 of 
the 11 criteria are required to make a diagnosis. Over half of the XL-CGD carriers 
met at least 3 of the ARA SLE criteria. The number of criteria met is shown in 
Table 5-29.  
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Table 5-29: Number of ARA SLE Criteria met in XL-CGD carriers 
Number of SLE Criterion 
Met 
Number of Carriers (%) 
None 10 (12.3%) 
1 9 (11.1%) 
2 17 (20.9%) 
3 24 (29.6%) 
4 +  21 (25.9%) 
Neuropsychiatric SLE symptoms were evaluated in addition to the other SLE 
criteria. The frequencies of these manifestations are shown in Table 5-30. The 
most commonly occurring were headache and anxiety.  
Table 5-30: Neuropsychiatric SLE features in XL-CGD carriers 
Symptom  Number of Carriers Affected (%) 
Aseptic Meningitis 0 
Cerebrovascular disease 2 
Demyelinating syndrome 0 
Headache (including migraine and 
benign intracranial hypertension) 
15 
Movement Disorder (chorea) 0 
Myelopathy 0 
Seizure Disorder 0 
Acute confusional state 0 
Anxiety Disorder (HADS>10) 26 
Cognitive Dysfunction 0 
Mood Disorder 5 
Psychosis 0 
Peripheral Nervous System 0 
Joint Symptoms 
Participants were asked about the presence of joint problems.  Participants 
described episodic involvement with pain, swelling and associated fatigue lasting 
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up to 3 days at a time. There were 48 (59%) XL-CGD carriers who suffered from 
recurrent joint symptoms with 36 reporting more than one joint being affected. 
Participants were asked which joints were affected and these results are 
summarised in Table 5-31.  Where multiple joints were affected in an individual 
participant they are all included. There were 36 XL-CGD carrier who reported 
symptoms in more than one joint.  
Table 5-31: Affected Joints in XL-CGD carriers 
 Affected (% of all XL-CGD carriers) 
Any Joint 48 (59) 
Multiple Joints 36 (44) 
Fingers 13 (16) 
Small Joints of Hand 14 (17) 
Wrist 8 (10) 
Shoulder 11 (14) 
Neck 3 (4) 
Jaw 1 (1.2) 
Back 12 (15) 
Hips 15 (19) 
Knees  26 (32) 
Ankles 6 (7) 
Feet 4 (5) 
Toes 2 (2) 
The neutrophil oxidative burst values and autoantibody results were compared 
between the affected and unaffected groups. These results are shown in Table 
5-32. There was no significant difference found between the groups. Those 
affected by joint symptoms were significantly older than those without joint 
symptoms. There was no difference in smoking status between the affected and 
unaffected groups.  
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Table 5-32: Neutrophil Oxidative Burst Values in XL-CGD carriers affected and unaffected with joint 
symptoms 





Mean NOB  
(% normal) 
47.26 49.94 0.468  
Autoantibody 
Positive (%) 
10 3 0.625 
Median Age (years) 43.3 36.9 0.0345 
Smoking 
(smokers/total) 
7/44 2/28 0.535 
Autoimmune features outside of SLE found in the XL-CGD carriers are shown in 
Table 5-33 with Raynaud’s phenomenon being the most commonly described. 
Table 5-33: Autoimmune Features in XL-CGD carriers 
 Number XL-CGD Carriers (%) 
Raynaud’s Phenomenon 27 (35.5) 
Alopecia 6 (7.7) 
Sjogren 1 (1.2) 
Lupus-Like Diagnosis 15 (18.5) 
5.6 Other Medical Problems 
Medical problems outside those already discussed were also recorded and are 
shown in Table 5-34. 
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Table 5-34: Other Medical Problems in XL-CGD Carriers 
 Number of Carriers (%) 
Hypothyroid 4 (5) 
Diabetes Mellitus 1 Gestational  
1 Type 2 
Vitamin B12 Deficiency 2 (2.5) 
Recurrent Blackouts/Faints 3 (3.6) 
Two of the XL-CGD carriers reported suffering from seizures in the neonatal 
period relating to hypocalcaemia. It was not possible to find any further details 
about this.  
Dental  
Three of the XL-CGD carriers reported suffering from slightly unusual dental 
problems and these are shown in Table 5-35. 
Table 5-35: Dental Complaints in XL-CGD Carriers 
Carrier ID Problem 
60 All teeth came through at 18 months of age. The teeth were black and 
conical and required removal. Normal adult teeth 
63 Extra teeth required removal 
76 Lost all teeth at the age of 50 years. Her mother had lost all teeth at the 
age of 30 years 
Gynaecological Problems 
There were 9 XL-CGD carriers who reported suffering from at least one 
miscarriage. A comparison between those reporting miscarriage and those not is 
shown in Table 5-36. 
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Table 5-36: Recurrent Miscarriage and Associations in the XL-CGD Carrier Cohort 
 Miscarriage No Miscarriage P value 
Number  9 72  
Mean Age (years) 37.7  43.2 0.19 













Gynaecological problems outside of miscarriage were also reported and these 
results are shown in Table 5-37. All problems were reported infrequently.   
Table 5-37: Gynaecological Problems in the XL-CGD Carriers 
Problem Number of XL-CGD Carriers Affected 
(%) 
Polycystic Ovaries 1 
Chronic Endometritis 1 
Breast Fibroadenoma 2 
Ectopic Pregnancy 1 
Menorrhagia 2 
Ocular Problems 
The ocular problems reported or volunteered by the XL-CGD carriers are shown 
in Table 5-38. They are all reported in low numbers. Coats disease is a rare, 
hereditary condition, which in this case resulted in the eye being removed.  
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Table 5-38: Ocular Manifestations in XL-CGD Carriers 
Problem Number of XL-CGD Carriers  
Chorioretinitis 2 
Retinal Infection (non specific) 1 
Photopsia 1 
Esotropia 1 
Coats’ Disease 1 
Cardiovascular Disease 
The XL-CGD carriers volunteered cardiovascular problems and these are shown 
in Table 5-39. Only four reported hypertension but Figure 5-10 shows that 9 XL-
CGD carriers are prescribed anti-hypertensive medication suggesting that this 
number may be higher. The same is also true for high cholesterol, with two XL-
CGD carriers reporting it as a problem but five XL-CGD carriers have been 
prescribed a statin as a cholesterol lowering agent.  
Table 5-39: Cardiovascular Problems in XL-CGD Carriers 
Problem Number of XL-CGD Carriers Affected  
Hypertension 4 
High Cholesterol 2 
Palpitations 2 
Atrial Fibrillation 1 
LBBB on ECG 2 




There were 3 XL-CGD carriers who had been diagnosed with malignancy and 
these are shown in Table 5-40. 
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Table 5-40: Malignancy in XL-CGD Carriers 
Type of Malignancy Number of XL-CGD Carriers 
Ovarian Cancer 1 
Renal Cancer 1 
Basal Cell Carcinoma 1 
5.8 Medications  
Prescribed medications were recorded from XL-CGD carriers and confirmed 
from GP records. The medications were then classified according to their class. 
45 of the XL-CGD carriers were prescribed at least one medication including 
topical treatments. The frequency of the prescription of different classes of 
medications in XL-CGD carriers is shown in Figure 5-10 with analgesics, anti-
depressants and hydroxychloroquine being the most frequently prescribed. 
Patients with CGD who are managed conservatively are on regular antibiotic and 
antifungal medication and frequently topical skin treatments. These were 
prescribed in a small number of the XL-CGD carriers.  Of particular interest is the 
use of agents similar to those used in CGD patients including septrin and 
steroids.  
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Figure 5-10: Prescribed Medications in XL-CGD carriers 
 
There were 4 XL-CGD carriers who were prescribed prophylactic antibiotics. The 
breakdown of prophylactic antibiotic use is shown in Figure 5-11, with septrin 
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Figure 5-11: Prophylactic Antibiotic Use in XL-CGD carriers 
 
5.9 Combination of Symptoms 
We looked for symptom patterns. Figure 5-12 shows the number of XL-CGD 
carriers affected by joint symptoms, bowel symptoms and photosensitivity. 
Where the symptoms overlap the number affected by the combination is shown 
in bold. The number in the centre shows the number of XL-CGD carriers affected 





















Figure 5-12: Number of XL-CGD Carriers affected by Bowel and Joint Symptoms and Photosensitivity 
 
A comparison in the NOB and age for the XL-CGD carriers affected by different 
combinations of symptoms is shown in Table 5-41. It can be seen that the most 
frequently occurring combination is photosensitivity and joint symptoms, and 
this combination has the youngest median age.  
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5.10 Blood Results 
5.10.1 Neutrophil Oxidative Bursts 
The NOB values for enrolled participants were shown in Table 5-11. Further 
analysis of NOB values was undertaken per kindred. Where there were three 
generations represented these NOB values against age are shown in Figure 5-13. 
Here it can be seen that in two of the families, the NOB was lower with increasing 
age but in one family this trend was reversed.  
Figure 5-13: NOB and Age for 3 generations in 3 families 
  
Where there were less than three generations represented, these results are 
shown Figure 5-14. Here it can be seen in four of the five families represented, 
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Figure 5-14: NOB and Age for 2 generations in 5 families 
 
NOB and Symptoms 
Table 5-42 shows a comparison in NOB value in those affected and unaffected by 
symptom. It shows that there was a significant difference in NOB in those 
suffering from recurrent abscesses and those who were prescribed prophylactic 
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Table 5-42: NOB Values in affected and unaffected XL-CGD carriers by symptom 
 Affected Mean 
NOB 
Unaffected NOB P Value 
Raynaud’s 
Phenomenon 
48.68 45.7 0.68 
Joint Symptoms 46.55 47.15 0.46 
Ulcers 45.65 53.67 0.13 
Photosensitivity 46.31 48.54 0.38 
Skin Abscesses 30.13 49.73 0.0088 
Miscarriage 47.00 48 0.54 
Hydroxychloroquine 39.2 47.133 0.16 
Antibiotic 49.03 23.167 0.0025 
Antifungal 46.61 32 0.100 
Infection  47.51 45.5 0.39 
Fatigue 42.88 51.07 0.085 
NOB and Number SLE Criteria 
There was no significant difference between the number of SLE criteria met and 
the NOB result when compared using the one way test of ANOVA (p=0.58). 
5.10.2 Autoantibodies Immunofluorescence 
An autoantibody panel was performed by immunofluorescence in 56 XL-CGD 
carriers. The number of positive autoantibodies is shown in Figure 5-15. The 
majority of XL-CGD carriers had no positive autoantibodies, as measured by 
immunofluorescence, and only two XL-CGD carriers had more than one 
autoantibody positive.  
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Figure 5-15: Number of Autoantibodies Positive in an Individual XL-CGD Carrier as measured by 
Immunofluorescence 
 
The type of autoantibody found in the XL-CGD carriers is shown in Table 5-43. 
ANA was the most frequently positive autoantibody, with anti-gastric parietal 
cell antibody the next most common.  
Table 5-43: Type of Autoantibody Positive 
 Positive (%) Negative (%) 
ANA 8 (14) 48 (86) 
Anti Gastric Parietal Cell 
Antibody 
4 (7) 52 (93) 
Anti Mitochondrial Antibody 1 (1.8) 55 (98.2) 
Anti Smooth Muscle 
Antibody  
1 (1.8) 55 (98.2) 
 
5.11 Summary of Clinical Results 
 The mean NOB in the XL-CGD carriers was 47%, with the majority falling 
in the range of 21-60% 
 Infective, inflammatory and autoimmune features were seen in the XL-
CGD carriers 
 23% suffered recurrent or significant infection and overall this did not 





























 Recurrent skin abscesses were seen in 17% and there was a significant 
correlation with lower NOB in those suffering abscesses 
 53% XL-CGD carriers in this study suffered gastrointestinal symptoms. 
Overall, there was no association with NOB value. However, those 
suffering from abdominal pain and diarrhoea had significantly lower NOB 
values 
 59% suffered recurrent joint symptoms but there was no correlation with 
NOB or autoantibodies 
 Photosensitivity was seen in the majority of XL-CGD carriers with 74% 
affected and 40% suffered from DLE-type skin rashes. These did not 
correlate with NOB values.  
 Features of SLE were common in the XL-CGD carriers with 30% of XL-
CGD carriers meeting 3 criteria and 26% meeting 4 or more of the criteria 
 Overall, there was poor correlation of medical symptoms with NOB with 
the exception of recurrent skin abscesses and the gastrointestinal 
symptoms 
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Chapter 6: Psychological Health 
Results 
This chapter will present the results of the psychological assessment. 
6.1 Anxiety and Depression 
There were 61 XL-CGD carriers who completed the HADS and 7 controls (MD 
carriers).  
6.1.1 Anxiety 
Anxiety in XL-CGD Carriers 
The frequency of a pre-existing diagnosis of anxiety or anxiety and depression is 
reported in Table 6-1.  Only 1 XL-CGD carrier suffered from isolated anxiety, but 
a greater number had a diagnosis of mixed anxiety and depression. There were 
12 XL-CGD carriers who had been prescribed antidepressants.  
Table 6-1: Pre-existing Anxiety and Depression Diagnoses and Treatment 
Diagnosis Number of XL-CGD Carriers % Affected 
Anxiety 1 1.6 
Depression 7 11.6 
Mixed anxiety and depression 6 10 
Prescribed antidepressants 12 20 
There were 61 XL-CGD carriers who completed the HADS. The mean score was 
9.47 (SD 4.05). The distribution of XL-CGD carriers in the anxiety categories is 
shown in Table 6-2. Over 40% of XL-CGD carriers suffered from moderate or 
greater levels of anxiety with only one third being classified as normal.  
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Table 6-2: Anxiety Categories in XL-CGD Carriers 
HAD Anxiety Category Number of Carriers  % 
Normal (0-7) 21 34.4 
Mild (8-10) 14 23.0 
Moderate (11-14) 22 36.1 
Severe (>14) 4 6.5 
Total 61 100 
Anxiety scores were reviewed in the context of the relationship of the XL-CGD 
carrier to the index case and these results are shown in Figure 6-1. The most 
striking feature is that 50% of the grandmothers suffered moderate anxiety. The 
distribution across anxiety categories is otherwise similar, irrespective of the 
relationship to the index case.  
Figure 6-1: Anxiety Categories by Relationship to Index Case in XL-CGD Carriers 
 
The differences in HAD-A scores between the relationship groups did not reach 





































Table 6-3: HAD-A Scores in XL-CGD carriers by relationship to index case 
 Number of Carriers HAD-A Mean (SD) p-value 
Mother 39 9.5 (4.05) 
0.98 
Grandmother 6 9.8 (3.76) 
Sister 10 9.5 (5.25) 
Other 6 8.8 (3.11) 
As there were small numbers in the groups, a comparison of mothers and all 
other relatives was also made. There was no significant difference when the 
mothers were compared to the rest of the group as a whole (p=0.56). 
There was no significant difference in mean anxiety scores of the XL-CGD 
carriers when considered with regard to age categories of the index case 
(p=0.27).  
The comparison in anxiety scores between participants where the index case had 
undergone HSCT and those where they had not is shown in Table 6-4. The 
anxiety scores were higher in the relatives where the index case had undergone 
HSCT, but they were not significantly higher.  
Table 6-4: Anxiety Scores in XL-CGD Carriers where the index case had undergone HSCT compared 
with those where the index case had not undergone HSCT 
 HSCT in index 
case 
No HSCT in index 
case 
p-value 
Number  24 13 
0.56 
Mean 9.13 8.92 
Anxiety in XL-CGD Carriers Compared to Other Populations 
The mean scores for HAD-A in the control group of MD carriers is shown in Table 
6-5 and compared to the mean scores in XL-CGD carriers. It can be seen here that 
the mean score was lower, but that this did not reach statistical significance.  
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Table 6-5: HAD-A Scores in XL-CGD Carriers and the MD Control Group 
 XL-CGD Carriers MD Controls p-value 
Number  61 7 
0.12 Mean 9.47 8.86 
SD 4.05 4.52 
The proportion of XL-CGD carriers affected by anxiety was compared to the 
proportion of CF parents in Besier et al’s [251] published study. The comparison 
is shown in Table 6-6. A significantly higher proportion of XL-CGD carriers 
suffered from abnormal levels of anxiety compared with the parents of children 
with CF. The parents of children with CF were less likely to suffer from anxiety 
compared to the XL-CGD carriers.  





CF Parents[251]  
% (n) 
p-value 
Normal (0-7) 34.4  (21) 62.7 (408) <0.01 
Borderline (8-10) 22.9 (14) 20.2  (131) 0.30 
Abnormal (>10) 42.6 (26) 17 (111) <0.001 
Anxiety Scores in the XL-CGD carriers were compared with published scores 
from SLE patients [140, 229] and parents of children with CF [251]. The 
demographics and results are shown in Table 6-7. XL-CGD carriers suffered 
significantly greater levels of anxiety than the CF parents and also than SLE 
patients categorised as having low pain. However, there was no significant 
difference in anxiety scores when compared with the SLE patients in Tench et 
al’s[140] study and the results were comparable with the SLE patients suffering 
high levels of pain.  
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Number 61 20 64 120 650 
Median 
Age 




9.54 9 4 9 7.52 
p-value  0.18 <0.01 0.18 0.0002 
Factors Affecting Anxiety 
Higher anxiety scores were significantly (p<0.05) correlated with higher 
depression scores, lower self-esteem and the presence of joint or bowel 
symptoms.  Higher anxiety scores were also significantly correlated with higher 
levels of fatigue. There was no significant correlation of high anxiety scores with 
age, relationship to the index case or a diagnosis of SLE. These results are shown 
in Table 6-8. There was no difference in anxiety scores when the age of the index 
case was considered by age category (p=0.268).  
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Table 6-8: Relationship of Anxiety with other factors in XL-CGD Carriers  
 Correlation Coefficient (rho) p-value 
Depression (HAD-D) 0.62 <0.0001 
Self-esteem (Rosenberg) -0.74 <0.0001 
Total PIP 0.29 0.19 
Fatigue (total) 0.50 0.0031 
Bowel Symptoms 0.47 0.0059 
Joint Symptoms 0.43 0.012 
Lupus Diagnosis 0.21 0.24 
Number of ARA Criteria 0.14 0.42 
Age 0.20 0.26 
Relationship to Index Case 0.23 0.20 
HSCT in Index Case  0.003 0.98 
MH (SF-36) -0.6 <0.0001 
6.1.2 Depression 
Depression in XL-CGD Carriers 
There were 61 XL-CGD carriers who completed the HAD (depression 
component).  The mean score was 5.03 (SD 3.76). The distribution of XL-CGD 
carriers amongst the defined categories is shown in Table 6-9. Nearly three 
quarters of the cohort are categorised as normal, with only 1 XL-CGD carrier in 
the severe category. Depression was considerably less prevalent than anxiety in 
the XL-CGD carriers.  
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Table 6-9: Depression Categories in XL-CGD Carriers 
HAD Depression 
Category (Score) 
Number of XL-CGD 
Carriers 
% 
Normal (0-7) 45 73.8 
Mild (8-10) 11 18.0 
Moderate (11-14) 4 6.6 
Severe (>14) 1 1.6 
Total 61 100 
The categorical distribution for depression is shown in relation to relationship to 
index case in Figure 6-2. Here it can be seen that the distribution was similar 
independent of the relationship to the index case.  
Figure 6-2: Depression Categories by Relationship to Index Case in XL-CGD Carriers 
 
The differences in HAD-D scores between the relationship groups did not reach 











































Table 6-10: HAD-D Scores in XL-CGD Carriers by relationship to index case 
 Number of XL-CGD 
Carriers 
HAD-D Mean p-value 
Mother 38 5.26 (4.09) 
0.14 
Grandmother 6 6.33 (3.01) 
Sister 10 3.9 (2.42) 
Other 6 2.4 (2.7) 
As there were small numbers in the groups, a comparison of mothers and all 
other relatives was also made. There was no significant difference when the 
mothers were compared to the rest of the group as a whole (p=0.77). 
There was no significant difference in the depression scores (p=0.36) when the 
XL-CGD carriers were considered between index case age categories.  
The comparison in depression scores between participants where the index case 
had undergone HSCT and those where they had not is shown in Table 6-11. The 
scores were higher in the relatives of the XL-CGD patients who had undergone 
HSCT compared with those managed conservatively, but this did not reach 
statistical significance.  
Table 6-11: Depression Scores in XL-CGD Carriers where the index case had undergone HSCT 
compared with those where the index case had not undergone HSCT 
 HSCT in index 
case 
No HSCT in index 
case 
p-value 
Number  24 13 
0.65 
Mean 5.75 5.23 
Depression in XL-CGD Carriers compared to Other Populations 
The mean score for HAD-D in the control group of MD carriers is shown in Table 
6-12. It can be seen here that the mean score was higher in the MD control group 
and that this reached statistical significance, meaning the MD carriers were, on 
average, more depressed than the XL-CGD carriers.  
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Table 6-12: HAD-D Scores in XL-CGD Carriers and MD Control Group 
 XL-CGD Carriers MD Controls p-value 
Number Completed 61 7 
0.05 Mean 5.03 5.86 
SD 3.76 3.13 
The proportion of XL-CGD carriers with borderline or abnormal HAD-D scores 
was compared with the proportion seen in a published cohort of CF parents 
[251]. These results are shown in Table 6-13. There were no significant 
differences in the proportion in each category. 
Table 6-13: Comparison of proportion of XL-CGD carriers with abnormal HAD-D scores with CF 
Parents 
HAD-D Cat XL-CGD Carriers 
% (n) 
CF Parents [251]  
% (n) 
Proportion Test  
p-value 
Normal 73.7 (45)  72 (468) 0.62 
Borderline 18  (11) 16.4 (107) 0.63 
Abnormal 8.3 (6) 11.6  (75) 0.66 
The mean scores for HAD-D were compared with published data in SLE patients 
with low and high pain scores and also with the CF parents. These results are 
shown in Table 6-14. XL-CGD carriers suffered significantly greater depression 
scores than the SLE low pain group. The scores were comparable to the CF 
parents and SLE patients in Tench et al’s study[140]. 
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5.08 8  3 6 4.36 
p-value  1.0 <0.01 0.98 0.084 
Factors Affecting Depression  
Correlation of HAD-D scores and potential contributing factors are shown in 
Table 6-15. Higher depression scores were significantly correlated with higher 
anxiety scores, lower self-esteem and higher fatigue scores. There was no 
significant correlation of HAD-D scores and age, relationship to index case and 
clinical symptoms (gastrointestinal and joint symptoms, diagnosis of SLE-like 
disorder and number of ARA SLE criteria met).  
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Table 6-15: Correlation of Associated Factors with HAD-D Scores 
 Correlation Coefficient (rho) p-value 
Anxiety (HAD-A) 0.61 0.0001 
Self-esteem (Rosenberg) -0.74 <0.01 
Total PIP 0.21 0.25 
Fatigue (total) 0.54 0.0013 
Bowel Symptoms 0.23 0.20 
Joint Symptoms 0.31 0.080 
Lupus Diagnosis 0.14 0.44 
Number of ARA Criteria 0.20 0.25 
Age 0.20 0.27 
Relationship to Index 
Case 
0.11 0.55 
HSCT in index case 0.03 0.84 
MH (SF36) -0.67 <0.0001 
6.2 Self-Esteem   
There were 61 XL-CGD and 7 MD control carriers who completed the Rosenberg 
questionnaire to assess self-esteem.  The median score for XL-CGD carriers was 
19 (IQR 14-24). Table 6-16 shows the distribution of XL-CGD carriers in the 
categories for self-esteem. Nearly half of the XL-CGD carriers fell into the normal 
category, with one third being categorised as having low self-esteem.  
Table 6-16: Categories of Self-Esteem in XL-CGD Carriers 
Category Number of XL-CGD Carriers % 
Low 19 31 
Normal 28 46 
High 14 23 
Total 61 100 
The median and IQRs of the Rosenberg Self-Esteem Scale in the different 
relationship categories are shown in Figure 6-3.  
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Figure 6-3: Median and IQR of Rosenberg Self-Esteem Scores by Relationship to Index Case 
 
Table 6-17 shows a comparison of the Rosenberg scores in mothers of the index 
case compared to all other relatives. There was no significant difference when 
the two groups were compared.  
Table 6-17: Comparison of Rosenberg Self-Esteem Scores in Mothers vs. Other Relatives 








XL-CGD Carriers Self-Esteem compared with MD Controls  
There were 7 MD carriers who completed the Rosenberg Self-Esteem Scale. A 
comparison between the median scores in the XL-CGD carriers and the MD 
control group is shown in Table 6-18. There was a significant difference between 
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Table 6-18: Rosenberg Self-Esteem Scores in XL-CGD carriers and MD Control Group 
 XL-CGD Carriers MD Controls p-value 
Number Completed 61 7 
<0.001 Median 19 23 
IQR 14-25 13-29 
Correlation in Self-Esteem 
There was a significant correlation of anxiety and depression scores with self-
esteem scores in the XL-CGD carriers, with higher scores in anxiety and 
depression correlating with lower self-esteem. Total and frequency scores from 
the PIP were approaching statistically significant correlation with self-esteem 
scores, with higher scores in these domains correlating with lower self-esteem. 
There were no other significant correlating factors. These results are shown in 
Table 6-19. 
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Table 6-19: Correlation of Associated Factors with Self-Esteem Scores in XL-CGD Carriers 
 Correlation Co-efficient p-value 
Anxiety (HAD-A) -0.74 <0.01 
Depression (HAD-D) -0.74 <0.01 
PIP-T -0.30 0.084 
PIP-F -0.29 0.095 
PIP-S -0.25 0.15 
Skin Disease -0.26 0.13 
Joint Symptoms -0.37 0.004 
Bowel Symptoms -0.23 0.19 
Age of Participant 0.13 0.45 
Index Case Age 0.091 0.60 
Relationship to Index 
Case 
-0.06 0.72 
6.3 Caring for a Child with Chronic Illness  
The Pediatric Inventory for Parents (PIP), which assesses the stresses associated 
for caring for a child with chronic illness, was completed by 36 XL-CGD carrier 
mothers and 7 of the control group (MD mothers).  A numerical value is 
generated for PIP total (PIP-T), PIP Severity (PIP-S) and PIP frequency (PIP-F), 
with a higher score indicating higher levels of distress.  Data were normally 
distributed.  Table 6-20 shows the mean scores in each domain for the XL-CGD 
carriers.  
Table 6-20: Summary Statistics for PIP in XL-CGD Carrier Mothers 
 Mean SD 
PIP-Total 214.8 63.5 
PIP-Frequency 112.3 30.3 
PIP-Severity 103.0 35.3 
Table 6-21 shows the breakdown of scores compared with the age of the index 
case. The highest scores were seen in the 7-12 year old group, with lower scores 
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seen in the older groups. The lowest scores were seen in the over 18 year old 
group. However, none of these differences reached statistical significance.  






























































A comparison in PIP scores between those where the index case had undergone 
HSCT and those where they had not are shown in Table 6-22. The scores in the 
no HSCT group were higher than in those without, but no statistical significance 
was observed.  
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Table 6-22: Comparison of PIP Scores in XL-CGD Mothers of index case who had undergone HSCT 
with those who had not undergone HSCT 
 Index Case 
undergone HSCT 
No HSCT  p-value 
Number 19 6  
Total PIP 210.6 241.3 0.14 
PIP – F 112.0 123.0 0.19 
PIP – S 97.9 118.0 0.12 
Comparisons of XL-CGD Mothers with other Populations 
Table 6-23 shows the mean scores for all three domains of the PIP in XL-CGD 
mothers and in the control group of MD carrier mothers. The MD group scored 
significantly higher in the severity domain, whilst the XL-CGD mothers scored 
significantly higher in the frequency domain. The overall scores were not 
significantly different. There were too few to compare across the age categories.  
Table 6-23: PIP Scores in XL-CGD mothers compared to MD carriers 
 XL-CGD Carriers 
(Mean + SD) 
MD Carriers 




36 7  
Frequency (PIP-F) 
Score  
112.3 (30.3) 104.4  (41.1) 0.06 
Severity (PIP-S) 
Score  
103.0 (35.3) 115.6 (36.8) 0.02 
Total (PIP-T) 214.8 (63.5) 220.0 (73.8) 0.31 
Comparison with Published Data 
The PIP scores were compared with published data from parents of children 
with an oncological diagnosis. These results are shown in Table 6-24. There was 
a significant difference seen in the frequency domain, with XL-CGD carrier 
mothers scoring more highly. There was no significant difference in total or 
severity scores.  
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Table 6-24: Mean PIP Scores in XL-CGD Mothers compared with published data from oncology 
parents 
 XL-CGD Cohort 
Mean Scores ±SD 
 Oncology Parents [255] 
Mean Scores ±SD 
p-value 
PIP-T 214.8 ±63.5 206 ± 34.2 0.20 
PIP-F 112.3 ±30.3 94.0 ±33.3 0.0005 
PIP-S 103.0 ±35.3 112.4 ± 35.1 0.06 
Correlation of PIP Total 
There was no association between total PIP scores and the age of the XL-CGD 
carrier. The correlation between total PIP score and the number of children an 
XL-CGD carrier had approached statistical significance, as was the association 
with anxiety level. There were no other significant correlations found. The 
results are shown in Table 6-25. 
Table 6-25: Correlation of Associated Factors with Total PIP Scores in XL-CGD Carriers 
 Correlation Coefficient p-value 
Age of XL-CGD carrier -0.073 0.69 
HSCT -0.13 0.56 
Number of Children  0.32 0.067 
Number of Affected 
Children 
0.07 0.69 
Age of Index Case -0.19 0.30 
Anxiety (HAD-A) 0.32 0.057 
Depression (HAD-D) 0.27 0.11 
6.4 IQ Assessment 
The WAIS was completed by 9 XL-CGD carriers. The scores and per centile for 
each domain and the total for the XL-CGD carriers are shown in Table 6-26. For 6 
of the XL-CGD carriers the lowest result (when considered by per centile) was 
seen in the working memory domain.  
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1 109 (73) 108 (70) 123 (94) 89 (23) 102 (55) 
5 123 (94) 114 (82) 119 (90) 128 (97) 114 (82) 
8 97 (42) 98 (45) 104 (61) 95 (37) 92 (30) 
11 102 (55) 91 (27) 111 (77) 95 (37) 114 (82) 
17 98 (45) 98 (45) 98 (45) 92 (30) 105 (63) 
18 81 (10) 72 (3) 90 (25) 83 (13) 97 (42) 
20 104 (61) 107 (68) 111 (77) 86 (18) 102 (55) 
21 94 (34) 83 (13) 94 (34) 102 (55) 105 (63) 
43 110 (75) 110 (75) 96 (39) 128 (97) 102 (55) 
6.5 Summary of Psychological Results 
 High rates of anxiety seen in XL-CGD carriers with 40% of the XL-CGD 
carriers having moderate or greater anxiety symptoms, with lower rates 
of depression (74% no significant depressive symptoms) 
 There was no difference in anxiety symptoms if the index case had 
undergone HSCT or when considering the relationship to the index case 
 Anxiety symptoms in XL-CGD carriers did not significantly differ from the 
MD control group  
 Anxiety more common in XL-CGD carriers than in other published parent 
groups and similar to that seen in SLE patients with high pain 
 Anxiety and depression were more common in XL-CGD carriers suffering 
physical symptoms 
 Depression symptoms were seen less frequently in XL-CGD carriers than 
in the MD control group 
 When depression scores were compared with other published groups, the 
XL-CGD carriers suffered less depression than SLE patients and were 
similar to the parents of children with CF 
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 Depression symptoms did not differ depending on relationship to the 
index case 
 Self-esteem well preserved in XL-CGD carriers 
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Chapter 7: Fatigue Results 
This chapter will present the results of the fatigue component of the research 
including fatigue questionnaires and cytokine measurement.  
There were 60 XL-CGD carriers who completed the MFSI-SF questionnaire along 
with 7 controls.  
7.1 Fatigue in XL-CGD Carriers 
There were 37 XL-CGD carriers who reported that they felt they suffered from 
excessive levels of fatigue when asked about any medical problems. This was 
quantified using the MFSI-SF in all XL-CGD carriers and these results are shown 
in Table 7-1. In all domains except vigor, a higher score reflects greater fatigue. 
In the domain of vigor, a higher score reflects less fatigue. The highest, most 
significant, levels of fatigue are seen in the general domain with lowest scores 
seen in the physical domain. The vigor scores reflect protective features.  
Table 7-1: XL-CGD Carrier MFSI Fatigue Scores in all domains 
 XL-CGD Carriers 
Median (IQR) 
Number Completed 60 
Total 20 (2.5-43.5) 
General 9 (5-20) 
Physical 4 (1-12) 
Emotional 6 (3-11) 
Mental 6 (4-10) 
Vigor 10 (7-13) 
Scores for the MFSI-SF were compared between those that reported fatigue and 
those who did not and these are shown in Figure 7-1. The scores were 
significantly higher in those who reported fatigue (p<0.0001).  
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Figure 7-1: MFSI-SF Scores in XL-CGD Carriers reporting Fatigue vs. those who did not 
 
MFSI Domains Correlation 
The MFSI domains were significantly correlated with each other and with the 
total score showing that each domain contributed to the total score. The MFSI 
was also significantly inversely correlated with the VT domain of the SF-36. 
These results are shown in Table 7-2. 
Table 7-2: Correlation of MFSI Domains (correlation coefficient and p-value) 
 Total General Physical  Emotional 
General 0.92 
<0.0001 





























Correlation of MFSI domains with other psychological and clinical factors are 



















of the MFSI and the vitality component of the SF36. There was also a significant 
correlation between joint symptoms and fatigue.  
Table 7-3: Fatigue Correlations in XL-CGD carriers (Correlation coefficient with associated p-value) 























































































































































The scores for MFSI in the XL-CGD carriers and the MD control group are shown 
in Table 7-4. The scores in the MD control group are higher than the XL-CGD 
carriers in all, domains except vigor, demonstrating that the MD controls 
suffered greater fatigue in all domains. The scores for vigor were very similar, 
but the XL-CGD carriers had a slightly higher score.  
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Table 7-4: Fatigue Scores in XL-CGD Carriers and MD Control Group 









60 7  
Total 
20 (2.5-43.5) 34 (1-60) 0.56 
General 
9 (5-20) 16 (3-22) 0.92 
Physical 
4 (1-12) 9 (0-15) 0.81 
Emotional 
6 (3-11) 10 (4-16) 0.45 
Mental 
6 (4-10) 11 (0-17) 0.61 
Vigor 
10 (7-13) 11 (7-13) 0.70 
SF36 VT 
37.5  (25-62.5) 20(25-75) 0.57 
7.2 Fatigue and Regression 
In order to assess the factors affecting fatigue in the XL-CGD carrier cohort, a 
logistic regression analysis was undertaken, with fatigue caseness defined as 
excessive fatigue present.  There were no significant associations and the results 
are shown in Table 7-5. 
Table 7-5: Logistic Regression for Fatigue in XL-CGD Carriers 
 Odds Ratio 95% CI P-Value 
Age 1.00 0.91, 1.10 0.977 
Index Case Age 0.99 0.95, 1.03 0.654 
Relationship to Index Case 0.79 0.25, 2.52 0.690 
Number of Children 1.93 0.48, 7.70 0.352 
Anxiety (HAD-A) 1.20 0.78, 1.83 0.406 
Depression (HAD-D) 1.43 0.74, 2.75 0.284 
Joint Pains 2.05 0.12, 34.60 0.618 
SLE Criteria 1.05 0.44, 2.52 0.906 
Bowel Sx 0.95 0.84, 1.07 0.418 
A linear regression analysis, with total MFSI score as the outcome was 
undertaken and the results are shown in Table 7-6. 
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Table 7-6: Linear Regression of Total Fatigue in XL-CGD Carriers 
 Coefficient 95% CI p-value 
Anxiety (HAD-A) 1.73  -0.83, 4.30 0.176 
Depression (HAD-D) 0.89  -1.12, 2.90 0.368 
Parental Distress (PIP) 0.07     -0.06, 0 .21 0.264 
Age -0.48    -1.58, 0 .62 0.376 
Relationship 20.60     -8.36, 49.57 0.155 
Number of Children  -3.15   -12.95, 6.65 0.512 
Age of Index Case 0.367   -0.88,  1.62 0.549 
Bowel Symptoms 1.62    -11.76, 15.00 0.804 
Joint Symptoms -0.41    -23.44, 22.62 0.971 
Number of SLE Criteria 5.39    -0.26, 11.04 0.061 
7.3 Fatigue and Neutrophil Oxidative Burst  
The NOB values were compared between the fatigued and non-fatigued groups 
and the results are shown in Table 7-7. It can be seen that there is a lower NOB 
value in those who reported fatigue. 
Table 7-7: NOB in Fatigued and Non-Fatigued Patients 
 Fatigued Non-Fatigued p-value 
Number 25 28 
0.085 
NOB (mean) 42.88 51.07 
 
7.4 Fatigue and Correlation with other symptoms     
Fatigue and Physical Symptoms 
Figure 7-2 compares the MFSI total scores between those XL-CGD carriers 
suffering from gastrointestinal symptoms with those XL-CGD carriers who 
suffered no joint symptoms. The XL-CGD carriers suffering from gastrointestinal 
symptoms scored significantly more highly in the fatigue questionnaire 
(p=0.011) 
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Figure 7-2: MFSI Total Scores in XL-CGD Carriers affected and unaffected by gastrointestinal 
symptoms 
 
Figure 7-3 compares the MFSI total scores between those XL-CGD carriers 
suffering from joint symptoms with those XL-CGD carriers who suffered no joint 
symptoms. XL-CGD carriers suffering from joint symptoms, scored significantly 



















Figure 7-3: MFSI Total Scores in XL-CGD Carriers affected and unaffected by joint symptoms 
 
Fatigue and PIP 
Figure 7-4 compares total PIP scores in XL-CGD carriers who did and did not 
suffer from excessive fatigue.  Those XL-CGD carriers who suffered excessive 



















Figure 7-4: Total PIP Scores in Fatigued and Non-Fatigued XL-CGD Carriers 
 
Fatigue and Psychological Health 
Figure 7-5 and Figure 7-6 show fatigue scores (total MFSI) compared with 
categories for anxiety and depression. The number of XL-CGD in each category 
for anxiety and depression is shown in Table 7-8, whilst the comparison of 
median scores and distribution is shown in Figure 7-5 and Figure 7-6.There were 
significant differences in the fatigue scores when they were compared by anxiety 
and depression category (p<0.001).  
Table 7-8: Number of XL-CGD carriers in each category for Anxiety and Depression 
 Anxiety Depression 
Normal 21 45 
Mild 14 11 
Moderate 22 4 























Figure 7-5: MFSI Scores and HAD-A Categories in XL-CGD Carriers 
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7.5 Fatigue and Cytokines 
Table 7-9 shows the median values for serum cytokines in XL-CGD carriers 
compared with healthy controls and Sjögrens patients. The Sjögrens patients 
were divided into low and high fatigue. There was a significant difference in the 
IL8 measurements; with XL-CGD carriers demonstrating significantly higher 
values compared with healthy controls and Sjögrens patients.  
Table 7-9: Serum Cytokine Values in XL-CGD Carriers compared with Healthy Controls and Sjögrens 



















IL5 0.62 0.62 0.89 0.60 0.60 2.67 <0.001 
IL8 110.8 28.2 0.02 15.18 0.039 20.48 0.031 
IL17 
4.71 4.71 0.84 7.99 0.35 63.29 0.016 
IL10 1.66 1.66 0.63 2.34 0.067 7.585 <0.001 
IFN 
2.9 2.46 0.49 6.66 0.14 14.21 0.0031 
IL1 
4.71 4.71 0.78 7.99 0.15 63.29 <0.001 
IFN 
5.05 6.88 0.02 8.33 0.01 7.75 0.0012 
7.6 Summary of Fatigue Results 
 Excessive fatigue reported in 50% of XL-CGD carriers 
 Higher levels of IL-8 seen in XL-CGD carriers when compared with 
healthy controls and Sjögrens patients 
 Higher levels of serum IL-8 in XL-CGD carriers reporting fatigue than 
those who did not report fatigue 
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Chapter 8: Quality of Life Results 
This chapter will present the findings from the assessment of quality of life 
(QoL).  
There were 62 XL-CGD carriers who completed the SF-36 quality of life 
questionnaire along with 7 of the control group (MD carriers).  The mean scores 
of the XL-CGD carriers for each domain are shown in Table 8-1. The highest score 
for each domain is 100 and it can be seen that the lowest scores are seen in GH, 
VT, MCS and PCS.  
Table 8-1: QoL Scores in XL-CGD Carriers 
Domain XL-CGD Carriers  
Mean Scores (SD) 
Physical Function (PF) 78.85 (28.3) 
Role Physical (RP) 73.33 (32.6) 
Bodily Pain (BP) 63.44 (30.6) 
General Health (GH) 54.93 (28.7) 
Vitality (VT) 44.23 (25.7) 
Social Functioning (SF) 67.37 (30.1) 
Role Emotional (RE) 70.14 (30.9) 
Mental Health (MH) 62.70 (17.6) 
Mental Component Score (MCS) 42.41 (10.8) 
Physical Component Score (PCS) 49.05 (12.6) 
8.1 Comparison of XL-CGD Carriers with other groups 
Table 8-2 shows the QoL scores in the XL-CGD carriers compared with the MD 
control group. The XL-CGD carriers had significantly worse scores in GH, VT, RE 
and MCS. The MD control group scored significantly worse in BP. 
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Table 8-2: QoL Scores in XL-CGD Carriers and MD Control Group 
Domain XL-CGD Carrier  
Mean Scores (SD) 
MD Control Group  
Mean Scores (D) 
p-value 
 
PF 78.85 (28.3) 76.43 (35.8) 0.234 
RP 73.33 (32.6) 77.68 (30.4) 0.169 
BP 63.44 (30.6) 54.14 (27.6) 0.0095 
GH 54.93 (28.7) 65.71 (29.1) 0.002 
VT 44.23 (25.7) 50 (23.7) 0.035 
SF 67.37 (30.1) 60.71 (22.2) 0.508 
RE 70.14 (30.6) 89.29 (21.4) <0.0001 
MH 62.70 (17.6) 63.57 (21.9) 0.342 
MCS 42.41 (10.8) 46.27 (9.3) 0.0034 
PCS 49.05 (12.6) 47.82 (15.9) 0.223 
Table 8-3 shows a comparison of the XL-CGD carrier QoL scores in each domain 
compared with published UK population data of women aged 35 to 54 
years[257]. The XL-CGD carriers scored significantly lower in all domains.  
 162 
Table 8-3: QoL in XL-CGD Carriers compared with UK Population Data 
Domain XL-CGD Carriers 
Mean (SD)  






78.85 (28.3) 89.4 (18.3) 0.0025 
Role Physical 73.33 (32.6) 84.0 (32.0) 0.007 
Bodily Pain 63.44 (30.6) 79.4 (22.0) 0.0001 
General Health 54.93 (28.7) 74.1 (20.3) 0.0001 
Vitality 44.23 (25.7) 58.2 (19.9) 0.002 
Social Function 67.37 (30.1) 86.7 (20.5) 0.001 
Role Emotional 70.14 (30.9) 80.3 (33.6) 0.0067 
Mental Health 62.70 (17.6) 71.6 (17.8) 0.0001 
Table 8-4 shows QoL scores in the XL-CGD carriers compared with adult CGD 
patients. The XL-CGD carriers scored significantly worse than the CGD patients, 
indicating poorer QoL in the BP, VT and SF domains.  However, the XL-CGD 
carriers scored significantly better than the CGD patients in the PF and RP 
domains. 
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Table 8-4: QoL in XL-CGD Carriers compared with Adult CGD Patients 
Domain XL-CGD Carriers  
Mean Scores (SD) 
CGD Adult Patients 
[258] 




78.85 (28.3) 70.0 (34.4) 0.007 
Role Physical 73.33 (32.6) 66.7 (41.9) 0.049 
Bodily Pain 63.44 (30.6) 83.8 (26.4) <0.001 
General Health 54.93 (28.7) 52.4 (26.5) 0.23 
Vitality 44.23 (25.7) 58.3 (26.1) <0.001 
Social Function 67.37 (30.1) 77.8 (33.5) 0.004 
Role Emotional 70.14 (30.9) 75.0 (34.8) 0.11 
Mental Health 62.70 (17.6) 65.0 (27.5) 0.15 
Table 8-5 shows a comparison between QoL scores in XL-CGD carriers and adult 
carers of patients with brain tumours. The XL-CGD carriers scored significantly 
worse in PF, BP, VT and GH, but scored significantly better in RE, MH and SF. 
Table 8-5: QoL in XL-CGD Carriers compared to Carers of Patients with brain tumours 
Domain XL-CGD Carriers  
Mean Score 
(SD) 
Brain Tumour Carers [211] 




78.85 (28.3) 92 (14.39) 0.0003 
Role Physical 73.33 (32.6) 76.76 (33.19) 0.23 
Bodily Pain 63.44 (30.6) 74.43 (25.06) 0.0029 
General Health 54.93 (28.7) 68.81 (17.29) 0.0002 
Vitality 44.23 (25.7) 50.55 (19.9) 0.024 
Social Function 67.37 (30.1) 58.66 (26.97) 0.014 
Role Emotional 70.14 (30.9) 48.09 (36.79) <0.001 
Mental Health 62.70 (17.6) 48.32 (21.56) <0.001 
Table 8-6 shows a comparison in QoL scores in the XL-CGD carriers compared 
with published research about SLE patients[140].  Overall, the scores in the SLE 
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patients are worse in the SLE group, although XL-CGD carriers scored lower in 
the vitality (fatigue) domain.  
Table 8-6: QoL in XL-CGD Carriers compared with SLE Patients 
 SLE Patient Scores [140]  
Median (IQR) 
XL-CGD Carrier  Scores 
 Median (IQR) 
Physical Functioning 63 (40-85) 90 (75-100) 
Role – physical 25 (0-75) 93.75 (50-100) 
Bodily Pain  51(22-74) 72 (41-84) 
General Health 42 (25-57) 60 (30-82) 
Vitality 40 (25-55) 37.5 (25-62.5) 
Social Functioning 50 (38-75) 75 (50-100) 
Role – emotional 33(0-100) 75 (50-100) 
Mental Health 60 (48-76) 65 (55-70) 
HSCT in the Index Case 
Information about HSCT in the index case was available for those XL-CGD 
carriers who completed the SF36. There were 30 XL-CGD carriers where the 
index cases had undergone HSCT.  QoL scores in where the index case had 
undergone HSCT were compared with those who had not and these results are 
shown in Table 8-7. There were no significant differences, but BP and MH were 
approaching statistical significance with worse scores in the XL-CGD carriers 
where the index case had undergone HSCT. 
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Table 8-7: Comparison of QoL Scores in XL-CGD Carriers where the index case has and has not 
undergone HSCT 
Domain Index Case HSCT 
Mean Scores (SD) 
Index Case No HSCT 
Mean Scores (SD) 
p-value 
Physical Function 80.5 (29.0) 78 (28.0) 0.73 
Role Physical 77.0 (33.6) 71.5 (32.0) 0.52 
Bodily Pain 70.4 (25.6) 58.4 (33.0) 0.12 
General Health 58.2 (27.2) 53.4 (28.8) 0.54 
Vitality 44.0 (27.3) 45.2 (23.8) 0.87 
Social Function 68.0 (30.5) 68.0 (29.3) 0.99 
Role Emotional 66.7 (32.2) 74.0 (29.6) 0.36 
Mental Health 59.0 (17.5) 66.9 (16.3) 0.07 
There were 40 of the participants who completed the SF36 who were mothers of 
the index case and 22 who were other relatives. Table 8-8 shows a comparison in 
means QoL scores between these groups. There were no significant differences 
found.   
Table 8-8: QoL Scores in XL-CGD carrier Mothers compared with XL-CGD carrier other relatives 
Domain XL-CGD Carrier 
Mothers 
Mean Scores (SD) 
XL-CGD Carrier Other 
Relatives 




80 (28.0) 77.3 (28.8) 0.64 
Role Physical 73.7 (33.8) 73.6 (30.7) 0.50 
Bodily Pain 62.6 (32.2) 65.0 (27.2) 0.61 
General Health 57.5 (28.8) 50.6 (28.0) 0.18 
Vitality 44.7 (26.2) 42.7 (25.0) 0.62 
Social Function 68.4 (32.2) 65.3 (25.9) 0.65 
Role Emotional 70.3 (31.2) 70.1 (30.3) 0.98 
Mental Health 62.6 (19.4) 62.7 (13.4) 0.98 
-  
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8.2 Correlation with Psychological Health 
Table 8-9 shows the correlation coefficient and p values for the association of 
mental health and physical health component scores of the QoL questionnaire in 
XL-CGD carriers with psychological health assessments. It can be seen there is a 
significant correlation for the MCS with anxiety, depression, self-esteem and 
fatigue but no significant correlation with the PIP scores. The PCS was 
significantly correlated with fatigue and the other domains were significant, but 
not highly significant.  The correlation between mental health and physical 
health was not significant.  
Table 8-9: Correlation Coefficient and P Value for MCS and PCS Domains of QoL with Psychological 
Factors 


































8.3 Correlation with Physical Health 
Table 8-10 shows the correlation of MCS and PCS with physical factors. It can be 
seen that there are significant associations between PCS and all the physical 
factors except the skin manifestations of photosensitivity and recurrent 
abscesses.  The are significant associations between MCS and joint pains, 
gastrointestinal and respiratory symptoms, number of ARA criteria fulfilled and 
recurrent skin abscesses.  
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Table 8-10: Correlation Coefficient and P value for MCS and PCS Scores of QoL with Physical Factors 







































8.4 Correlation with Social Factors 
Table 8-11 shows the correlation of social factors with mental and physical 
component health scores in QoL assessment. It can be seen that there were no 
statistically significant associations, although the age of participant was 
approaching significance with the PCS scores.  
Table 8-11: Correlation Coefficient and P value for MCS and PCS Scores of QoL with Social Factors 
 MCS PCS 



























8.5 Regression  
A logistic regression analysis to evaluate the factors affecting QoL (physical 
function) in XL-CGD carriers was undertaken. The results are shown in Table 
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8-12, which shows that depression was significantly associated with increasing 
odds of poor physical function QoL. The presence of fatigue and gastrointestinal 
symptoms were approaching statistical significance.  
Table 8-12: Logistic Regression for Factors affecting Physical Function domain of Quality of Life in 
XL-CGD Carriers 
 Odds Ratio 95% CI p-value 
Anxiety (HAD-A) 0.91 0.65, 1.27 0.59 
Depression (HAD-D) 0.62 0.39, 0.99 0.05 
Self-esteem 1.05 0.83, 1.34 0.67 
Fatigue 0.87 0.74, 1.03 0.11 
GI Symptoms (IBD Score) 0.87 0.73, 1.02 0.089 
Respiratory Symptoms 0.96 0.91, 1.01 0.17 
SLE Criteria 0.70 0.29, 1.71 0.44 
Relationship to index case 1.25 0.28, 5.67 0.77 
Age 0.98 0.89, 1.08 0.66 
8.6 Summary of QoL Results 
 QoL is reduced in XL-CGD carriers overall 
 Compared with data from women in the UK, XL-CGD carriers reported 
significantly poorer QoL in all domains 
 QoL of XL-CGD carriers was poorer than that reported in adult CGD 
patients in several domains 
 The presence of physical symptoms correlated with poorer QoL 
 Anxiety and depression correlated with poorer QoL 
 Fatigue correlated with poorer QoL 
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Chapter 9: Discussion 
This study has generated a considerable amount of data on a wide range of 
issues. In this chapter, I will discuss the findings of the study, initially as separate 
sections; clinical findings and investigations, fatigue, psychological and quality of 
life. Finally, in chapter 10, I will draw together the discussion as a whole. 
The principal finding of this study is that XL-CGD carriers suffer from more 
medical problems than previously described. The majority of the XL-CGD 
carriers suffered from at least one significant medical complaint.  
Broadly, the medical problems may be categorised in a similar manner to those 
experienced by CGD patients, namely, infective, inflammatory, autoimmune and 
miscellaneous features. I will discuss each in turn.  
9.1 Infective Manifestations  
Infection is one of the hallmarks of CGD and, as outlined in chapter two, patients 
suffer recurrent, severe infection with characteristic organisms, including fungi 
and catalase positive organisms [28]. Significant or recurrent infections in XL-
CGD carriers have been only sporadically reported in the literature, as discussed 
[74, 80]. Although it is likely that only significant, unusual or life threatening 
infections would be reported in the literature, and subsequently, there may be a 
greater burden of infection in XL-CGD carriers which has not yet been described.   
This study demonstrated that 19 (23.5%) XL-CGD carriers suffered some form of 
significant or recurrent infection. The causative organism was not known in the 
majority of cases, but of particular interest was one case of fungal pneumonia, 
which is unusual in an otherwise immunocompetant individual, and whilst this is 
an individual case, it can be hypothesised that it is related to the XL-CGD carrier 
status and inability to handle fungus. Other significant infections included 
meningitis and pneumonia, which do occur in the general population, but may 
relate to the XL-CGD carrier status. However, there was no association with 
degree of reduction in NOB in those XL-CGD carriers affected by significant 
infection. 
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Recurrent infection was seen in the form of recurrent urinary tract infection 
(UTI) or recurrent skin abscesses. Six (7%) XL-CGD carriers suffered from 
recurrent urinary tract infection. The symptoms of this may be similar in nature 
to genitourinary obstructive symptoms. Whilst in the general population, 
infection is more common, obstructive symptoms may be present in the XL-CGD 
carriers. As the participants had not been investigated, this is speculation only.  
Recurrent skin abscesses have been described in the literature in XL-CGD 
carriers and have also been problematic, requiring antibiotics and, at times, 
surgical drainage [70, 76, 77, 81]. They have been shown to isolate CGD typical 
organisms including Staphlyococcus Aureus [82].  
This study confirmed this finding and demonstrated that it was a frequently 
occurring problem. Recurrent skin abscesses were reported in 14 (17%) of the 
XL-CGD carriers and all reported requiring antibiotic treatment.  
Published literature considers an NOB value greater than 5% sufficient to 
prevent significant infection [58, 260]. This study evaluated whether there was 
an association between per cent functioning neutrophils and susceptibility to 
infection. Due to the small numbers, infections were evaluated as either systemic 
or skin and an association with NOB sought.  
There was a significant association between the presence of recurrent skin 
abscesses and a lower NOB value.  This was not found when infections outside of 
skin abscesses were considered. In all other infections there was no significant 
difference in NOB value between affected and unaffected. The mean NOB values 
were lower in the affected group, but not significantly. The lack of significance 
may relate to the relatively small numbers. However, given that CGD is a rare 
disease and the coverage of this cohort study, it is unlikely that the UK would be 
able to generate a larger study cohort of XL-CGD carriers.   
Salmonella infection was reported in the European registry [10] as a significant 
problem in CGD patients. This was not replicated in the XL-CGD carrier 
population as only one XL-CGD carrier reported suffering from salmonella 
infection.  
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The reports of abnormal reaction to vaccination with BCG by 3 (4%) of the XL-
CGD carriers demonstrates a striking resemblance to the report by Lee et al [33] 
of a similar finding in the CGD patients, supported by the large European registry 
report [10]. It is possible that the reactions reported from the XL-CGD carriers 
are due to abnormal response to the BCG as a result of their carrier status due to 
the similarities with the reports from CGD patients, but with such small numbers 
it is difficult to draw definitive conclusions. A documented complication of BCG 
vaccination is abscess, particularly if given incorrectly by the intramuscular 
rather than intradermal route [261], and this may be a factor in this case. 
However, the similarities of the descriptions suggest that there may be an 
association and further observations should be noted.  
The lack of published literature about infection in XL-CGD carriers perhaps 
indicates a lack of significant infection in XL-CGD carriers and this study 
corroborates this. Infection was not reported as a significant problem in the 
majority of carriers and there were no reported deaths from sepsis or severe 
infection in the XL-CGD carrier population.  
There were few infections reported in this cohort of XL-CGD carriers. Whilst this 
is the largest number of XL-CGD carriers studied, the rates of infection are still 
low. However, there were reports of some XL-CGD carriers suffering from CGD-
like infections including lymphadenitis and fungal pneumonia. It has not been 
possible to determine why some suffer from infection and others do not. It would 
appear that there is no correlation with NOB value and risk of recurrent or 
significant infection with the exception of recurrent skin abscesses.  
There were eight XL-CGD carriers on prophylactic antibiotics and four on 
prophylactic antifungal. This may have affected the infection rate in the XL-CGD 
carriers, but it cannot be certain. The lack of severe infections found in this 
cohort would not support routine prophylactic antibiotics or antifungal agents in 
XL-CGD carriers.  
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9.2 Inflammatory Manifestations 
9.2.1 Skin Disease 
Skin disease is the most commonly described problem in XL-CGD carriers with 
an association with discoid lupus erythematosis (DLE) well described [69, 72, 84, 
85]. It was also the first reported medical problem in XL-CGD carriers as it was 
first described in 1970 [6]. Unsurprisingly, therefore this study has found 
significant skin disease in the XL-CGD carriers.  
The majority (74%) of the XL-CGD carriers suffered from at least one skin 
manifestation. The most common problem was photosensitivity, which was seen 
in a large majority of the XL-CGD carriers (74%). This is in keeping with 
previously published work, although at a higher rate. In the largest published 
study to date, photosensitivity occurred in 58% of their 19 XL-CGD carriers 
[69].The higher rate reported in this study compared to previous studies may 
relate to the methodology used. All recruited participants were directly asked 
how they reacted to sunlight, rather than waiting for them to volunteer this 
information. XL-CGD carriers of all ages reported photosensitivity in this study, 
which was persistent through life.  
After photosensitivity the most common skin complaints were a malar rash 
(resembling or confirmed as DLE) and eczema. Other frequently reported 
complaints were rosacea and adult acne, although it is possible that these 
diagnoses were not accurate as there was little evidence of investigation or 
expert opinion. The skin manifestations demonstrated in the XL-CGD carriers 
may reflect cutaneous inflammation. A high number of XL-CGD carriers also 
described recurrent episodes of hives, which may also reflect an inflammatory 
process. Without examining XL-CGD carriers during an outbreak or without 
photographic evidence it is difficult to be clear exactly what this represents.  
Further to the diagnosed skin complaints described, two of the XL-CGD carriers 
complained of poor wound healing. It is difficult to be certain of how to interpret 
this information. The information was volunteered by the XL-CGD carriers and 
described as a significant problem, but it was not actively asked about. 
Therefore, this may represent an underestimate of the problem. CGD patients 
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may suffer from poor wound healing particularly after surgery [28]. It may be 
that this manifestation is related to carrier status, but in this study it is too 
infrequently described to be certain of the association. It is difficult to quantify 
this problem due to normal variations in wound healing.  
There was one case of skin malignancy, which although noteworthy, as an 
isolated case does not advance our understanding about the health of XL-CGD 
carriers, but given the photosensitivity prevalence it should not be ignored.  
Mechanism 
The mechanism for the skin manifestations in XL-CGD carriers is unclear. The 
significant number of XL-CGD carriers who suffered from dermatitis may suggest 
that there is an inflammatory component.   
There was no association between NOB value and photosensitivity or other skin 
manifestation seen. Additionally, there was no association between skin 
manifestations and autoantibody positivity when measured by 
immunofluorescence. 
Freemer et al [134]found that there were higher rates of cutaneous lupus 
features in SLE patients who smoked. However, there was no association 
between smoking status in XL-CGD carriers and photosensitivity or other skin 
manifestations.  
Strengths and Weaknesses 
The main strength in this study is in the direct questioning of all XL-CGD carriers 
about photosensitivity. Responses to initial open questions frequently did not 
yield comments about photosensitivity, but when asked how they reacted to 
being in the sun, many more reported photosensitive eruptions.  
A weakness of this study is the lack of involvement of a dermatologist. All skin 
manifestations were reliant upon self-reporting and pre-existing diagnoses. For 
conditions such as photosensitivity, history alone is sufficient, but for the more 
complicated or less well-defined diagnoses, history alone is less reliable. Very 
few of the XL-CGD carriers with skin complaints had undergone skin biopsy. Skin 
biopsy, whilst not essential, is helpful in confirmation of the diagnosis and in 
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increasing our understanding of the causation. The other limitation is perhaps 
unavoidable; the nature of many of the skin complaints is that they are transient, 
meaning that they were frequently not present at the time of enrolment and 
history taking. Time did not allow for frequent follow up with every individual 
participant. Medical photography may have been a useful adjunct for this aspect 
of the study.  
Skin Implications 
There are clinical implications from the findings of this study. XL-CGD carriers 
should be counselled that they are likely to suffer from photosensitivity. They 
should be given advice about sun protection; high factor sun screen, remain 
covered and ideally sun avoidance. What is unclear is whether the presence of 
photosensitivity puts the XL-CGD carriers at increased risk of skin malignancy. 
This was a predominantly middle aged cohort with a mean age of 42 years. 
Longer-term follow-up is required to see if there is an increased risk of 
developing skin malignancy in this cohort.  
Uncertain dermatological manifestations in women who are XL-CGD carriers 
should be referred for accurate diagnosis (potentially including histopathological 
diagnosis) in order to focus treatment. From a research perspective this would 
also ensure a better understanding of the on-going pathological process. 
Skin Future Work 
The photosensitivity seen in the XL-CGD carrier cohort is now well described and 
this study has added considerable weight to the evidence that it is highly 
prevalent. What is unclear is the mechanism by which this occurs. Future work 
could involve photo testing the XL-CGD carriers which would determine the 
exact sensitivity e.g. UVA, UVB which may aid understanding about causation.  
Biopsies were not available in the majority of XL-CGD carriers. Histological 
findings in the past from XL-CGD carriers manifesting DLE rashes have been 
similar to typical DLE [84]. However, all studies evaluating the DLE-like 
manifestations have been small scale making conclusions not well supported. 
Therefore, a large-scale study with skin biopsies from all symptomatic XL-CGD 
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carriers would be useful to further understand the causation of this 
manifestation.  
Treatment of skin disease has not been well studied in the XL-CGD carrier 
population and for some it may be particularly problematic. Hydroxychloroquine 
has been trialled in the carrier population, but not in a systematic manner. A 
randomised control trial or at least an observational study of the use of 
hydroxychloroquine or similar agent would be helpful to advance treatment 
options.  
9.2.2 Gastrointestinal  
This study has found that XL-CGD carriers suffer from significant gastrointestinal 
(GI) symptoms, with over 50% suffering at least one symptom.  
As discussed in chapters one and two, patients with CGD, and particularly XL 
disease [37], suffer from gastrointestinal disease, particularly colitis. 
Children with CGD may present with poor growth or failure to thrive [28].  This 
was not seen in the XL-CGD carrier cohort where BMI was used to assess 
nutritional status. Less than 10% of the XL-CGD carriers fell into the underweight 
category with the majority falling into the healthy BMI range. When compared 
with female UK population data, the XL-CGD carriers are similar although the 
proportion in the underweight and overweight categories was significantly 
higher. This may reflect the small numbers and the inclusion in the XL-CGD 
carrier group of participants who were under 18 years, which may have skewed 
the results. Overall, the XL-CGD carriers have similar BMIs to the UK female 
population suggesting that gastrointestinal symptoms do not impact significantly 
upon weight in XL-CGD carriers.   
This study found GI symptoms were present in over 50% of the XL-CGD carriers 
recruited, with abdominal pain and diarrhoea the most frequently reported. This 
has not been previously demonstrated with only sporadic cases reported [69, 
90]as discussed in the literature review. In this study, one third suffered from 
frequent abdominal pain, one-third recurrent diarrhoea; one quarter regular 
rectal bleeding and just over ten per cent suffered constipation. Other symptoms 
including urgency and vomiting were infrequently described.  
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The types of gastrointestinal symptoms suffered in the XL-CGD carrier cohort 
were similar to that seen in the CGD patients, with abdominal pain and diarrhoea 
the most frequent. When compared with published data from CGD patients, the 
pattern of symptoms was slightly different in the XL-CGD carriers. Rectal 
bleeding was significantly more frequent in the XL-CGD carrier cohort and fewer 
suffering from abdominal pain, although it remained the most common symptom 
in both groups. Constipation was significantly more common in the XL-CGD 
carriers. It is possible these symptoms are unrelated to their XL-CGD carrier 
status and is an incidental finding, which may be reproduced in the general 
population, but the similar presentation and symptoms in carriers and patients 
suggests that there may be a unifying underlying pathological process.  
The severity of symptoms and their impact can be assessed using the scores from 
the IBD disability index. Those who were affected by GI symptoms scored 
significantly higher than those who were unaffected. The high scores reflect the 
impact the GI symptoms have upon quality of life. Therefore, irrespective of the 
pathogenesis of the gastrointestinal symptoms, this study shows that they are of 
clinical importance to the XL-CGD carriers themselves.  
Unfortunately, the majority of the XL-CGD carriers who were found to have GI 
symptoms had not undergone investigation, making drawing conclusions about 
the cause of their symptoms difficult, as there is limited information about the 
histopathology.  
The reasons for lack of investigation may be multiple. It may represent under 
reporting of their symptoms to medical practitioners outside of the study. 
Alternatively, in those who had reported their symptoms, failure to undergo 
investigation may be due a presumptive diagnosis of an IBS-like diagnosis being 
made.  The XL-CGD carriers frequently volunteered IBS as an explanation for 
their symptoms and, whilst we can only speculate as to the reason, it may be that 
the XL-CGD carriers underplayed the significance of their own symptoms.    
Those who were investigated, and where results were available, showed a range 
of findings. The most interesting finding is in the two XL-CGD carriers who were 
diagnosed with Crohn’s disease. As discussed in chapters one and two, the 
histopathological appearance of IBD and particularly Crohn’s is very similar to 
 177 
the findings in CGD colitis[15, 38] and it may not be possible to confidently 
distinguish between them, especially if the individual examining the tissue is not 
aware of CGD carrier status. One XL-CGD carrier, after investigation, was 
diagnosed with CGD colitis and had required extensive surgery. 
In one symptomatic XL-CGD carrier, minor, non-specific inflammation was found 
on colonoscopy and was reported in the pathology sample as non-significant. 
However, it would be interesting to compare samples from other symptomatic 
XL-CGD carriers to see if they had any degree of inflammation and whether this 
finding was reproducible. 
From those XL-CGD carriers who had undergone investigation, it can be 
hypothesised that their GI involvement is on a spectrum with those suffering 
from IBD and CGD colitis. It seems likely that there is a unifying pathology, 
although it has not been possible to prove this.  
Appendicitis was reported in the European cohort [10] as occurring at similar 
rates to the population as a whole. In the XL-CGD carrier cohort, four had 
undergone appendicectomy. Histopathology was not available, therefore it is not 
possible to comment if this represents granulomatous disease.  
Associations of GI Symptoms 
As not all XL-CGD carriers suffered from gastrointestinal symptoms, and of those 
who did not all suffered to the same degree, associations were evaluated to see if 
there were tools, which could be used to differentiate the symptomatic from the 
asymptomatic and aid in the understanding of the underlying pathogenesis.   
NOB and GI Symptoms  
Neutrophil Oxidative Burst values were significantly lower in those suffering 
from abdominal pain and in those reporting diarrhoea. However, there was no 
significant difference when considering gastrointestinal symptoms as a whole, 
suggesting, firstly, that NOB will not help as a screening tool to identify those XL-
CGD carriers at risk and, secondly, that it may not be the only factor in the 
pathogenesis of GI disease.  
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Kuhns et al [14] found no correlation between residual NADPH oxidase function 
and the presence of colitis, despite the association between residual NADPH 
oxidase and survival. There was an association between specific mutation and 
residual NADPH oxidase function. 
In XL-CGD carriers the degree of residual NADPH oxidase function is, in part, 
related to the degree of skewing, reflected by the per cent NOB, and, in part, due 
to the specific genetic mutation. Therefore, if an individual is an XL-CGD carrier 
of a mutation conferring high residual NADPH oxidase function, they could have 
near normal NADPH oxidase function, whereas an XL-CGD carrier with a 
mutation conferring minimal residual function, who demonstrates extreme 
skewing would have virtually no NADPH oxidase function.  
As the exact mutation was not known in the majority of the XL-CGD carriers in 
this study, it is not possible to make the same evaluations about XL-CGD carriers 
as Kuhns et al made in the study of CGD patients. All that can be said is that the 
degree of reduction in NOB does not correlate with GI symptoms as a whole. 
However, correlation with the mutation may be evaluated by using the index 
case as a surrogate marker for mutation.  
Further associations of NADPH oxidase function and IBD have been 
demonstrated in a recent study by Dhillon et al[262] and specifically very early 
onset disease. Dhillon et al [262]demonstrated that patients suffering from very 
early onset IBD carried functional hypomorphic variants of NADPH oxidase 
components.  Whilst this study of XL-CGD carriers has not been able to 
confidently conclude that the GI symptoms are associated with XL-CGD carrier 
status, the increasing understanding of NADPH oxidase suggest that there is 
likely to be a link, and that XL-CGD carriers are a further part of this spectrum of 
inflammatory bowel diseases. 
The per cent of functioning neutrophils was derived from peripheral blood. It is 
not known if there is tissue-to-tissue variability in the number of functioning 
neutrophils and if this may account for why some are affected and others remain 
unaffected. The per cent of normally functioning neutrophils within the GI tract 
may differ to that found in peripheral blood and this may account for why some 
XL-CGD carriers are affected and not others. Sharp et al [263] found that in older 
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women, there was a significant difference in the degree of severe skewing 
between tissue types when they evaluated urine, buccal swab and blood DNA. 
This was less pronounced in younger women, however, and they suggested that 
this might be the result of secondary selection. It is, therefore, possible that there 
is a different degree of skewing in the gastrointestinal tract of those XL-CGD 
carriers who are affected by GI symptoms, compare with those who are not, 
particularly with increasing age.  
It may also be that there is failure of clearance of an infective agent, which 
subsequently stimulates excessive inflammation. As outlined in chapter 2, in CD 
it is thought that underlying inflammation is caused by a high bacterial load 
triggering chronic inflammation as a result of patients being unable to clear the 
infective organism. Defective neutrophil recruitment has been implicated in CD. 
In XL-CGD carriers, there may be failure of clearance of organisms within the gut 
due to a similar mechanism. The reduced number of functioning neutrophils may 
be unable to clear the infective agent and thus result in on-going inflammatory 
changes.   
Index Case Colitis and GI Symptoms 
As discussed in chapters one and two, not all CGD patients suffer from colitis or 
GI manifestations of disease. Large studies support the higher prevalence of GI 
manifestations in XL disease, compared with AR disease[11]. 
The exact mutation was not confirmed in all of the XL-CGD carriers and it was 
assumed to be the same as the index case from which they were identified. As a 
surrogate marker for mutation, the index case was used and we looked for 
correlation between the presence of GI symptoms in the XL-CGD carrier and 
colitis in the index case to consider if there was an association with the mutation. 
There was a significant association found, with XL-CGD carriers suffering from GI 
symptoms were more likely to have an index case suffering colitis. This suggests 
that there may be mutations more associated with GI disease than others in the 
XL-CGD carrier cohort.  
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Autoantibodies and Gastrointestinal Symptoms  
There was no association found between the presence of GI symptoms and 
positive autoantibodies by immunofluorescence.  However, the autoantibody 
panel performed was a baseline screening assessment only. It was not designed 
to be specific for gastrointestinal disease and as such, different autoantibody 
testing may have yielded a different result. For example, work by Lodes et al 
[264]in 2004 identified bacterial flagellin as a potent antigenic stimulant in 
patients with Crohns disease. Broader evaluation of potential antigens may have 
yielded better understanding of the mechanism of causation for GI disease in XL-
CGD carriers.  
Other Factors Affecting GI Symptoms 
Numerous factors, including smoking, anxiety and age, have been shown to 
exacerbate underlying bowel inflammation particularly in the presence of 
inflammatory bowel disease (IBD) both at the onset of symptoms and in the 
presence of an established diagnosis [265] and these factors were studied in the 
XL-CGD carrier cohort.  
There was a significant correlation between increasing age and gastrointestinal 
symptoms. No correlation was found with smoking.  
As highlighted in the literature review, psychological factors may impact upon 
gastrointestinal symptoms, both in exacerbating existing conditions, including 
IBD, and in precipitating symptoms. We, therefore, looked for an association 
between anxiety and depression symptoms and the presence of gastrointestinal 
disease. A significant correlation was found between anxiety and the presence of 
gastrointestinal symptoms. However, what it is not possible to extrapolate the 
direction of the relationship between psychological distress and GI disease. This 
association has important treatment implications. It may be that those with 
gastrointestinal disturbance become anxious in part as a result of these 
symptoms, or it may be that there is a predisposition to anxiety, which 
precipitates GI disease or increases symptoms of underlying disease.  
There was a significant correlation between fatigue as scored by the MFSI and 
the presence of gastrointestinal symptoms. As with the psychological correlation, 
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it is not possible to determine the direction of this relationship, but it would be 
useful to monitor fatigue levels after optimising gastrointestinal treatment.  
The association of fatigue and anxiety with the gastrointestinal symptoms in XL-
CGD carriers are similar to that described in the IBD patients[183]. XL-CGD 
carriers have not been shown to be significantly unwell prior to this study, but 
the findings of the gastrointestinal disease in XL-CGD carriers and the similar 
associations to those seen in IBD patients, show that not only are the XL-CGD 
carriers unwell, but they have similar factors exacerbating their symptoms as 
inflammatory bowel disease of other aetiology.  
Strengths and Weaknesses of Gastrointestinal Research 
Previous studies of XL-CGD carriers have not asked about gastrointestinal 
disease. This study actively asked about gastrointestinal symptoms and assessed 
their impact on quality of life using the IBD disability index. On direct 
questioning, many XL-CGD carriers admitted that they suffer from symptoms, 
which they had not previously divulged. Had the XL-CGD carriers not been 
questioned about gastrointestinal symptoms, this study would not have 
discovered the extent of the problem in the cohort.  
Conversely, it is possible that by actively seeking out symptoms of 
gastrointestinal disease, this study has overestimated the severity of the problem 
with individuals reporting symptoms that may not be problematic. 
Gastrointestinal symptoms are subjective and this may be reflected in the 
individual reporting.   
Additionally, formal results of GI investigations undergone by XL-CGD carriers 
were not always available despite being actively sought.  Where possible, 
investigation reports were collated by the researcher to gain as much 
information as possible. This was due to the investigations being undertaken at a 
high number of centres and a lack of response to written requests for 
information. Informal results from the XL-CGD carriers themselves lacked the 
detailed information required for a study such as this.  
BMI was used as a surrogate marker of nutrition. Poor growth is seen in the boys 
with CGD as already discussed and as such height and weight recorded in the XL-
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CGD carriers to see if this was an important manifestation of disease. However, a 
more detailed assessment of nutrition may have been appropriate including 
more detailed measurements such as midarm circumference and triceps 
thickness, to accurately assess nutritional status. However, BMI was used as a 
crude assessment to look for hidden disease and as such is likely to be an 
acceptable screening tool.  
Not all of the symptomatic XL-CGD carriers were investigated, making it difficult 
to draw conclusions about the pathogenesis. In those who were investigated, not 
all results were available despite being actively sought. This was due to the 
number of centres involved in the investigation and management of the XL-CGD 
carriers. A further limitation to this study is that not all of the specimens were 
examined at a specialist centre. As discussed in chapters one and two, 
differentiating between IBD and CGD specimens is difficult, particularly if the 
assessments are infrequent and this may be of particular importance in the XL-
CGD carriers.  
The specific mutation was not known at the time of analysis in a high number of 
families. The index case was used as a surrogate marker of mutation, but it 
would have been preferable to confirm the exact mutation in each XL-CGD 
carrier.   
Implications and Meaning 
This study has demonstrated significant GI symptoms in XL-CGD carriers, but no 
clear pathology and this has several clinical implications.  
Firstly, the identification of gastrointestinal symptoms as a significant problem in 
the XL-CGD carriers means that appropriate clinical follow up and referral 
should be organised.  As highlighted, there are many XL-CGD carriers who have 
not been investigated and as such, do not have a formal diagnosis and 
subsequently are not receiving optimal treatment. XL-CGD carriers should be 
specifically asked about gastrointestinal symptoms with an appreciation that 
they may not volunteer them otherwise.  
Secondly, this greater awareness of gastrointestinal symptoms demands that 
there should be greater consideration of how these XL-CGD carriers should be 
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treated.  Currently, treatment of gastrointestinal symptoms in XL-CGD carriers is 
erratic. Those with a formal diagnosis, such as Crohn’s or ulcerative colitis, are 
managed as IBD patients. These patients may respond to conventional IBD 
therapy but may need to be treated as CGD patients. They should perhaps be 
considered along the spectrum of CGD colitis rather than IBD. Whilst there is 
considerable overlap in therapy, there may be differences to consider. Those 
without a diagnosis, have a wide array of treatments with steroids, anti-motility 
drugs, protein pump inhibitors and anti-spasmodic agents all reported. That 
symptoms are still described, along with an apparent impact upon quality of life, 
shows that there is considerable under or ineffective treatment.  
A standardised approach to investigation and treatment of XL-CGD carriers with 
GI symptoms needs to be formulated. As more is learned about the pathology 
associated with these symptoms treatment options can be considered in greater 
depth. Closer liaison with gastroenterology services may improve the 
management options of all XL-CGD carriers and subsequently optimal treatment 
of these symptoms may improve QoL in XL-CGD carriers.  
Gastrointestinal Future Work  
This study has clearly demonstrated that there are significant gastrointestinal 
symptoms in the XL-CGD carrier population. What is not clear is the underlying 
pathology and mechanism of these symptoms. The significant correlation with 
the index case disease (and therefore specific mutation), the similarity in 
symptoms with the CGD patients and the findings in those investigated, implies 
there is a unifying pathology related to their XL-CGD carrier status. Future work 
needs to be directed at identifying the cause and pathogenesis of these 
symptoms.  
Ideally, a future study would involve thorough investigation, including 
endoscopy, colonoscopy and biopsies, in both symptomatic and asymptomatic 
XL-CGD carriers for comparison. Ethically and practically, this may not be 
possible, but at the very least it would be beneficially to fully investigate all those 
who are symptomatic. It has not been possible to gather all histopathological 
results in this study. In future, it would be preferable to have all biopsy samples 
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evaluated at one of the specialised centres, where there is considerable 
experience of both CGD and IBD and their differentiation. 
Further to microscopic examination of samples from the GI tract, an evaluation 
of tissue specific neutrophil function would aid the investigation of causation. It 
can be hypothesised that in XL-CGD carriers with GI symptoms there may be a 
lower number of functioning neutrophils in affected gastrointestinal tissue.  
This study has not gathered information about the gut microbiota in XL-CGD 
carriers. This may be an important consideration in the pathogenesis. There is a 
growing body of evidence about the differences between the gut microbiota in 
healthy and affected individuals in conditions outside of CGD, including IBD 
[266] and necrotising enterocolitis in premature infants[267], amongst others. 
This may be of particular relevance in XL-CGD carriers who may be more 
susceptible to infection due to their reduced NOB and may be unable to clear GI 
infection. Analysis of the microbiota of XL-CGD carriers may aid this 
understanding.  
9.2.3 Respiratory Disease 
There is no published literature about respiratory disease in XL-CGD carriers, 
despite it being one of the commonest sites of disease in studies of CGD patients 
[8, 10, 11].   
In this study, respiratory complaints were described in 15 participants. The most 
common problem was a diagnosis of asthma. Asthma is a common medical 
condition, and may frequently be over diagnosed when there is an alternative 
explanation for respiratory symptoms [268], perhaps suggesting some of the 
asthma diagnoses may not be accurate. 
Cough was reported in three of the XL-CGD carriers as a significant problem, and 
all those reporting cough as a problematic symptom were non-smokers.  
The results from the SGRQ when compared to the population data show that 
there was no significant difference between scores. This means that the XL-CGD 
carriers did not suffer respiratory symptoms significant enough to impact upon 
their quality of life. Those who did score highly on the SGRQ had an alternative 
diagnosis such as alpha-1-antitrypsin deficiency, which was more likely to 
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account for their symptoms and higher score. Co-existing XL-CGD carrier status 
and alpha-1-antitrypsin deficiency is previously unreported.  
A limitation of this study is that no formal assessment of respiratory function or 
chest imaging was undertaken. It would have been useful to assess respiratory 
function in order to be confident that there were no respiratory manifestations 
of disease in the XL-CGD carrier cohort. Imaging in the symptomatic group would 
also have been a useful addition as this may have clarified the cause and 
elucidated more about the pathological process.  
Despite the limitations, from this study, it is reasonable to conclude that XL-CGD 
carriers do not suffer from respiratory disease at a rate greater than that 
expected in the general population. However, further information about those 
with a diagnosis of asthma would be useful to explore that potential association.  
9.2.4 Other Inflammatory Manifestations 
This study did not examine for evidence of chorioretinitis as this has been 
previously well studied and XL-CGD carriers found to be at risk of chorioretinitis 
[34]. 
Inflammation of the urinary tract in CGD patients was discussed in chapters 1 
and 2. There were 2 XL-CGD carriers who were prescribed bladder stabiliser 
medication and 6 XL-CGD carriers reporting recurrent UTI. Stress incontinence 
was also reported. There were no associated investigations documented in these 
women and these symptoms, may in fact represent inflammation within the 
genitourinary tract. In future, it may be prudent to undertake investigation in XL-
CGD carriers presenting with urinary symptoms. 
9.3 Autoimmunity and Autoimmune Symptoms  
9.3.1 Mouth Ulcers 
Recurrent, painful mouth ulcers have been previously described in XL-CGD 
carriers [69]. Sillevis Smitt’s study found 70% of the 16 XL-CGD carriers 
surveyed suffered recurrent apthous ulcers [72].   
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This study confirmed this with 55 (75%) of the XL-CGD carriers suffering from 
painful, recurrent mouth ulcers, which is a slightly higher rate than described in 
earlier studies.  
The presence of mouth ulcers did not correlate with the NOB value. However, 
there was an association between the presence of mouth ulcers and the presence 
of gastrointestinal symptoms. Oral ulcers are frequently seen in gastrointestinal 
disease including, but not exclusively, IBD [158]. Oral ulceration also form part of 
the ARA diagnostic criteria for SLE and will, therefore, also be considered in this 
context. Subsequently, there may be two mechanisms resulting in such a high 
rate of mouth ulcers in this cohort; a lupus like illness and inflammation of the 
gastrointestinal tract.   
It would have been useful to photograph these mouth ulcers in order to provide 
a more accurate description and to demonstrate the similarities with those seen 
in the CGD patients. Biopsy results may improve our understanding of the cause.  
Several of the XL-CGD carriers reported particularly problematic oral ulceration, 
which is difficult to quantify. Additionally, treatment of these oral ulcers was 
erratic. During the study, two XL-CGD carriers commenced hydroxychloroquine 
specifically for treatment of oral ulcers, but the response is not clear at the time 
of writing. Further evaluation of the use of hydroxychloroquine is required 
before it may be recommended for all XL-CGD carriers with problematic 
ulceration.   
9.3.2 Joint Symptoms 
Joint symptoms were reported in 47 (61%) of the XL-CGD carriers. Whilst they 
have been occasionally described in XL-CGD carriers previously [69] they have 
not been found at such high rates. All those in whom joint symptoms were a 
significant problem, reported episodic inflammation, pain and redness, often 
associated with a sensation of extreme fatigue, suggesting an inflammatory 
rather than degenerative pattern.  
The most commonly affected joints were the hips and knees, and the small joints 
of the hands and fingers. The affected joint pattern may aid in the diagnosis of 
many rheumatological conditions, for example the small joints of the hand are 
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commonly affected in rheumatoid arthritis. Within the XL-CGD carrier cohort, 
there was an equal distribution of affected joints between lower and upper 
limbs.  
Rheumatological conditions may also be categorised according to the presence 
or absence of autoantibodies, seronegative or seropositive. An association 
between autoantibody positivity and the presence of joint symptoms was 
investigated.  More affected XL-CGD carriers were autoantibody positive then in 
the unaffected group. However, those suffering from joint problems were not 
universally autoantibody positive.  
Increasing age may also affect the presence of non-inflammatory joint 
complaints such as osteoarthritis. The median age in the affected group was 
significantly higher and this may suggest that some of those affected by joint 
problems were suffering from age associated degenerative arthritis.  More 
detailed information, including imaging, would improve the distinction between 
the different joint problems and allow for a comparison of factors affecting the 
development of joint problems in the different groups.  
There was no significant difference between the NOB values in the affected and 
unaffected groups, suggesting that percent functioning neutrophils does not 
impact upon the presence of joint symptoms and does not predict which XL-CGD 
carriers are likely to be at risk of joint symptoms.  
Non-erosive arthritis forms part of the ARA diagnostic criteria of SLE. The joint 
symptoms in the XL-CGD carriers will now be considered in the context of lupus 
criteria.  
9.3.3 Systemic Lupus Erythematosus 
As discussed in the section about skin disease, this study confirmed the findings 
from early literature that XL-CGD carriers have a high rate of discoid lupus 
manifestations. However, this study has found other features of SLE to be 
prevalent in the XL-CGD carriers.    
The most striking finding in this study is that 26% of the XL-CGD carriers met 4 
or more of the ARA criteria for a diagnosis of SLE and 30% met 3 of the criteria. A 
diagnosis of SLE is usually made when 4 or more ARA criteria are met. However, 
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despite this, only 18% had been diagnosed with a lupus-like disorder and the 
majority affected had not been diagnosed with SLE. Anecdotally, the XL-CGD 
carriers with SLE-like symptoms had been told that they did not have SLE as they 
had negative autoantibodies and some had not reported their symptoms prior to 
this study, which may account for the lack of SLE diagnoses.  
Compared with patients with a diagnosis of SLE, XL-CGD carriers have similar 
manifestations. However, the pattern of disease is different, and therefore 
perhaps Lupus-like is a more appropriate diagnosis than SLE. A comparison of 
proportions was made between a large European study of SLE patients [129] and 
this cohort of XL-CGD carriers. The XL-CGD carriers were significantly more 
likely to suffer from photosensitivity, oral ulcers and Raynaud’s phenomenon 
than the SLE patients. They also had significantly higher rates of arthritis and 
death. Nephropathy, serositis and neurological manifestations were more 
common in typical SLE than in the XL-CGD carrier cohort.  
Previous reports have referred to a ‘lupus-like’ disease in XL-CGD carriers due to 
the lack of positive ‘lupus autoantibodies’ in these patients[69, 100]. However, 
the different pattern of symptoms may suggest that the process seen in XL-CGD 
carriers is a different process and forms part of the spectrum of disease of SLE, 
rather than is simply SLE. This is in keeping with what has been written about 
SLE, where authors have questioned if SLE, as it is currently defined, is one 
disease or many [137]. 
Neuropsychiatric lupus, as already discussed, includes manifestations, which are 
non-specific including anxiety and depressive disorders. Outside of mood 
disorder, the only neurological manifestations of SLE seen in the XL-CGD carrier 
cohort were headache, which is again non-specific, and cerebrovascular disease.  
Mood disorder will be considered at a later stage as it may or may not be part of 
a lupus pathogenesis.  
The findings from this study are much more extensive than previously seen. 
Arthritis, photosensitivity and oral ulcers have already been discussed and 
shown in previous studies. This study, however, is the first to demonstrate the 
extent to which XL-CGD carriers may be affected by lupus like disease, and the 
first to note the different pattern. This study has also demonstrated that a 
 189 
significant number of the XL-CGD carriers are suffering from sufficient numbers 
of the ARA criteria to be diagnosed with SLE, but a diagnosis has not been made. 
The importance of this is that it means many XL-CGD carriers are currently 
undiagnosed and untreated. SLE has a better outcome when treatment is 
initiated early [127] and SLE may impact upon quality of life (QoL), with patients 
with SLE reporting poorer QoL [140]. QoL in the XL-CGD carriers will be 
discussed later in this chapter and comparisons with SLE patients made.  
9.3.4 Miscarriage 
Recurrent miscarriage has been shown to be associated with SLE and specifically 
with APS [145]. There have also been reports, as highlighted in the literature 
review, that any extreme skewing of the X-chromosome may result in recurrent 
miscarriage[269]. Additionally, Haidar et al[270] reported one XL-CGD carrier 
with a poor obstetric outcome.  
Nine XL-CGD carriers suffered at least one miscarriage, with one XL-CGD carrier 
suffering from more than one miscarriage. Miscarriage was not actively asked 
about, but was documented if it was volunteered or if it was evident in the GP 
medical records. Therefore, the rate of miscarriage and even recurrent 
miscarriage may have been higher than actually reported.  
In this cohort of XL-CGD carriers, there was no association of miscarriage with 
NOB value. The assumption made is that NOB is an accurate surrogate marker 
for percentage skewing of the X-chromosome. This may be an accurate 
measurement but it will not reflect tissue to tissue variability, as already 
discussed, which may be an important consideration.  Additionally, it is possible 
that the per cent of functioning neutrophils and NOB value may alter over time. 
In this study, NOB was only available at enrolment and in 33% of cases an 
historical value but not at the time of pregnancy or miscarriage which may be 
important.  
There was no difference in NOB, number of ARA SLE criteria met or those 
diagnosed with lupus-like disease, between those who reported miscarriage and 
those who did not. Those who had suffered a miscarriage were younger in mean 
age, but this did not reach statistical significance.  The XL-CGD carriers who 
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reported suffering miscarriage were not more likely to have positive 
autoantibodies, but specific autoantibodies associated with antiphospholipid 
syndrome were not tested.  
Additionally two XL-CGD carriers described ‘fertility’ or ‘reproductive’ issues but 
did not elaborate. Fertility is a sensitive subject and women are frequently 
reluctant to discuss this in detail. It is also difficult to quantify what an individual 
means when they describe difficulties with conception. It is therefore, difficult to 
draw conclusions about this sub-group and know how to interpret this.  
At least one of the XL-CGD carriers had received steroids during early pregnancy 
due to previous miscarriage. She delivered a full term baby without any obstetric 
complications. However, this is a simple case report. In order to determine if 
there is a benefit to steroids in early pregnancy a more structured approach is 
required and ideally a randomised, control trial. However, due to the small 
numbers of XL-CGD carriers it is unlikely that such a trial could be conducted in a 
useful time period. Therefore, more information is required about obstetric 
complications in XL-CGD carriers and miscarriage.  
It is plausible that the reproductive issues, including miscarriage, described are 
related to being an XL-CGD carrier, but there is insufficient evidence from this 
study to support this. However, if an XL-CGD carrier suffers from lupus-like 
features, even in the absence of positive autoantibodies, and presents with 
fertility difficulties or miscarriage it may be reasonable to manage them as an 
SLE patient and a trial of steroids. This information should be collated centrally 
in order that the effect may be seen and further conclusions drawn.   
9.3.5 Other Autoimmune Phenomena 
Raynaud’s phenomenon was seen in 27 (35.5%) of the XL-CGD carriers and was 
seen across all age groups. The prevalence of Raynaud’s phenomenon in the 
general population is quoted as between 6-21%[271] in women. Therefore, the 
rate found in the XL-CGD carrier population is surprisingly high. Furthermore, in 
the XL-CGD carriers, Raynaud’s phenomenon was seen in all age groups. Whilst 
Raynaud’s phenomenon alone is not a life threatening medical complaint, it may 
cause significant discomfort and thereby potentially impact upon quality of life. 
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It also has associations with autoimmune conditions such as scleroderma [271], 
which may be more significant and further highlight an autoimmune 
pathogenesis in the XL-CGD carriers.  
Alopecia was seen in 6 (7.7%) XL-CGD carriers. Alopecia may also have an 
association with autoimmunity[272]. It is difficult to be certain as to whether 
this is a significant finding in the XL-CGD carriers given the small number 
affected. As a finding alone it is unlikely to be relevant, but viewed in the context 
of the other autoimmune features, it adds weight to the hypothesis that XL-CGD 
carriers are at risk of autoimmunity.  
SLE was the most commonly seen autoimmune disorder in the XL-CGD carriers. 
However, one XL-CGD carrier suffered from Sjögren’s disease.  
9.4 Other Medical Problems 
9.4.1 Malignancy 
The literature review highlighted case reports of increased risk of malignancy in 
CGD patients[50-52], although this was not replicated in the large registries [8, 
10].This study of XL-CGD carriers did not report high rates of malignancy with 
only three XL-CGD carriers reporting any form of malignancy.  
9.4.2 Dental 
There are several examples of dental abnormalities associated with primary 
immunodeficiencies, for example Hyper IgE syndrome with the persistence of 
baby teeth and NEMO defects with conical incisors [273]. Delayed primary tooth 
loss has been described in patients with XL-CGD[274] 
There have been few reports of XL-CGD carriers with dental problems and as 
such, recruited participants were not actively asked about dental problems. 
However, three XL-CGD carriers volunteered that they had unusual dental 
complaints.  
The findings are of interest but given their low frequency and lack of detailed 
information or photographic evidence, it cannot be immediately assumed that 
these dental manifestations are part of the spectrum of problems from which XL-
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CGD carriers suffer. However, as XL-CGD carriers suffer from recurrent mouth 
ulcers, there is already sufficient reason to encourage enhance oral health care to 
include regular dental follow up. Highlighting this as a potential problem may 
enable further evaluation of this as a potential are affecting XL-CGD carriers.  
9.4.3 Ocular 
Chorioretinitis was demonstrated to be prevalent in the XL-CGD carriers in 
Goldblatt et al’s study [34] in 1999. This study did not aim to replicate this and 
chorioretinitis was not screened for. However, many of the XL-CGD carriers will 
have participated in both studies. Two of the XL-CGD carriers volunteered that 
they had chorioretinitis and this information is shown for completeness, but this 
low frequency is explained by the lack of screening.  
Other ocular problems, photopsia and esotropia are reported in this cohort but 
at low frequencies. It is difficult to assess the significance of these findings and it 
seems likely that they are not particularly associated with XL-CGD carrier status.   
However, the one case of retinal infection is of particular interest. In this case the 
retinal infection resulted in the XL-CGD carrier becoming partially sighted. There 
is a clear potential mechanism to associate risk of infection with the outcome, 
and this has been described in CGD patients[275]. There was limited information 
available in this case and more information may have provided better 
understanding of the relevance of this finding.  
9.4.4 Cardiovascular 
Increased cardiovascular risk has been found in chronic inflammatory conditions 
such as rheumatoid arthritis [276]. Subsequently, cardiovascular disease may be 
particularly pertinent in the XL-CGD carrier cohort. One of the two deaths in this 
cohort was as a result of coronary heart disease in an individual known to suffer 
from SLE. It important that cardiovascular risk is further studied in order to be 
considered in the context of other modifiable risk factors and primary 
prevention of cardiovascular disease in XL-CGD carriers. 
Only four XL-CGD carriers volunteered that they were hypertensive, despite a 
greater number being prescribed anti-hypertensive medications. This highlights 
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the drawbacks to interviewing individuals about their medical health; there may 
be a discrepancy between what the patient believes to be wrong with them and 
what their physician considers to be their main medical complaints.  
9.5 Patterns of Clinical Symptoms 
A wide range of medical symptoms were described, therefore, patterns of clinical 
symptoms were looked for. The first observation is that it was rare to have 
significant physical symptoms and not suffer from photosensitivity, although 
photosensitivity as a solitary symptom was not infrequent. This suggests that if 
photosensitivity is not present, other symptoms are less likely, although possible.  
Secondly, the most frequently occurring combination of symptoms was 
photosensitivity with joint symptoms affecting almost half of the XL-CGD 
carriers. This combination of joint symptoms and photosensitivity is suggestive 
of an autoimmune or SLE-type disease, which is in keeping with what has been 
described in earlier sections. The mean age in those affected by joint symptoms 
and photosensitivity was lower than in the other groups, highlighting that 
symptoms were not confined to the older XL-CGD carriers.  
Thirdly, a quarter of the XL-CGD carriers suffered from joint and bowel 
symptoms and photosensitivity. Those XL-CGD carriers suffering from this trio of 
symptoms had a lower mean NOB than the other combination of symptoms. This 
may reflect a further symptom cluster and further work on evaluation of the 
different groups may improve understanding of aetiology. It is also important to 
observe that this was not an uncommon pattern, occurring in a quarter of XL-
CGD carriers, despite it being the least common combination.  
In summary, analysis of the combination of symptoms highlights that there may 
be different patterns of disease amongst the XL-CGD carriers, with those 
suffering from autoimmune or SLE-like diseases representing just one pattern. It 
also highlights that the majority of XL-CGD carriers suffer from more than one 
medical problem and that symptoms other than the presenting problem should 
be actively asked about. The analysis of NOB values in the patterns will be 
discussed in more detail in section 9.7.1.  
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9.6 Current Management of XL-CGD Carriers 
Current management of XL-CGD carriers in the UK is erratic. The majority are not 
seen in a hospital setting, but those who are, are seen by a number of specialities 
with gastroenterology, immunology and rheumatology all involved.  
45 of the XL-CGD carriers were on at least one prescribed medication. The broad 
spectrum of prescribed medications reflects the diversity of symptoms seen in 
the XL-CGD carriers. The commonest medications were hydroxychloroquine, 
antidepressants and analgesic agents other than paracetamol.  
The large number of different classes of medications prescribed highlights two 
important features of the current management of XL-CGD carriers. Firstly, it 
shows a lack of uniform approach reflecting the poor understanding of the 
medical health of these women. Secondly, it reflects the diverse range of 
symptoms suffered. The medications are treating symptoms rather than an 
underlying pathology, which may be particularly important when considering 
psychological health and anxiety or depressive symptoms.  
Due to the relatively small number of patients and the large number of 
medications, it is difficult to ascertain the impact of medications upon symptoms. 
Not all those who were symptomatic with lupus-like symptoms had been 
prescribed hydroxychloroquine. In SLE, early intervention is important to 
improve outcome [127]. The use of hydroxychloroquine has not been evaluated 
in XL-CGD carriers and further research is required to see if this may improve 
symptoms.  
Prophylactic antibiotics were prescribed in eight (10%) of the XL-CGD carriers 
with 4 co-trimoxazole and 4 an alternative agent. Significant or recurrent 
infection occurred in 25% of the XL-CGD carriers. These infections were not 
associated with the degree of reduction in NOB. However, XL-CGD carriers were 
more likely to be prescribed prophylactic antibiotics with a lower NOB. It is 
unclear from this study whether prophylactic antibiotics should be 
recommended in XL-CGD carriers. The low rate of significant infection would 
suggest that overall there is no clear indication for prophylactic antibiotics. 
However, if an XL-CGD carrier suffers a significant infective episode or had 
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troublesome recurrent bacterial infections then a trial of co-trimoxazole may be 
appropriate.  
The fact that recurrent skin abscesses were associated with a lower NOB may 
suggest these individuals would benefit from prophylactic antibiotics. During the 
course of the study, at least one XL-carrier suffering from recurrent skin 
abscesses commenced prophylactic co-trimoxazole. Further long-term follow up 
in this group of carriers is needed to determine the benefit of prophylactic 
antibiotics.  
Four carriers were on prophylactic anti-fungal agents. However, fungal infection 
was not reported as a significant problem with only one episodes described. 
Therefore, it cannot be recommended from this study that prophylactic 
antifungal agents be part of standard care.  
Steroids had been prescribed in five XL-CGD carriers. The reason for steroid 
prescription was varied. Steroids have been used with good effect in 
inflammatory rheumatological conditions including SLE. There may be a role for 
the use of steroids in XL-CGD carriers who suffer from joint symptoms but more 
information about the pathogenesis of symptoms is required and steroids should 
be used in a more formal trial setting to ascertain if there is a role for their use. 
At least one XL-CGD carrier had been prescribed steroids due to concerns about 
recurrent miscarriage.  
9.7 Blood Investigations  
9.7.1 Neutrophil Oxidative Bursts  
The mean NOB in this cohort was 47% with a range of 7 to 94%. Published data 
prior to this study revealed a slightly smaller range of 20 to 80%[69]. This study 
is the largest available of XL-CGD carriers and this is likely to account for the 
wider range seen compared with previous studies. NOB was performed at 
enrolment, but historical data were available regarding neutrophil oxidative 
burst on 27 (33%) of the XL-CGD carriers.  
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Comparison of enrolment NOB results with historical NOB results revealed that 
there was a significant decrease in value. Whilst this is an interesting finding, it 
cannot be assumed that this reflects what happens to NOB with age.  
Subsequently, NOB values were studied in comparison with the age of the 
individual. No significant correlation was found. However, this was comparing 
NOB value against age on a population (cohort) level rather than an individual 
level. There may be more subtle or significant changes when examined on an 
individual basis, but this would require a larger population-based sample.  
This study was not designed to assess longitudinal NOB values and the methods 
used in historical and enrolment NOB tests may have differed. However, it does 
raise the question of whether NOB values change with increasing age. In order to 
look at the effect of ageing on change in per cent functioning neutrophils a 
longitudinal study is required to look at individuals at regular intervals over a 
prolonged study period. This work is currently underway as a joint project with 
GOSH, GNCH and Amsterdam.  
Koker et al [59] reviewed three generations of XL-CGD carriers and 
demonstrated that there was a reduction in the per cent of normal neutrophils 
with increasing age over the three generations thus suggesting that as age 
increased, the per cent of functioning neutrophils reduced. In the current study, 
three families had three generations represented allowing evaluation of the 
different NOB values over the generations. Two of the families concurred with 
Koker’s finding with lower NOB values with increasing age and generation. 
However, one family did not follow this pattern and in fact reversed the trend 
with the lowest value in the youngest generation and the highest value in the 
oldest generation.  
Five families had two generations represented. In all five of these families, the 
lower NOB values were seen in the younger generation. One family had 2 
generations, but 2 branches represented. In this family, there were higher values 
seen in the younger generation. 
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The lack of pattern through the generations in this study demonstrates that 
factors other than age are clearly important in the percentage of functioning 
neutrophils.  
As highlighted in chapter 2, there are differing opinions over how lyonisation is 
governed, with increasing interest directed towards the genetics of controlling 
this apparently random process of X inactivation. Studying different generations 
of XL-CGD carriers gives us a small insight into how this process may manifest. 
Our observation is that there is no consistent pattern, with different generations 
showing highly different levels of skewing across different families, highlighting 
the need to investigate this further. Age alone cannot be the only factor 
determining the degree of skewing. As XL-CGD is a rare disease, research into 
more common XL genetic conditions may yield answers more quickly as to what 
governs this process.  
NOB as a predictor of which XL-CGD carriers are likely to suffer from symptoms 
is not straightforward. Some correlation of NOB and symptoms was seen, as 
discussed earlier, with recurrent skin infection and specific gastrointestinal 
symptoms associated with lower values, but this did not correlate with all 
clinical symptoms.  Additionally, some significantly affected XL-CGD carriers had 
greater than average NOB function. 
However, when patterns of clinical symptoms were considered NOB values did 
differ between groups. The lowest NOB values were seen in the group where 
photosensitivity, joint symptoms and bowel symptoms were all present, with the 
next lowest seen in those affected by photosensitivity and joint symptoms.  
It is difficult to be certain of the exact significance of this finding but nevertheless 
it is an important observation. The combination of photosensitivity and joint 
symptoms appears to be the connecting factor associated with lower NOB values 
suggesting it is those with autoimmune and SLE-type features who have lower 
NOB values, rather than simply those who are most affected.  
9.7.2 Autoantibodies 
Where it was possible to test for autoantibodies, the majority of XL-CGD carriers 
had negative autoantibodies. This is in keeping with previous research[69, 100]. 
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In those who did have positive autoantibodies, it was most frequently that there 
was a positive ANA pattern. 
Where autoantibodies were positive symptoms were present. However, not all 
XL-CGD carriers with physical symptoms, even in those with significant disease, 
had positive autoantibodies. Therefore, the absence of autoantibodies does not 
equate to the absence of disease. Anecdotally, this has led to XL-CGD carriers not 
having their lupus-like symptoms managed as they would be for SLE patients as 
it has led to uncertainty of diagnosis.  
The lack of positive autoantibodies and correlation with clinical symptoms 
suggests one of two possibilities. Either autoantibodies are not present and 
another underlying mechanism is involved in the pathogenesis of disease in XL-
CGD carriers or they are present but in insufficient quantities to detect by 
conventional methods. Measurement of autoantibodies was by 
immunofluorescence, and it may be that using more sophisticated techniques 
further autoantibodies would be detected.  
At present, using conventional testing, autoantibodies cannot be used as a 
screening tool for symptoms of disease in XL-CGD carriers.  
9.8 Clinical Summary 
In summary, from this study it can be said that XL-CGD carriers are at risk of 
infective and inflammatory manifestations of CGD which, on the whole, do not 
correlate with the degree of reduction in NOB. XL-CGD carriers also suffer from a 
range of autoimmune phenomena.  
It is unclear how affected individuals can be predicted with current standard 
non-invasive investigations. There are no clear guidelines about how symptoms 
in XL-CGD carriers should be managed.  
9.9 Fatigue 
Excessive fatigue was reported unprompted in over half of the XL-CGD carriers. 
Subsequently, fatigue was evaluated using the fatigue questionnaires, the MFSI 
and the vitality (VT) domain of the QoL SF36.  
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As outlined in chapter two, fatigue as an independent symptom has generated 
increasing interest over the past decade as it is recognised as an important 
feature of inflammatory conditions. However, it has also been described in the 
general population. Cale et al [69] commented in their study of 19 XL-CGD 
carriers, that the XL-CGD carriers reported fatigue, but it was not quantified or 
assessed using a validated tool. There is no other published literature about 
fatigue in XL-CGD carriers.  
In this study, validated assessment tools supported the reporting of fatigue by 
the XL-CGD carriers, with those reporting excessive fatigue scoring higher in the 
MFSI than those who did not report fatigue as a significant problem. Fatigue was 
a consistent finding in the XL-CGD carriers irrespective of which tool was used to 
assess fatigue, as there was a significant correlation between the VT scores and 
all of the domains in the MFSI, thus demonstrating a degree of internal 
consistency. The VT domain has been shown to correlate with other fatigue 
questionnaires [179] and suggests that, however fatigue is measured, it was 
present as a problem in this cohort of XL-CGD carriers.  
As already highlighted, fatigue is multidimensional and the MFSI allows for 
comparison between categories of fatigue. In the XL-CGD carriers, the highest 
scores were seen in the general category with mean scores in all other domains 
similar. This suggests an equal contribution of each domain to the overall high 
scores and subsequently, does not help to ascertain the cause of the fatigue.  
The MFSI in XL-CGD carriers was compared with the scores from the MD carrier 
control group. The scores in the XL-CGD carriers did not demonstrate 
significantly higher levels of fatigue. Higher scores were seen in the MD carrier 
group. However, only 7 MD carriers completed the questionnaire compared with 
60 in the XL-CGD carrier group. This makes a direct comparison unreliable. 
Additionally, one MD carrier reported suffering from Chronic Fatigue Syndrome, 
which in a small sample may skew the results. It may be that this woman was 
suffering as a result of being a carer of a child with a chronic illness, but it may be 
that she represents an outlier in this group. In a small cohort one individual may 
significantly affect the results. The MD carriers scored higher in the general 
domain than in any other domain. The MD and XL-CGD carriers had very similar 
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scores in the vigor domain. However, the MD carriers may also suffer from 
fatigue as a result of their own carrier status and disease.  
Figure 9-1 shows the possible contributing factors to the aetiology of fatigue in 
XL-CGD carriers and each will now be considered in turn. 
Figure 9-1: Potential Contributors to Fatigue in XL-CGD Carriers 
 
Firstly physical symptoms were considered. Conditions outside of CGD, where 
there is chronic inflammation have been associated with fatigue as a significant 
problem. Literature about SLE, Sjögrens, IBD, sarcoid and primary biliary 
cirrhosis all report fatigue as a predominant feature, and frequently the most 
significant problem for patients [141, 214, 277]. As discussed in chapter two, a 
logical hypothesis may be that XL-CGD carriers suffer similar chronic 
inflammation resulting in the symptom of fatigue. Supporting this hypothesis is 
the association of the physical symptoms in the XL-CGD carriers with the 
presence of fatigue.  
There was a significant correlation between level of fatigue and the presence of 
joint symptoms. XL-CGD carriers frequently described episodes of significant 
joint pain and swelling along with overwhelming fatigue. Those patients with 
joint pain scored higher on the MFSI than those without joint pain. Similarly, 
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highlights the similarities between SLE and the symptoms seen in XL-CGD 
carriers, as fatigue has been reported as an overwhelming feature in SLE [214].  
The joint and bowel symptoms correlating with fatigue scores reflect the 
physical component of fatigue and may reflect a chronic, inflammatory process 
on going in the XL-CGD carriers. Due to this association, we hypothesised that the 
fatigue seen in the XL-CGD carriers could be the result of ongoing chronic 
inflammation and thus may be driven by pro-inflammatory cytokines.  
The findings of raised IL-8 in the XL-CGD carriers support this hypothesis. There 
were significantly higher levels of IL-8 in the XL-CGD carriers compared with the 
healthy control group. When the XL-CGD carrier groups were divided into those 
who reported excessive fatigue and those who did not, there was a significant 
difference with fatigued XL-CGD carriers having higher IL-8 levels than the non-
fatigued. A further comparison strengthened this hypothesis. IL-8 levels in the 
XL-CGD carriers were higher than Sjögrens patients who also suffered fatigue. 
The number of samples in this aspect of the study was small and the study was 
not statistically powered to look for differences and it demonstrates an 
association, but not direct causation.  
However, the association of IL-8 with fatigue in XL-CGD carriers supports the 
concept of a biological component to the fatigue described. It is conceivable that 
XL-CGD carriers suffer fatigue due to a similar mechanism as that seen in the 
patients with chronic inflammatory conditions such as SLE, IBD and Sjögrens and 
may in fact be more pronounced. The overlap of fatigue in XL-CGD carriers with 
the symptoms seen in these chronic inflammatory conditions, in addition to the 
raised IL-8 levels support the hypothesis of chronic inflammation in XL-CGD 
carriers. 
Secondly, psychological factors were considered. Fatigue may be a manifestation 
of depression and it could therefore be expected that if the fatigue seen was 
associated with depression, XL-CGD carriers with high fatigue scores would have 
higher depression scores and that there would be a correlation between fatigue 
and depression. Significant correlation was seen between HAD-D scores and 
fatigue levels; however, the HAD-D scores fell within the normal range 
suggesting that the depression levels were not significant. As the depression 
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scores were within normal limits, it would be surprising if they were significant 
enough to cause fatigue, but it cannot be ignored as a potential contributing 
factor.  
Conversely, the anxiety scores were significantly higher than the general 
population and fell outside of the normal range. There was a significant 
correlation between anxiety scores (HAD-A) and level of fatigue. Correlation 
does not explain the relationship between the factors examined, but it could be 
hypothesised that persistent anxiety may result in fatigue. However, as there was 
also an association with joint pains, it may be that anxiety is the result of physical 
symptoms and the fatigue is a primary symptom from which anxiety develops.  
Thirdly, social factors were considered. The number of children, age of the index 
case and relationship to the index case were considered as potential contributors 
to the fatigue scores. The impact of caring for a child with a chronic illness was 
also considered. There was a significant correlation seen between the number of 
children a participant had and level of fatigue. This is not surprising. It is logical 
that an individual may be more fatigued with a higher number of dependents 
and this may not be specific to being an XL-CGD carrier and may be reproducible 
in the general population. The age of the index case was not significantly 
correlated with fatigue level, suggesting that the age of a child does not impact 
upon fatigue levels.  
The PIP was used to assess the impact of caring for a child with chronic illness. 
The scores were not significantly different between the fatigued and non-
fatigued group. The lack of correlation suggests that whilst the role of carer may 
contribute to fatigue levels, it is not the sole contributor.  
There have been mixed reports of the impact of age on fatigue levels, with 
younger age being more associated with fatigue in conditions such as sarcoid 
[182]. There was no association between age and fatigue levels in XL-CGD 
carriers meaning age cannot account for the fatigue seen.  
There are limitations in the assessment of fatigue in this study. Firstly, the 
participants only completed the assessment at one time point. This, therefore, 
does not take into account the variations, which may occur over time. The 
 203 
questionnaire specifically asks the participant to consider the past 7 days, which 
may not be truly representative of an individual’s fatigue levels.  This study 
would have been improved by assessing fatigue at multiple time points to gain a 
better understanding of fatigue in the XL-CGD carriers. Secondly, there are no 
population data with which to compare the XL-CGD carrier responses. Thirdly, 
the difficulties in recruitment of the control group meant that there was no direct 
sizeable comparable group.  
This study confirms the informal results found in the CGD Society survey that 
fatigue is a problem in XL-CGD carriers, as yet not widely recognised. Whilst the 
causation of the fatigue remains unclear, the importance should not be unstated. 
Physical, psychological and social factors all affect the degree of fatigue seen in 
XL-CGD carriers. The fatigue reported in the MD control group suggests that 
there is an inherent fatigue associated with caring for an unwell child. However, 
the physical factors are more specific to XL-CGD carriers and were also 
significant, demonstrating that the aetiology of fatigue in XL-CGD carriers is not 
limited to the social and psychological factors, a hypothesis supported by the 
association of raised IL8 seen in the XL-CGD carriers. From this study, it is not 
possible to determine which factors are the most important.  
As previously discussed, physicians do not always consider fatigue as an 
important symptom. However, it is frequently one of the most important 
complaints considered by patients and impacts significantly on QoL.  
In the XL-CGD carriers, fatigue may be improved by optimal treatment of the 
newly identified physical complaints. Additionally there may be benefits in 
offering treatment of anxiety both for the anxiety and in order to improve fatigue 
levels. The social factors, whilst not modifiable, may be improved by further 
support. In fatigue that is not improved by treatment of the physical and 
psychological symptoms alternative therapies need to be considered. In order to 
direct therapies appropriately, further understanding of the mechanism of the 
aetiology of fatigue is required.  
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9.10 Psychological  
9.10.1 Anxiety 
Symptoms of anxiety were found in a high number of the XL-CGD carriers with 
40% suffering mild or greater anxiety symptoms when screened using the HADS. 
The mean value for anxiety in XL-CGD carriers as an overall group was 9.47, 
which is above the accepted symptomatic cut off and is on the 75th per centile for 
UK women [248], demonstrating that the group, as a whole, suffer more anxiety 
than would be expected in the general population.  
Only one XL-CGD carrier had a pre-existing diagnosis of anxiety, whilst six had a 
diagnosis of mixed anxiety and depression. By screening for anxiety, this study 
found that there were more than these pre-defined 7 XL-CGD carriers suffering 
significant levels of anxiety. This suggests that anxiety is currently under-
recognised and under-diagnosed in the XL-CGD carrier cohort. There is no 
published literature about XL-CGD carriers and anxiety and therefore, the 
findings from this study are novel and direct comparisons cannot be made.  
 XL-CGD carriers with a HADS-A score greater than 8 would warrant 
consideration of treatment independent of the cause of the anxiety. As only 20% 
of the XL-CGD carriers were prescribed antidepressants, which are the mainstay 
of medical treatment of anxiety, this leaves a considerable number (at least 20%) 
who were suffering symptoms but not receiving treatment.  
Not all individuals with anxiety symptoms choose to take medication, but this 
study suggests that the medical team were not aware of the presence of anxiety 
symptoms in the XL-CGD carriers, meaning that they would not offer treatment. 
Identification of anxiety symptoms is the first step in the management of anxiety.  
Having established that anxiety is a problem amongst this cohort of XL-CGD 
carriers, further evaluation of causation was undertaken. The mean scores for 
anxiety were considered by relationship to the index case.  There was no 
significant difference across the categories, suggesting that anxiety is present 
independent of the relationship to the index case, and that other factors may 
contribute to the development of anxiety. This was a surprising finding as it may 
be expected that those most closely related, particularly mothers, to the index 
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case would suffer the greatest levels of anxiety. However, the highest scores 
were seen in the grandmothers. Although this was not statistically significant, 
this could suggest that those who are less closely involved are more anxious. The 
lack of association between relationship and anxiety suggests that there are 
other important factors in the aetiology of anxiety or that it may be intrinsic to 
being a carrier rather than external factors. Alternatively it may also suggest that 
the wider family may be at risk for the development of anxiety. However, the 
numbers in the study are relatively small and may lack statistical power, 
particularly when considering across more than one category.  
As psychological health may change with age[212], anxiety scores were 
evaluated in respect to this. This study did not find a significant association with 
increasing age and anxiety; therefore, this is unlikely to account for the small 
differences seen between mothers and other relationships, specifically 
grandmothers.  
A proportion of the index cases had undergone HSCT. The stresses for parents of 
the HSCT process were discussed in chapter two. A comparison of anxiety levels 
of the relatives where the index case had and had not undergone HSCT showed 
that the anxiety scores were higher where HSCT had been undertaken. The 
difference did not reach statistical significance, but this does demonstrate that 
anxiety persists despite the cure of the index case. The importance of this finding 
is twofold. Firstly, clinicians must be aware that psychological distress may 
persist even after the index case has undergone definitive treatment. Secondly, it 
suggests that there may be factors other than caring for a child with a chronic 
illness that are important in the development of anxiety in this group, including 
intrinsic factors of being a carrier. Alternatively, it may also reflect that parents, 
do not have the same confidence that physicians have that HSCT is curative.   
How does anxiety in XL-CGD carriers compare to other groups? 
As the anxiety scores were significantly higher than the UK norms and there are 
no previously published studies in the XL-CGD carriers, comparisons were made 
with published data from groups who may have similar factors affecting them.  
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Firstly, anxiety scores were compared with published data from parents of 
children with other chronic medical conditions to evaluate if a similar picture 
was seen in conditions outside of CGD.  
Published data were available from CF parents[251]. The studies used the same 
assessment tool and were both one-off assessments of anxiety, with similar 
study designs allowing for comparisons to be made. CF is a chronic condition 
with a reduced life expectancy and requires parental involvement in medical 
care. Thus, there are considerable similarities with CGD.  
Significantly more XL-CGD carriers suffered greater than normal anxiety 
symptoms compared to CF parents. The mean anxiety score was also higher in 
the XL-CGD carriers. Although this was not part of the same study, the use of the 
same tool allows for this direct comparison. The significantly higher scores in the 
XL-CGD carrier group, suggest that either diagnosis and living with CGD is 
associated with greater anxiety than CF or that factors outside of parenting a 
chronically unwell child play an important role in the causation of anxiety 
symptoms.  This is further supported by the lack of correlation of anxiety scores 
with the perceived stresses of parenting shown in the PIP, which will be 
discussed later. One further consideration is that the CF study included fathers as 
well as mothers, which may have impacted upon their findings. Women are more 
likely to suffer from anxiety than men [212] and the lower scores in the CF group 
may reflect the lack of inclusion of fathers. 
The anxiety scores were compared with a second group of parents, the MD 
control group. The findings were similar. The XL-CGD carriers had higher anxiety 
scores, although this did not reach statistical significance. The control group 
recruited was considerably smaller, but support the findings from the 
comparison with the CF parents, and a larger cohort of MD carriers may have 
validated this.  
Secondly, as reasons outside of parenting a chronically unwell child may have 
impacted upon the high anxiety rates in the XL-CGD carrier group, anxiety scores 
were also compared to published data from SLE patients [140, 229]. As SLE 
symptoms have been described in the XL-CGD carrier cohort, anxiety in SLE is of 
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particular interest as there may be a common pathogenesis, particularly as 
anxiety is one of the possible diagnostic criteria for neuropsychiatric SLE[138].  
The data published about SLE patients were divided into those with high and low 
levels of pain. Waldheim et al’s[229] study found significantly higher levels of 
both anxiety and depression in the high pain group and concluded that pain was 
an important contributing factor. Anxiety scores in the XL-CGD carriers were 
most similar to the SLE patients with high pain (non significantly higher mean) 
and significantly higher than SLE patients with low pain. It is difficult to draw 
conclusions from this comparison but it furthers our appreciation that XL-CGD 
carriers are more comparable to SLE patients than the general population with 
regards to both physical and psychological symptoms, and suggests physical 
symptoms may contribute significantly to psychological health.  
A study by Tench et al[140] also assessed anxiety in SLE patients and found 
similar results with a mean of 9 for anxiety as well. There was no significant 
difference between the XL-CGD carriers and the SLE patients in Tench’s study, 
supporting the similarities between these groups.  
Causation and Association  
The presence of high rates of anxiety in XL-CGD carriers has been well 
demonstrated in this study, but the reason for the anxiety is less clear. As 
outlined in chapter 2 there are several possible contributing factors.  
As already discussed, despite that it might be expected that being a mother of a 
case may be associated with greater anxiety levels, there was no significant 
increase in anxiety score for mothers of the index case when compared to non-
mother relatives. This suggests that it is not solely the relationship with the 
index case that determines anxiety. It may be that mothers have more 
involvement in daily care and feel more in control, thus lessening their anxiety 
symptoms, whilst grandmothers are more on the periphery although still 
affected by genetic guilt and concern for their grandson.   However, this is 
speculation and was not the primary aim of the study. A qualitative study would 
be required to establish the answer to this question. 
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There was no significant association between anxiety scores and the assessment 
of caring for a child with chronic illness (PIP). This concurs with the lack of 
association between anxiety and relationship to the index case and is further 
evidence that the anxiety present in XL-CGD carriers is not solely related to 
parenting a child with chronic illness.  
The similar levels of anxiety to SLE patients, and particularly with the high pain 
group, suggest that physical symptoms may be an important contributor and 
therefore, these were evaluated. There was a significant correlation between 
anxiety score and the presence of both bowel and joint symptoms in the XL-CGD 
carriers. Due to the cross-sectional nature of this study, it is unclear in which 
direction this association is. It may be that those with symptoms of urgency or 
diarrhoea are anxious as a direct result of this, or, as previously highlighted; 
there may be more gastrointestinal disturbance in those with an underlying 
anxiety. The correlation of anxiety scores with the presence of joint symptoms 
also reached statistical significance. It is less likely that anxiety may predispose 
to joint pain and stiffness. However, the association of anxiety with high pain in 
the SLE study suggests that this may be a significant factor, which has been 
replicated in the XL-CGD carrier cohort.  
As neuropsychiatric lupus may present with mood disorder and may be 
associated with other features of SLE, correlation with other SLE symptoms was 
evaluated. There was no significant association with either an established 
diagnosis of lupus-like disorder or the number of the ARA SLE diagnostic criteria 
met in the XL-CGD carriers. Whilst neuropsychiatric SLE may present without 
other systemic manifestations, the lack of correlation with these criteria may 
also reflect a different underlying mechanism in the development of anxiety. 
Anxiety has been associated with chronic inflammation as discussed in chapter 2, 
and this may be an important component of the anxiety seen in XL-CGD carriers. 
As was demonstrated with the raised IL-8 and fatigue in XL-CGD carriers, an 
inflammatory component may be important in psychological health.  
There was a significant correlation between scores for anxiety and the total 
fatigue score. Fatigue is a well-recognised symptom of depression[212], but it is 
less well described in isolated anxiety.  
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Impact of Anxiety on Other Psychological Factors  
A significant association was seen between anxiety scores and depression scores, 
despite the fact that very few XL-CGD carriers suffered significant depression. An 
association was also seen between anxiety and self-esteem with those who were 
most anxious suffering the lowest scores in self-esteem. This may suggest that 
the presence of anxiety impacts upon other aspects of psychological health, 
reiterating the importance of identifying anxiety and managing it appropriately.  
Anxiety also appeared to impact upon QoL, with those who were most anxious 
suffering from lower QoL. This is further evidence of the importance of 
identifying and managing anxiety in XL-CGD carriers.  
Anxiety Summary 
In summary, the XL-CGD carriers suffer high rates of anxiety, which is significant 
in several cases. This has not been previously demonstrated. The anxiety does 
not correlate with relationship to the index case, age or the presence of SLE-type 
symptoms, but does appear to correlate with the presence of bowel and joint 
symptoms, fatigue and higher depression scores. It is not more significant in the 
mothers than non-mothers and is more prevalent than in parents of children 
with other chronic conditions.  
The identification of high rates and degrees of anxiety which were previously 
undiagnosed, highlight the need for screening tools to be introduced into clinical 
practice. All XL-CGD carriers should be screened regularly for the presence of 
anxiety symptoms and managed appropriately.  
9.10.2 Depression  
Depressive symptoms were less frequent than anxiety in the XL-CGD carriers 
with only 27% suffering from depressive symptoms. The mean HAD-D score was 
5.08 in the overall XL-CGD carrier group. Whilst this mean score falls into the 
normal category, when compared to UK female norms this falls on the 66th per 
centile [248] suggesting there are slightly more symptoms than in the average 
population. Similarly to anxiety, there appears to be a greater burden of 
depression than previously appreciated, as only 13 (16%) XL-CGD carriers had a 
 210 
pre-existing diagnosis of depression or combined anxiety and depression rather 
than the 27% found on screening. This may reflect under diagnosis or lack of 
reporting of symptoms. 
There was no significant difference in depression scores when the relationship to 
the index case was considered. Slighter higher scores were seen in the cohort of 
grandmothers, but this did not reach statistical significance.  
How does this compare to other groups? 
The depression scores from this study were compared to results from other 
published studies.  
The proportion of XL-CGD carriers suffering from depressive symptoms was very 
similar to the published work by Besier et al[251] about CF parents and there 
was no significant difference. In both the CF group and the XL-CGD carrier group, 
very few individuals suffered from significant depression. This suggests that the 
stresses of having a child with chronic illness do not manifest as depression. This 
is further supported by the lack of correlation between the total PIP scores and 
depression scores. Those with higher PIP scores did not have higher HAD-D 
scores.  
The depression scores in the XL-CGD carriers were similar to those seen in the 
control group of MD carriers and were, in fact, slightly better. There are many 
factors, which may explain this. Firstly, it may relate to the lack of a definitive 
curative treatment for MD, whereas HSCT remains a curative treatment option 
for CGD. Secondly, it may reflect that other factors, outside of chronic illness 
impact upon depression. This supports the findings from the comparison with 
the MD carrier group.  
When compared with the SLE patients, the results were mixed. XL-CGD carriers 
suffered greater depression scores than SLE patients classified as low pain from 
Waldheim et al’s study [229], but were not as significant as the SLE patients with 
high levels of pain. This may reflect the importance of physical symptoms to the 
psychological health. 
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Factors affecting depression 
Correlation between physical symptoms and depression scores were examined. 
Unlike anxiety, there was no significant association between the depression 
score and the presence of gastrointestinal and joint symptoms, and similarly 
there was no association with a diagnosis of lupus-like disease or the number of 
SLE ARA criteria met. Previously, in the general population depression has been 
associated with increasing age [251], but this was not found in the XL-CGD 
carriers where there was no correlation between age and depression score.  
An association was seen between depression and anxiety as previously outlined, 
and the impact upon self-esteem by depression was also significant. There was a 
significant association between depression scores and overall fatigue scores. 
Fatigue has been described as a biological symptom of depression. However, the 
relationship between fatigue and depression in XL-CGD carriers may be bi-
directional.  There was no difference when HSCT in the index case was 
considered.  
Depression Summary  
In summary, depression scores were slightly higher in the XL-CGD carrier cohort 
than population data would predict, however, the majority of XL-CGD carriers 
did not suffer significant depression symptoms. There was no association with 
physical symptoms, with the exception of fatigue, age or caring for a child with 
chronic illness. Depression scores correlated with self-esteem and anxiety.  
Implications of Anxiety and Depression Findings 
The presence of anxiety within the XL-CGD carriers, irrespective of the cause, has 
important clinical implications.  
All XL-CGD carriers should be screened for the presence of anxiety and 
depression symptoms given the high rates uncovered in this study, which were 
previously undiagnosed. Clinicians caring for children and families with CGD 
need to be aware of the high rates of anxiety in the XL-CGD carriers. Both anxiety 
and depression may present with non-specific symptoms and, as this study has 
shown, may not be overtly evident unless actively sought. Severe anxiety or 
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depression may impact upon the ability to manage complex medical needs 
without support. Anxiety and depression may also impact upon an individual’s 
quality of life, which with treatment may be improved.  
Those who are detected to suffer from anxiety or depression should be managed 
appropriately and offered medical or psychological therapy.  
The findings from this study may be transferrable to conditions outside of CGD 
and particularly other primary immunodeficiencies and further studies should 
investigate this.  
This study supports the development of psychological support services for the 
families and specifically the carriers.  
9.10.3 Self-Esteem 
Self-esteem was assessed in both the XL-CGD carriers and the control group.  
Normal self-esteem was largely preserved in the XL-CGD carriers with 46% 
falling in the normal range. However, one third did suffer from low self-esteem 
and this was associated with higher scores in both anxiety and depression 
domains suggesting that anxiety and depression may impact upon self-esteem 
and highlighting the need for appropriate management.  
There was no significant difference in self-esteem scores across the relationship 
groups. However, XL-CGD carriers scored significantly lower in self-esteem than 
the MD control group. Given the small numbers in the MD control group, it is 
difficult to be certain as to the significance of this difference. All that can be said 
is that there is reduced self-esteem in the XL-CGD carriers, which is out of 
keeping with that seen in another cohort of carriers of another chronic disease.  
9.10.4 Psychology Summary 
In summary, this study has demonstrated high rates of anxiety in the XL-CGD 
carriers and moderate rates of depressive symptoms, irrespective of age, 
relationship to index case and assessment of stresses associated with caring for a 
child with chronic illness. Screening for anxiety and depression should be 
implemented.  Clinicians should be aware that these problems may impact upon 
self-esteem and quality of life.  
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9.11 Caring for a child with chronic illness 
Unsurprisingly, this study has found that there are significant stresses associated 
with caring for a child with a chronic, life limiting condition, which is evidenced 
by the high scores seen in the PIP questionnaire. The scores were higher in 
frequency than severity.  
There may be many factors affecting the difficulties of caring for a child with a 
chronic illness. The age of the child may impact upon caring; older children may 
be more challenging, as they will be required to cooperate with treatments 
whilst younger children have little autonomy. The older child may already have 
developed more significant complications of CGD or had several prolonged 
hospital stays. Despite these possibilities, there was no significant difference in 
the PIP scores when age of the index case was accounted for. This was 
unexpected but may be accounted for by the small numbers within each age 
category explaining why the differences did not reach statistical significance. The 
highest scores were seen where the children were aged 7-12 years. There were 5 
mothers of index cases over the age of 18 who completed the assessment and 
this group showed the lowest scores in all aspects of the PIP (total, frequency 
and severity). However, it should be noted that several of the mothers of older 
index cases declined to complete the PIP assessment as they felt it was not 
appropriate as they were not involved in their son’s medical care. Therefore, 
these scores would be even lower if these individuals were included.  
The number of children a participant had correlated with higher PIP scores, but 
did not reach statistical significance, although it was approaching significance. 
Again, it is not surprising that having more children creates more distress, but 
this study has demonstrated that those with more children may require greater 
support.  
The scores in the XL-CGD carrier mothers were compared to Streisand et al’s 
[255] study in parents of children with an oncological diagnosis. The scores were 
overall similar, but the XL-CGD mothers scored significantly higher in the 
frequency domain, meaning that the regularity with which they were having to 
attend to their child’s medical needs was more of a concern. These similarities 
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suggest that the condition per se is not the determining factor and raise the 
possibility that these findings would be transferrable to other conditions 
including other PIDs. This is further evidence of the need to support the mothers 
(and families) of children with CGD.  
The XL-CGD mothers were also compared to the MD control group. The XL-CGD 
mothers score significantly higher in the frequency domain, whilst the MD 
carriers scored more highly in the severity domain. This comparison further 
supports the comparison with the oncology patients in demonstrating that the 
disease itself is not the determining factor.  
The impact of the stresses of caring for a child with a chronic illness was 
evaluated by looking at the effect on psychological health and quality of life. As 
discussed earlier, the PIP scores did not correlate with anxiety and depression, 
suggesting that the stresses of caring for a child with a chronic illness were not 
the significant contributor to impaired psychological health.  
Cole et al [278] demonstrated that quality of life in children with CGD was better 
having undergone HSCT, but there has been no formal assessment of how this 
impacts upon the mothers. A comparison was made between mothers of those 
who had undergone HSCT and those whose children were managed 
conservatively. This demonstrated that the PIP scores were lower where the 
child had undergone HSCT. However, these results did not reach statistical 
significance, but suggest that after a successful HSCT, improvements are seen in 
the mothers as well as children with lower levels of distress, although anxiety 
symptoms persisted.  
The findings from this study are not surprising, but are important, as they have 
not previously been demonstrated on this scale. Within the field of PID, there has 
been limited research into the impact upon families. This study clearly shows 
that there are significant stresses associated with caring for a child with CGD. 
This may be more widespread within the family, but this was not assessed in this 
study.  It highlights the need for support for the carers, as well as the patients. 
Parental distress may not only impact upon their own mental health, but may 
impact upon their child. A recent study in parents of children with IBD[279] 
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demonstrated that high levels of parenting stress predicted depression in their 
adolescent children. This has not been evaluated in the XL-CGD children but 
highlights the importance of parental distress for the entire family as well as the 
individual parent.   
This study was designed to evaluate the health of the female XL-CGD carriers and 
subsequently, we did not evaluate the impact upon fathers or male relatives. It 
may be useful to study this group in the future in order that services may be 
provided to best support the families as a whole.  
In summary, this study has shown there are significant difficulties in caring for a 
child with CGD, but that these are at similar levels to published work in other 
conditions. There was no association with the degree of perceived stress and the 
presence of depression in the XL-CGD carriers, although levels of anxiety 
appeared to correlate. The stresses of caring were not significantly associated 
with the age of the child, but this may be due to the small numbers within each 
category.  
9.12 IQ 
At the conception of this study, evidence from Pao et al’s[230] study suggested 
that CGD patients may have significantly more learning difficulties than the 
general population. Hence, IQ assessment in XL-CGD carriers was included in the 
study. However, as outlined in chapter two there were several flaws with their 
study and subsequently Cole et al[232] demonstrated no such deficit in CGD 
patients, albeit with a briefer IQ assessment.   
IQ assessment was undertaken in only a small number (9) of the XL-CGD 
carriers. The main reason for the small number completing this component of 
the study was the time consuming nature of the assessment, as each assessment 
takes an hour to complete. The small number of participants completing the 
WAIS makes it impossible to draw conclusions. Additionally, there may have 
been an unintentional selection bias, as more educated individuals may have 
been more likely to agree to IQ assessment, or those not in full time employment 
may have been more likely to be able to spare the time.  
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Despite the small numbers, it can be observed that in six of the nine XL-CGD 
carriers, their lowest scores compared with national per centiles, were seen in 
the working memory domain. IQ is affected by a number of factors with genetic 
and environmental factors all thought to play a role [280, 281]. Working memory 
has been of particular interest as it has been demonstrated to be reduced in 
chronic inflammatory conditions [282].  Further evaluation of IQ on a larger 
scale is needed before conclusions can be drawn as to whether this finding is 
significant.  
9.13 Quality of Life 
Quality of life (QoL) is reduced in patients with CGD [278] but there has been no 
assessment of QoL in XL-CGD carriers prior to this study.  
The most striking finding from this study is that quality of life was significantly 
worse in XL-CGD carriers than in the UK population. XL-CGD carriers have not 
been previously considered to be unwell or have poor QoL.  
This study found that XL-CGD carriers scored poorly overall in the QoL 
questionnaires. XL-CGD carriers scored particularly poorly in the vitality, bodily 
pain, general health and social function domains. The vitality domain reflects 
energy levels and correlates with the fatigue reported in the XL-CGD carriers. 
They also had low overall scores for both physical and mental health component 
scores.  
9.13.1 Comparison with other groups 
In order to interpret these findings and to view them in context the scores from 
the XL-CGD carriers were compared to population data and other affected 
groups.  
The QoL in the XL-CGD carriers was significantly lower than published UK norms 
when considered both as an overall score and when each domain was considered 
individually. XL-CGD carriers were significantly worse in all domains when 
compared to UK population data of a female cohort of similar age. This 
comparison confirms that the finding of reduced QoL in the XL-CGD carriers is 
significant and different to that found in the general population. It is of particular 
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importance that the comparison was made with population data from women of 
the same age and UK resident. As outlined in chapter two, gender may contribute 
to QoL and there may be variations between countries. The limitation to this 
assessment is that the data were not collected at the same time. It is possible that 
QoL at a population level is different at different time points due to the 
variability of factors affecting QoL.  
The particularly low scores in the general health and bodily pain domains 
highlight that the XL-CGD carriers rate their physical health poorly. The poor 
scores in the social function domain demonstrate the effect of the reduced QoL 
on daily functioning.   
QoL data were also compared with QoL data from adult CGD patients [258]. 
Interestingly, QoL was significantly worse in the XL-CGD carriers than in the CGD 
patient cohort in the bodily pain, vitality and social functioning domains. This 
was an unexpected finding, but we can hypothesise many reasons for this. It may 
be that the impact on QoL of caring for a relative with CGD, as evidenced by the 
high PIP scores, is greater than being unwell. Alternatively, the XL-CGD carriers 
own unmet health problems may have impacted upon their QoL. The 
psychological distress as evidenced by anxiety and depression symptoms may 
also have played an important contribution.  
To explore the relationship between QoL and the burden of caring, the XL-CGD 
carrier QoL data were compared with published data from other carers. A study 
of carers of adult brain tumour patients was used [211]. This study was 
performed in a similar manner and used the same QoL assessment tool allowing 
for direct comparisons of scores to be made. In all domains the XL-CGD carriers 
scored lower than the published data.  The XL-CGD carriers were significantly 
lower in four of the domains; vitality, general health, bodily pain and physical 
function.  
The significant difference suggests that caring for an unwell relative is not the 
sole contributory factor to poor QoL. It is of particular interest that the domains 
in which there was a significant difference were those in which physical health 
was likely to contribute, suggesting that whilst the psychological effects of caring 
may be constant, the physical domains of QoL are affected by other factors. 
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However, it may be that the major contributor is the unmet physical problems 
found in the XL-CGD carriers.  
In the brain tumour group, the majority of patients being cared for were adult 
patients. It is possible that there are differences between caring for an adult 
patient and a paediatric patient and that this may account for some of the 
differences. It is possible that whilst there are similarities in caring, whomever 
the patient, that caring for a child is more physically demanding than caring for 
an adult as evidenced by the worse scores in the physical domains for the XL-
CGD carrier cohort. However, the XL-CGD carriers scored better than the brain 
tumour carers in the mental health, including social functioning domains. This 
may suggest that caring for a child with a chronic illness is less socially isolating 
than caring for an adult and this may be protective with regards to the mental 
health components of the QoL assessment.  
The QoL scores in the XL-CGD carriers were compared with the MD control 
group of carriers. There were significant differences found between the groups. 
The XL-CGD carriers scored significantly worse in the general health, vitality and 
role emotional domains. The MD carriers were significantly worse in the bodily 
pain domain.  
The major limitation with the control group is the size. As only 7 MD carriers 
completed the SF36 compared with the 62 XL-CGD carriers who completed it, the 
control group may not be reflective of MD carriers as a cohort. This may account 
for the lack of pattern in the differences and makes it difficult to draw firm 
conclusions.  
However, the significantly lower scores in QoL in the XL-CGD carriers suggest 
that caring for a child with a chronic disease is not the only important factor in 
determining QoL. In the context of the other comparisons discussed, this further 
supports the hypothesis that intrinsic rather than extrinsic factors are important 
in QoL in XL-CGD carriers. MD carriers were chosen due to the similarities in the 
demands of caring for children with CGD and MD. Therefore, the lower scores in 
the XL-CGD carriers suggest that factors outside of caring for a child with chronic 
illness are important. The worse scores in the physical health domains reiterate 
the clinical findings of poor health in the XL-CGD carriers. The lower scores in 
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the vitality domain in the XL-CGD carrier cohort confirm the high levels of fatigue 
reported by the XL-CGD carriers and support the hypothesis that it is not related 
to caring, but that fatigue is associated with XL-CGD carrier status.  
As the general health scores were low in the XL-CGD carrier cohort, it may be 
that this was a significant contributor to the poor QoL. SLE is the most similar 
disease process or symptom pattern to the problems manifesting in the XL-CGD 
carriers. Therefore, QoL data were compared with published studies of QoL in 
SLE patients. The published data from SLE patients demonstrated that QoL in 
SLE patients was significantly worse in all domains[140].  
9.13.2 Factors Affecting QoL 
There are many factors which a have contributed to the pooor QoL scores seen in 
the XL-CGD carriers. Figure 9-2 outlines potential contributing factors to the QoL 
in the XL-CGD carriers, which will now be discussed.  
Figure 9-2: Potential contributing factors in quality of life in XL-CGD carriers 
 
Medical Health 
There was a significant association between QoL, in both physical and mental 








Caring for a 
relative with CGD
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carriers. Joint and bowel symptoms, poor scores on the respiratory health 
questionnaire and the presence of recurrent mouth ulcers all significantly 
correlated with poor QoL. There was also a significant association of the number 
of ARA SLE criteria met and QoL. More minor medical problems such as 
photosensitivity, did not correlate with poor QoL suggesting that the other 
medical problems suffered by the XL-CGD carriers were more significant.  
The importance of this association is twofold. Firstly, it demonstrates that 
impaired QoL is likely to be intrinsic to being an XL-CGD carrier and that their 
own medical problems are important factors, rather than solely being the 
relative of an unwell individual determines QoL. Secondly, there may be 
modifiable factors, which mean QoL can be improved for XL-CGD carriers.  
Psychological Health 
Psychological health may logically impact upon QoL and this was demonstrated 
in the XL-CGD carriers. Anxiety and depression scores correlated with QoL with 
both mental health and physical health component scores, although the 
correlation was more statistically significant for the mental health component 
scores. This is not surprising, as physical health problems were more 
significantly correlated with the physical health component score but highlights 
the overlap for both.  
Again, this demonstrates the importance of identifying any unmet psychological 
health problems in the XL-CGD carriers in order to improve their QoL as well as 
anxiety and depression symptoms.  
Social Factors 
There will be factors relating to caring for a family that may impact upon QoL.  
The XL-CGD carriers related to an index CGD case who had undergone HSCT 
were compared with those related to an index CGD case where HSCT had not 
been performed. The QoL scores in all domains were similar. The only significant 
differences were seen in the bodily pain and mental health domains. The mental 
health scores were lower in the HSCT group whilst bodily pain scores were 
worse in the non HSCT group. It is difficult to account for these differences 
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except that the amount of time elapsed since the HSCT was variable and whilst 
QoL assessment was deferred for at least a year after HSCT it may be that in 
some of the relatives these experiences remained heightened and contributed to 
mental distress. The lack of difference between the scores in the majority of 
domains may suggest that it is being an XL-CGD carrier that contributes to the 
poor scores rather than the impact of external influences such as a relative with 
CGD.  
To evaluate the impact of relationship to the index case upon QoL scores, the XL-
CGD carrier mothers were compared with the XL-CGD carrier other relatives. 
There were no significant differences found between the scores in each group. 
This highlights the need to address QoL in all family members and not solely the 
mothers and may reflect intrinsic issues for XL-CGD carriers rather than external 
factors, which is supported by the differences with the brain tumour carers.   
Caring for a child with a chronic illness was significantly correlated with the 
physical health component score but not with mental health component score. 
This perhaps supports the need for practical help for caring for a child, as the 
impact appears to be greatest in the physical domains.  
Implications  
This is the first study to have examined the QoL in XL-CGD carriers. It has not 
been previously recognised that XL-CGD carriers have significantly reduced QoL. 
As discussed, the reasons for this poor QoL are complex and multifaceted. Some 
of the factors affecting QoL are modifiable and therefore, improvements in these 
may result in an overall improvement in QoL. For example, it can be 
hypothesised that improving pain or managing bowel or other medical 
symptoms may improve overall QoL. Unrecognised, and therefore, untreated 
anxiety and depression may also be treated and an improvement in symptoms 
may alter perceived QoL.  
The impact of having a chronically ill child on maternal QoL may not be alterable, 
but an increased awareness of its impact may aid clinicians in caring for the 
entire family. It would be interesting to evaluate QoL in the fathers and also in 
the non-carrier relatives to see how they compare to the XL-CGD carrier 
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relatives. This would allow us to evaluate the direct impact of carrier status 
when other factors are the same.  
The effect of any treatments may be monitored using the SF-36, the results from 
which are reproducible.  
9.14 Strengths and Limitations 
9.14.1 Recruitment 
The major strength of this study is the recruitment number and approach. All 
known XL-CGD families were approached either in person or by post making it 
the most comprehensive study in the UK and worldwide. There were 11 XL-CGD 
families who did not respond to the invitation to participate in the study when 
contacted by post despite repeated attempts being made and there are several 
possible reasons for this. It is possible that those who did not reply differed in 
symptom burden to those recruited; affected individuals are more likely to be 
motivated to participate in the study and to complete the required 
questionnaires. However, it may also be that those who did not participate 
suffered from significant psychological symptoms and felt unable to participate. 
It is also possible that the addresses provided to the researcher were incorrect 
and the non-responding XL-CGD carriers simply did not receive the invitation. 
There may also have been reasons not considered here.  
Approaching families in person at clinic appointments reduced the potential for 
selection bias as even if XL-CGD carriers felt they did not have any medical 
problems they were invited to participate.   
The potential reasons for not returning completed questionnaires are similar to 
those for the non-responders. The questionnaires were kept as brief as possible 
to minimise the time required by each participant to complete the 
questionnaires, but lack of time have played an important role in those who 
failed to return questionnaires.  
The advertisement of the study via the CGD Society allowed the project to be 
advertised to families who were not known to the research team and also to 
families who would not have been approached due to the death of an index case. 
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This was advantageous to the study as allowed for wider recruitment. There 
were XL-CGD carriers recruited through this method in which the index case was 
deceased. However, it is likely that those recruited via this method are more 
likely to be symptomatic, as they will have proactively sought out information 
about XL-CGD carriers.  
There will also be unknown XL-CGD families and carriers in the general 
population in whom the defect has not been diagnosed. It is not possible to 
quantify this number. However, one such XL-CGD carrier was recruited to the 
study via the CGD clinic at the Royal Free Hospital when she presented to the 
immunology department with symptoms and was subsequently discovered to be 
an XL-CGD carrier.  
This was an observational study of a rare disease. The study recruited the 
majority of known XL-CGD carriers in the UK but, despite this, the number in the 
study remains small. This may have led to some associations not being observed 
due to a lack of power. However, as this is a rare condition and this study was 
looking at rare complications, it is unlikely that it would ever be possible to 
recruit a suitably powered cohort within the UK. This study recruited as many 
XL-CGD carriers as was possible.  
The recruited control group was considerably smaller than anticipated and there 
were several reasons for this. MD carrier controls were recruited from the MD 
clinic at the GNCH, Newcastle upon Tyne.  Attendance at the MD clinic was poor 
and identified potential carriers frequently did not attend. Additionally, there is a 
high new mutation rate in MD with a new mutation occurring in one third of 
patients[237]. Unpredictably, there were three families in which the patient no 
longer lived with their biological parents as they had been adopted or placed in 
foster care and subsequently the research team did not have access to these 
potential carriers. Motivation to participate as a control participant is less than 
for those in the study group and as a result there were a greater number of 
control carriers who declined to participate.  
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9.14.2 Medical History 
I extracted all data and took all medical histories. This provided consistency and 
ensured that questions were posed in the same manner throughout.  
Previous case reports have focussed on isolated symptoms or presentations in 
single cases or families. This study collected information about a broad range of 
symptoms and actively looked for symptoms, which may not have otherwise 
been revealed, but have proven to be important and prevalent in the XL-CGD 
carrier population as a whole.  
The assessments of non-specific symptoms, including those of fatigue are 
inherently difficult. This study attempted to account for this by using 
standardised questionnaires where possible. Specific interest was in symptoms 
seen in the CGD boys and therefore, questionnaires were chosen to look for these 
symptoms. The fatigue questionnaire was added at a later stage when it became 
clear that this was a problem volunteered by XL-CGD carriers and a method to 
quantify the symptom was required. This study also attempted to verify 
symptoms and diagnoses by accessing medical records in both primary and 
secondary care. However, due to the geographical distribution of the recruited 
individuals, it was not possible for the researcher to visit all general practices 
individual. Subsequently the information returned from the GP was determined 
not by the researcher but by the individual GP. This was therefore not 
standardised as it was not possible given time and staff limitations. However, the 
majority of the GPs sent the same documentation.  
9.14.3 General  
A limitation in this study is the lack of objective investigations to confirm the 
presence or absence of medical symptoms. However, at the outset it was not 
clear that the XL-CGD carriers would exhibit so many medical problems and 
therefore, it would have been impossible to predict which investigations would 
be appropriate. As the study progressed it became increasingly clear that there 
were significant medical problems. Furthermore, as this was a national study, the 
participants were located all over the UK making it difficult to perform 
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investigations in a timely and efficient manner, particularly as a single 
researcher performed the research.   
The exact mutation was only known in 20 of the XL-CGD carriers. It would have 
been useful if the exact mutation was known and the degree of residual function 
could have been correlated with the presence of symptoms in the XL-CGD 
carriers.  
9.14.4 Psychological Health 
There are limitations to the assessment of anxiety and depression in this study. 
Anxiety and depression were assessed at one point in time and may not be 
reflective of that individual at another time. This may, therefore, represent either 
an over or an under representation of anxiety symptoms. It would have been 
beneficial to repeat the assessment to allow for a more accurate picture. 
However, GP records were also accessed which allowed for pre-existing 
diagnoses to be noted and this was compared to the presence found in the study.   
Recruited XL-CGD carriers were put into a relationship category determined by 
the index case from which they were identified. However, in some cases this was 
artificial as there was more than one CGD patient within the family and 
therefore, each enrolled participant could be considered in more than one 
category. This may have affected the evaluation.  
This is the first study to examine in depth and in a large cohort, the psychological 
health of XL-CGD carriers. Whilst the data collection is limited to one time point, 
the strength is the inclusivity with a range of relatives and ages represented, 
along with both before and after HSCT. Psychological health concerns are under 
reported. The strength of this study is that by screening for anxiety and 
depression, previously unidentified distress will be captured.  
QoL assessment was delayed if the child had undergone HSCT to 1 year after this. 
It was felt that this would allow for a return to normality. However, McDowell et 
al’s[204] study suggests that this may not be sufficient time. On a practical level, 
this study was time limited and a pragmatic approach was therefore, adopted. 
The strengths and limitations for QoL assessment are similar to those discussed 
for anxiety and depression. Additionally, QoL may be more greatly affected by 
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physical symptoms.  As many of the clinical symptoms appear to be episodic, the 
assessment of QoL may have been affected by whether or not the physical 
symptoms were active or quiescent at the time of completion of QoL assessment.  
9.14.5 Blood Tests  
Neutrophil Oxidative bursts were all performed at the local recruiting centre 
owing to the time sensitive nature of the investigation. All laboratories used DHR 
and flow cytometry to assess the per cent of neutrophils producing an oxidative 
burst. As the investigations were performed at different centres it is possible that 
there were subtle differences in the techniques used and there may be 
variability. However, as outlined earlier, the most important consideration when 
assessing oxidative burst is that the sample is processed promptly and ideally 
within 12 hours. Therefore, on balance this was the most appropriate method 
but it should be acknowledged that there might be small differences.  
All autoantibody samples were performed at the Royal Victoria Infirmary, 
Newcastle upon Tyne as they do not require the same time-dependant 
processing. By performing them at a single centre this ensured that they were 
processed in a standardised manner thereby minimising differences between the 
handling of samples. This is of particular importance when considering reference 
ranges which may vary between laboratories.   
The ethnicity of the XL-CGD carriers is typical of that seen in CGD families in the 
UK, predominantly white British. As the majority of XL-CGD carriers will be 
diagnosed following the diagnosis of an index case, predominantly a son, the age 
range of this cohort is reflective of this with a median age of 41 years. The 
majority of the identified and recruited XL-CGD carriers were mothers, with the 
next most common being sisters and then grandmothers. The relative lack of 
other relatives reflects current attitudes toward carrier testing. The median age 
of the index cases was 12 years and as such their siblings are likely to be of 
similar ages.  
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Chapter 10: Conclusions and Clinical 
Recommendations 
10.1 General  
This study has demonstrated that XL-CGD carriers suffer a wide range of medical 
problems to varying degrees of severity. Subsequently, the first recommendation 
is that all XL-CGD carriers should be seen and assessed by a specialist in primary 
immunodeficiency in the first instance. 
10.2 Clinical  
Clinical symptoms should be actively asked about at an initial consultation and 
the lead clinician should not wait for the XL-CGD carriers to volunteer them. 
Specifically, XL-CGD carriers should be actively asked about symptoms of 
gastrointestinal disease including abdominal pain and urgency, diarrhoea and 
rectal bleeding. They should also be asked about previous gastrointestinal 
infections. 
XL-CGD carriers should be asked directly about episodes of joint pain, redness 
and swelling, which may be associated with fatigue. Ideally, XL-CGD carriers 
should see a rheumatologist when joint symptoms are active for assessment and 
consideration of treatment beyond simple analgesia.  
Dermatology referrals should be made where there is significant skin 
involvement or where there are rashes of uncertain aetiology. All XL-CGD 
carriers should be advised about the need for sun avoidance and high factor sun 
block.  
The role of, and need for, antibiotic prophylaxis in XL-CGD carriers remains 
unclear from this study. It should be considered where the XL-CGD carrier has 
suffered a significant infection or where they have recurrent, problematic 
infections such as skin abscesses. Co-trimoxazole would appear to be the logical 
choice, due to its proven efficacy in CGD patients [11, 60].  
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10.3 Clinical Follow Up 
For some XL-CGD carriers, a single consultation will be sufficient and no further 
investigations or assessment required. However, for those where symptoms are 
present referral should be made to the appropriate speciality but long term 
follow up coordinated by the primary immunodeficiency team in a specialised 
centre. This will allow an overview of the care for the XL-CGD carriers but also 
enable more to be learned about the course of their symptoms.  





Screen for GI symptoms
If present refer to 
gastroenterology for 
investigation
Recurrent or severe infections
Consider prophylactic Co-
trimoxazole
Autoimmune Features e.g ulcers, 
photosensitivity, joint symptoms
Consider Hydroxchloroquine and 
rheumatology and dermatology 
involvement
Counsel
Advice about reproductive risk 
and pre-implantation genetic 
diagnosis
Fatigue
Review contributing factors and 
treat as able
Consider cytokine measurement 
as a research tool
Psychological Health
Screen annually for 
anxiety and depression 
Medical and psychological 
treatment if required




Anxiety is highly prevalent and under-diagnosed in XL-CGD carriers of all ages. 
This persists even after an index case has undergone HSCT and appears to be 
independent of the relationship to the index case. Anxiety may be exacerbated by 
physical symptoms and is more prevalent in those suffering from 
gastrointestinal disease or joint symptoms. Conversely, very few XL-CGD carriers 
suffer from significant depression, although the scores are higher than the 
general population. 
XL-CGD carriers should be screened for anxiety and depression regularly and 
particularly where physical symptoms are present.  The HADS appears to be a 
useful screening tool for anxiety and depression and can be recommended as the 
screening tool of choice.  
Those who are found to score highly should be offered treatment, both 
pharmacological and psychological. Support for the family, as a whole should be 
offered as a standard part of care. Psychology services may need to be increased 
to meet these needs and good relationships with primary care should be 
established to facilitate optimal treatment.   
10.5 Implications on Carrier Testing 
Current guidance is that children under 16 years should only be tested for a 
genetic disease if it is of clinical benefit to the individual, and as such many of the 
siblings of children with XL-CGD are unaware of their carrier status. However, 
this study has demonstrated that there are significant clinical manifestations 
within the XL-CGD carriers and it may, therefore, be beneficial to test for carrier 
status at an earlier age. Unlike other genetic conditions where carrier status does 
not have clinical manifestations, this study has shown that XL-CGD carriers have 
clinical manifestations of disease, which may be improved by treatment, and 
diagnosis of carrier status has greater clinical implications than solely for 
reproductive risk. Therefore, with expert counselling, and psychological support, 
it may be appropriate to consider testing both younger children and wider family 
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members than is currently routine practice in order to facilitate earlier 
treatment.   
10.6 Summary of Future Research 
This study has highlighted a number of issues requiring further research. The 
main areas requiring further investigation are the identification of affected XL-
CGD carriers, the underlying mechanism of disease process in the XL-CGD 
carriers and the treatment of XL-CGD carriers. 
Pre-emptive identification of XL-CGD carriers may be beneficial in order to 
improve outcome and would aid counselling of XL-CGD carriers. Further 
understanding of the mechanism of the disease process would identify potential 
treatment targets and further understanding about possible manifestations of 
disease.  
Treatment of symptoms is an important aspect of future research. This study has 
demonstrated significant medical problems and reduced quality of life. There are 
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Older Child 9 – 12 years
 
Patient age 9-12 years information sheet – version 2 – 16.08.13 
 
 1 
 An Investigation into the General and Psychological Health of carriers of X-Linked Chronic Granulomatous Disease  
 
     
 
A collaborative study 
 
A Study of Carriers of CGD 
 
We are asking if you would take part in a project to help us understand more about being a 
carrier of CGD.  
   
Research is a way we try to find out the answers to questions. We want to find out what it is 
like to be a carrier of CGD and how it makes you feel. The researcher is also writing a project 
about this for university. 
 
Why have I been asked to take part? 
Your doctor has told us you are a carrier of CGD. We want to ask everyone like you to help 
us with this study. 
 
Do I have to take part? 
No. It is up to you and your family to decide if you want to be involved.  
 
What will happen to me if I take part? 
We will ask your family to answer some question about what your health is like and we will 
also meet you to ask you some questions. This will happen when you come to hospital for a 
normal check up. Your family can stay with you when we see you. This will all take about 45 
minutes in total.  
 
We will also look at the information your doctor keeps about how you are. We will write down 
and keep some of this information so we can find out how all CGD carriers are. 
 
When you have your blood tests done by your doctor we will take an extra sample of blood. 
 
Is there anything that might upset me? 
We know that it may be difficult to talk about your feelings. We can arrange for you to see 
someone to help with this. 
 
Will joining in help me? 
We cannot promise the study will help you immediately but the information we get from this 
study will help improve the treatment of people who are also carriers of CGD.  
 
What happens if I don’t want to do this anymore? 
If at any time you don’t want to do the research anymore, just tell your parents, doctor or 
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Younger Child 5- 8 years
 
Patient age 5-8 years information sheet – version 2 – 01.08.13 
 
 1 
 An Investigation into the General and Psychological Health of carriers of X-Linked Chronic Granulomatous Disease  
     
 
A collaborative study 
 
A Study of Carriers of CGD 
 
We are asking if you to be in a project to help us learn about being a carrier of CGD.  
   
Research is a way we try to find out the answers to questions. We want to find out what it is 
like to be a carrier of CGD and how it makes you feel. The person doing the study will write 
about the project for university. 
 
Why have I been asked to take part? 
Your doctor has told us you are a carrier of CGD. We want to ask everyone like you to help 
us with this study. 
 
Do I have to take part? 
No. It is up to you and your family to choose.  
 
What will happen to me if I take part? 
We will ask your family to answer some question about when you have been ill. We will also 
meet you to ask you some questions. This will happen when you come to hospital for a 
normal check up. Your family can stay with you when we see you.  
 
We will also look at the information your doctor keeps about how you are. We will write down 
and keep some of this information so we can find out how all CGD carriers are.This will take 
about 45 minutes. You can have a break if you need to.  
 
When you have your blood tests done by your doctor, we will ask them to take an extra bit for 
our project.  
 
Is there anything that might upset me? 
We know that it may be difficult to talk about your feelings. We can arrange for you to see 
someone to help with this. 
 
Will joining in help me? 
We cannot promise the study will help you immediately but the information we get from this 
study will help improve the treatment of people who are also carriers of CGD.  
 
What happens if I don’t want to do this anymore? 
If at any time you don’t want to do the research anymore, just tell your parents, doctor or 
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Please complete this as best as you can. Leave blank anything you do not want to share with the 
researcher.  
GP Name and Address: 
 
 
Family Members (Please complete as much as you are able – add new lines if needed) 
Family Member e.g. 
Son, Sister 
Age 




    
    
    
    
    
    
    
 
Your Own Health: 




Any Medications you take: 
 
Do you see any doctors for these medical problems? If so name and which hospital?: 
 
 
Are you a smoker? 
How much do you exercise per week? 
What is your weight? 




Modified ARA SLE Criteria Questionnaire V1, 1.11.11 




1.  Have you ever had a prominent, red rash over your nose and cheeks? Yes / No 





2.  Have you ever had a significant rash with raised patches? Have you ever seen a skin doctor 
(dermatologist)?         Yes / No 





3.  Have you ever had a rash caused by exposure to sunlight?   Yes / No 






1.  Do you suffer from ulcers in your mouth or on your nose that may not hurt?   Yes / No 
If yes: 
Do you get them often?         Yes / No 
Has your doctor ever seen them?       Yes / No 
 
Joints 
 Do you suffer from pain or swelling in any of your joints?     Yes / No 
If Yes: 
Have you seen a doctor about this?        Yes / No 
Have they diagnosed you with arthritis?       Yes / No 
Have you ever had an X-Ray of the joint?      Yes / No 
 
Hearts and Lungs 
 
1. Have you ever had a pleural effusion (fluid in the lungs)?   Yes / No 
If yes: 
Did you get admitted to hospital?       Yes / No 







Modified ARA SLE Criteria Questionnaire V1, 1.11.11 
Did you need treatment?        Yes / No 








2. Have you ever had pericarditis (fluid or inflammation around the heart)? Yes / No 
Were you admitted to hospital?       Yes / No 
 









1. Have you ever had a fit?       Yes / No 
If Yes: 
Did the doctors think it was to do with medications, recreational drugs or alcohol? Yes / No 
Was there a reason found for the fit?       Yes / No 







2. Have you ever been diagnosed as having a psychiatric event/problem, not related to drugs or alcohol?
            Yes / No 








Have you ever been told you had protein in your urine?  
If Yes, 
Did this continue?          Yes / No 
Did you have a urine infection?       Yes / No 
Were you referred to a specialist?       Yes / No 
Did you have to see your GP again?       Yes / No 





























Rosenberg Self Esteem Questionnaire
 
NICHD SECCYD—Wisconsin 
ROSENBERG SELF-ESTEEM SCALE 
 
The next questions ask about your current feelings about yourself. For each of the following, please 
circle the number that corresponds with the answer that best describes how strongly you agree or 











1. I feel that I am a person of worth, or at least on an 
equal plane with others. 
1 2 3 4 
2. I feel that I have a number of good qualities. 1 2 3 4 
3. All in all, I’m inclined to feel that I am a failure. 1 2 3 4 
4. I am able to do things as well as most other people. 1 2 3 4 
5. I feel I do not have much to be proud of. 1 2 3 4 
6. I take a positive attitude toward myself. 1 2 3 4 
7. On the whole, I am satisfied with myself. 1 2 3 4 
8. I certainly feel useless at times. 1 2 3 4 
9. I wish I could have more respect for myself. 1 2 3 4 

















Below is a list of statements that describe how people sometimes feel. Please read each item carefully, 
then circle the one number next to each item which best describes how true each statement has been 
for you in the past 7 days.  
 
Not at all  A little  Moderately Quite a bit Extremely 
1. I have trouble remembering things ...................0       1  2            3  4 
2.  My muscles ache...............................................0 1  2 3  4 
3.  I feel upset.........................................................0 1  2 3  4 
4.  My legs feel weak .............................................0 1  2 3  4 
5.  I feel cheerful ....................................................0 1  2 3  4 
6.  My head feels heavy .........................................0 1  2 3  4 
7.  I feel lively ........................................................0 1  2 3  4 
8.  I feel nervous ....................................................0 1  2 3  4 
9.  I feel relaxed .....................................................0 1  2 3  4 
10. I feel pooped .....................................................0 1  2 3  4 
11. I am confused....................................................0 1  2 3  4 
12. I am worn out ....................................................0 1  2 3  4 
13. I feel sad............................................................0 1  2 3  4 
14. I feel fatigued ....................................................0 1  2 3  4 
15. I have trouble paying attention .........................0 1  2 3  4 
16. My arms feel weak............................................0 1  2 3  4 
17. I feel sluggish....................................................0 1  2 3  4 
18. I feel run down ..................................................0 1  2 3  4 
19. I ache all over....................................................0 1  2 3  4 
20. I am unable to concentrate ................................0 1  2 3  4 
21. I feel depressed .................................................0 1  2 3  4 
22. I feel refreshed ..................................................0 1  2 3  4 
23. I feel tense .........................................................0 1  2 3  4 
24. I feel energetic ..................................................0 1  2 3  4 
25. I make more mistakes than usual ......................0 1  2 3  4 
26. My body feels heavy all over ...........................0               1  2 3  4 
27. I am forgetful ....................................................0               1  2 3  4  
28. I feel tired..........................................................0 1 2 3  4 
29. I feel calm .........................................................0 1 2 3  4 
30. I am distressed ..................................................0 1 2 3  4 
 
 
Multidimensional Fatigue Symptom Inventory-Short Form, Moffitt Cancer Center and University of South Florida, Tam pa, 
























Appendix 3: SOP for DHR and Autoantibodies by Immunofluorescence 
SOP for DHR
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Standard Operating Procedure:  File Name ID: IMM-LC-BRST-V5-2006 Copy No:  
Title: DIHYDRORHODAMINE 123 ASSAY FOR ANALYSIS OF GRANULOCYTE RESPIRATORY 
BURST 
Purpose of the Examination  
 
This assay allows the investigation of altered neutrophil oxidative burst activity. 
Reduced or absent burst activity is observed in inbourne defects such as chronic 
granulomatous disease (CGD). CGD is characterised clinically by repeated and 
life-threatening infections caused by bacterial and fungal organisms. It may 
mimic inflammatory bowel disease and lead to malabsorption and obstruction of 
the bowel. Abscesses are another feature involving the liver, lungs or lymph 
nodes. Different forms of CGD are described (X-linked and autosomal recessive 
patterns). 
Neutrophils from CGD patients fail to produce a significant oxidative burst 
following stimulation. NADPH oxidase is the enzyme system involved during 
intracellular killing as part of the phagocytic process. Superoxide anion is 
produced, which is quickly converted to hydrogen peroxide and hydroxyl radicals, 
which destroy bacteria in the phagosome. Abnormalities in the constitutive 
peptides of the NADPH oxidase enzyme system lead to the dysfunctions 
characteristic of CGD. 
This assay is performed along side the nitro-blue tetrazolium (NBT) assay 
allowing a rapid and sensitive method for the diagnosis of CGD and for the 
detection of X-linked carriers. 
 
2 Principle     
 
Upon stimulation, neutrophils (and monocytes) produce reactive oxygen 
intermediates (ROI), such as superoxide anion, hydrogen peroxide and 
hypochlorous acid that destroy bacteria in the phagosome.  
ROI’s produced upon activation of DHR loaded normal neutrophils; react with the 
DHR and the resulting increase in fluorescence is detected by the flow cytometer  
FL-1 detector. 
Chronic granulomatous disease (CGD) is characterised by the diminished or 
absent production of reactive oxygen intermediates (ROI). In the X-linked form, 
carriers can be detected by the presence of two different cell populations, one 
normal and one negative for ROI. 
 
3  Safety considerations 
 
Good laboratory practice is essential when performing all procedures. 
Disposable gloves must be worn when handling samples, but this does not 
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Appendix 4: Publications 
J Clin Immunol. 2013 Nov;33(8):1276-84. 
Clinical manifestations of disease in X-linked carriers of chronic granulomatous 
disease. 























Appendix 5: Oral Presentations 
UK PIN, Liverpool, December 2013: The Health of X-linked Carriers of Chronic 





Appendix 6: Poster Presentations 
European Society of Immunodeficiency (ESID), November 2014, Prague 
ESID-0170 The Psychological Health of X-Linked Carriers of Chronic 







Chronic Granulomatous Disease (CGD) is a rare primary immunodeficiency due to a defect in one of the NADPH oxidase complex subunits resulting in reduced or absent 
respiratory oxidative burst. UK incidence of CGD is approximately 1 in 125,000 and 70% of cases are X-linked (XL).  XL-CGD carriers are frequently confirmed after the 
diagnosis of the disease in a close family member.  
 
XL-CGD carriers have several potential risk factors for psychological health problems: a family member with chronic illness, their own medical problems and an 
association with Systemic Lupus Erythematosus (SLE). SLE is associated with anxiety and depression.  No studies have evaluated psychological health in this group. 
 
Aim 






THE PSYCHOLOGICAL HEALTH OF X-LINKED CARRIERS OF CHRONIC GRANULOMATOUS 
DISEASE IN THE UNITED KINGDOM 
Alex Battersby1*, Mark Pearce2, Helen Braggins3, Fiona McKendrick4, Catherine Cale5, David Goldblatt6, Andrew Gennery1 
1 Institute of Cellular Medicine, Newcastle University, 2Institute of Health & Society, Newcastle University, 3CGD Society, Great Ormond Street Hospital, London 
4Newcastle upon Tyne Hospitals Foundation Trust 5Clinical Immunology, Great Ormond Street Hospital, 6Institute of Child Health, University College London,  
Serum from 52 XL-CGD carriers was compared with inflammatory 
disease control groups of 10 high and 10 low fatigue Sjogren’s disease 
patients and 15 healthy controls. 
 
Results 
• XL-CGD families were identified from the UK CGD Registry and all families approached either in person or by post. 
• Participants completed validated psychological health questionnaires; Hospital Anxiety and Depression Score (HADS) and Pediatric 
Inventory for Parents (PIP) . 
• A HADS score above 7 (anxiety/depression) is abnormal [1]. 
• Symptom frequency was compared with parents of CF children [2].  HAD mean scores were compared with published data from SLE 
patients [3,4].  
• The PIP scores distress due to parenting a chronically unwell child with sub-scores about frequency (PIP-F) and severity (PIP-S). PIP’s 
validation in oncology patients provides comparison data [5]. Only mothers completed the PIP.  
• Data were compared to published norms and published data from comparable group.  
 
1.Zigmond, A.S. and R.P. Snaith, The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavica, 1983. 67(6): p. 361-370. 
2.Besier, T., et al., Anxiety, Depression, and Life Satisfaction in Parents Caring for Children With Cystic Fibrosis. Pediatric Pulmonology, 2011. 46(7): p. 672-682. 
3.Waldheim, E., et al., Health-related quality of life, fatigue and mood in patients with SLE and high levels of pain compared to controls and patients with low levels of pain. Lupus, 2013. 22(11): p. 1118-1127. 
4. Tench, C.M., et al., The prevalence and associations of fatigue in systemic lupus erythematosus. Rheumatology, 2000. 39(11): p. 1249-1254. 
5. Streisand, R., Braniceki, S, Tercyak, KP, Kazak, AE, Childhood Illness-Related Parenting Stress: The Pediatric Inventory for Parents. Journal of Pediatric Psychology, 2001. 26(3): p. 155-162. 
Waldheim, E., et al., Health-related quality of life, fatigue and mood in patients with SLE and high levels of pain compared to controls and patients with low levels of pain. Lupus, 2013. 22(11): p. 1118-1127. 
 
This is the largest study of CGD carriers to date and the only one to examine psychological health. 
XL-CGD carriers had significant rates of anxiety with scores significantly higher than the UK population and parents of CF patients. The 
scores are similar to SLE patients and particularly similar to SLE patients classified as having high pain. 
The PIP scores are similar to those from parents of oncology patients suggesting similar degrees of distress irrespective of diagnosis. 
Lack of correlation between HADS and PIP suggests the cause for anxiety was not solely related to their child’s disease.  
XL-CGD carriers have medical problems similar to SLE patients (poster ESID-0185) which may contribute to anxiety and account for the 
similar levels of anxiety in both conditions.  
This study highlights that XL CGD carriers suffer unrecognised but potentially significant psychological health problems which may impact 
upon their own lives and their ability to cope with the medical needs of their affected children. Anxiety appears to be independent of being a 
carer.   
Recruitment and Demographics 
80 Families identified 
79 XL-CGD Carriers recruited (2 deceased) 
Median Age: 43 years [3-77 years] 











































Anxiety and Depression in XL-CGD Carriers 
Anxiety 
Depression 















Number 61 1792 20 64 120 650 
HAD-A 
(Mean)  
9.54 6 9 4 9 7.52 
p-valu    <0.001 0.18 <0.01 0.18 0.0002 
Figure 1: Anxiety and Depression Scores in XL-CGD Carriers 
Table 2: PIP Scores in XL-CGD Carrier Mothers and Oncology Parents 
  XL-CGD Carrier 
Mothers  
 Oncology Parents 
[5] 
p-value 
PIP-T 214.8 63.5 206  0.20 
PIP-F 112.3 30.3 94.0 33.3 0.0005 
PIP-S 103.0 35.3 112.4  35.1 0.06 
Table 1: Comparison of Anxiety Scores in XL-CGD Carriers with Other Populations 
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Granulomatous Disease (CGD)
 
QUALITY OF LIFE IS REDUCED IN X-LINKED CARRIERS OF  
CHRONIC GRANULOMATOUS DISEASE IN THE UNITED KINGDOM 
Alex Battersby1*, Mark Pearce2, Helen Braggins3, Catherine Cale4, David Goldblatt5, Andrew Gennery1 
1 Institute of Cellular Medicine, Newcastle University, 2Institute of Health & Society, Newcastle University, 3CGD Society, Great Ormond Street Hospital, London  






1. Cole T et al, J Clin Immunol, 2013 Jan;33(1):8-13 
2. Ware, JE et al, The MOS 36-item Shortf-Form Health Survey (SF-36), Medical Care, 1992;30(6):473-483 
 
Chronic Granulomatous Disease (CGD) is a rare primary immunodeficiecny (PID) in which there is a defect in one of the 
subunits of NADPH oxidase, resulting in a defective respiratory burst.  Patients suffer recurrent incetion, inflammation and 
autoimmunity. 70% of cases are  X-linked (XL). Female carriers are frequently confirmed after diagnosis of an affected 
individual. 
 
Patients who do not undergo curative treatment have been demonstrated to heave poorer QoL than unaffected individuals 
[1].  XL-CGD carriers have several factors which may affect their QoL; unmet medical needs, caring for a child with chronic 





• The lowest scores were seen in the vitality, general health and mental health domains 
• QoL in XL-CGD carriers was significantly worse than UK population norms in all domains 
• QoL in XL-CGD carriers was comparable with adult CGD patients and worse in four domains 
• XL-CGD carriers have not previously been demonstrated to have significant problems. The importance of this 
study is that it demonstrates there is a significant impact upon their QoL 
• The factors contributing to poor QoL are multiple and include poor medical health, caring for a realtive with 




Aims and Methods 
• The aim of this study was to evaluate QoL in XL-CGD carriers in the UK 
• XL-CGD carriers were identified through the UK CGD Registry and approached either in person or by post   
• Participants completed the SF36v2 which is a validated QoL questionnaire [2]. The SF36v2 provides a numerical score for 8 
domains, along with an overall score for mental health and physical health. Lower scores indicate poorer QoL 
• Mean scores were compared with UK population data [3] and published data from other patient groups using a one sample t-
test 
Recruitment and Demographics 
80 Families identified 
79 X-linked Carriers recruited to date (2 
deceased) 
Median Age: 43 years [3-77 years] 
78 White British, 1 Chinese British 
62 completed the SF36v2 
55 (70%) were mothers of index case 
 
Domain	 CGD Carriers	 UK Norms  
(female age 35-54)[3] 
P-value	
Physical Function	79.28 (29.4)	 89.4(18.3)	 < 0.001	
Role Physical	 74.35(32.2)	 84.0(32.0)	 0.00235	
Bodily Pain	 66.24(30.5)	 79.4(22.0)	 0.002	
General Health	 56.31(28.5)	 74.1(20.3)	 < 0.001	
Vitality	 44.98(25.5)	 58.2(19.9)	 0.002	
Social Function	 69.68(29.5)	 86.7 (20.5)	 0.001	
Role Emotional	 71.88(31.3)	 80.3 (33.6)	 0.0341	
Mental Health	 63.16(16.8)	 71.6(17.8)	 0.005	
















XL-CGD Carriers vs Adult CGD Patients 
Patients 
XL-Carriers 
Figure 1 shows that XL-CGD carriers had similar QoL scores 
to adult CGD patients and in fact scored lower in 4 domains 
(Vitality, Emotional, Social fnction and mental health) 
Tbale 1 shows the comparison of XL-CGD carriers and UK 
population data for females of similar age 
No significant difference in scores between mothers and other 
relatives in any domain (data not shown) 
 
 
Table 1: Mean Scores in XL-CGD carriers compared with UK population data 
Figure 1: XL-CGD Carriers compared to Adult CGD Patients [4] 
3. Jenkinson, C. et alShort Form-36 (SF-36) Health Survey Questionnaire - Normative Data For Adults of 
Working Age. British Medical Journal, 1993. 306(6890): p. 1437-1440. 
4. Cole, T., et al,. Quality of life in adults with Chronic Granulomatous Disease over the last decade. in UK 




ESID-0185 The Health of Carriers of X-Linked Chronic Granulomatous Disease 




Chronic Granulomatous Disease (CGD) is a rare primary immunodeficiency due to a defect in one of the NADPH oxidase complex 
subunits resulting in reduced or absent respiratory oxidative burst. The incidence of CGD in the UK is approximately 1 in 125,000. 70% of 
cases are X-linked (XL), due to a CYBB mutation, resulting in defective production of gp91PHOX.  Patients suffer infective, inflammatory 
and autoimmune complications.  
 
XL-CGD carriers have a dual population of wild-type and mutant phagocytes. The proportion of functioning cells varies between 20-80%. 
Current literature about XL-CGD carriers is limited to small case series and anecdotal reports. They are conventionally considered 
healthy although a high incidence of discoid lupus is well described.  
 
Aims 
• To evaluate the presence and severity of medical symptoms in XL-CGD carriers in the UK 









Alex Battersby1*, Mark Pearce2, Helen Braggins3, Dawn Barge4, Catherine Cale5, David Goldblatt6, Andrew Gennery1 
1 Institute of Cellular Medicine, Newcastle University, 2Institute of Health & Society, Newcastle University, 3CGD Society, Great Ormond Street Hospital, London 
4Newcastle upon Tyne Hospitals Foundation Trust 5Clinical Immunology, Great Ormond Street Hospital, 6Institute of Child Health, University College London 
Serum from 52 XL-CGD carriers was compared with inflammatory 
disease control groups of 10 high and 10 low fatigue Sjogren’s disease 
patients and 15 healthy controls. 
 
Results 
THE HEALTH OF X-LINKED CARRIERS OF CHRONIC GRANULOMATOUS 
DISEASE IN THE UNITED KINGDOM 
• XL-CGD families were identified from the UK CGD Registry and approached either in person or by post 
• All enrolled participants complete detailed questionnaires about their medical history and presence of symptoms  
• Hospital and GP records were reviewed 





































  CGD Carriers CGD Patients [2] p-value 
Number Enrolled 77 140   
Abdominal Pain 34% 46 % 0.018 
Diarrhoea 33% 33 % 0.51 
Rectal Bleeding 23% 6 % <0.0001 
Constipation 11% 4 % 0.001 
Neutrophil Oxidative Burst Results 
Median 53%, Range  7-94% 
Recurrent Skin Abscesses associated with lower NOB (p=0.02).  
No other significant difference between  affected and unaffected 
groups 
Recruitment and Demographics 
80 Families identified 
79 X-linked Carriers recruited (2 deceased). Complete 
information available for 77 
Median Age: 43 years [3-77 years]; 78 White British 
§ This is the largest and most comprehensive study of XL-CGD carriers to date. 
§ NOB results are similar to previous with almost all carriers falling into the range of 20-80%.  
§ Autoimmune features are more common than previously reported and in particular joint problems occur more frequently than previously documented. 
§ Gastrointestinal symptoms have not previously been demonstrated and occurred in over 50% of this cohort. 
§ Skin manifestations concur in nature with previous studies, although are more frequent than previously described. 
§ Excessive fatigue was reported in half of patients which is a similar finding to other chronic inflammatory conditions. 
§ Symptoms do not appear to correlate with the degree of reduction in neutrophil oxidative burst.   
§ While carriers of XL-CGD may be asymptomatic, our survey shows an unexpected degree of clinical symptoms indicating carriers may require medical 
support 
§ Further work is required to identify which XL-CGD carriers are at risk and how they should be managed in the future. 
Inflammatory Complications 
• The most frequently occurring inflammatory manifestation were 
gastrointestinal symptoms (40/77 affected), which were similar in 
nature  to that seen in CGD patients. 
•  Table 1 shows a comparison of prevalence of GI symptoms between 
patients and XL-CGD carriers 
• Fatigue was reported in 50% (see poster ESID-0851) 
Infectious Complications 
Infection was reported  in  19 XL-CGD carriers. Type of 
infection is shown in figure 1 
Figure 1: Type of Infection in XL-CGD Carriers 
Figure 2: Autoimmune Features in XL-CGD Carriers 
Table 1: GI Symptoms in XL-CGD Carriers and CGD Patients 
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ESID-0222 Identification of Autoantibodies in Carriers of X-Linked Chronic 










• XL-CGD carriers have increased autoantibodies detectable by antigen microarray 
compared to normal controls. 
 
• This provides additional evidence that XL-CGD carriers are at increased risk of 
developing autoimmune symptoms 
 
• There are differences between microarray and ELISA results . It is currently 
unclear which correlates better with clinical symptoms 
 
• Further work is required to confirm the significance of these findings using ELISA 
techniques and further microarray studies as well as assessing the data in relation 
to clinical symptoms experienced by our carrier cohort.  
 
• Microarray data may identify potential biomarkers to assist in identifying XL-CGD 







Heat maps (Figure 1) graphically depict the range of IgG 
and IgM autoantibody positivity amongst the XL-CGD 
carriers compared to normal controls. The black to 
yellow scale illustrates positive autoantibodies.  
	
• A wide range of IgG and IgM autoantibodies to nuclear, 
cytoplasmic and phospholipid antigens were increased in 
the carriers, with variability in specificity and 
concentration amongst carriers. 
  
• 41/42 (97.7%) carriers were positive ≥1 IgG and IgM 
autoantibody   
• Several were positive for ≥ 25% of auto-antigens (IgG: 
11/43, 25.6%), (IgM: 6/42, 14.3%) potentially indicating 
the presence of polyreactive autoantibodies 
 
• The most frequently positive IgG autoantibodies were 
against glycated-albumin, heparan HSPG, 
nuculoporin-62 and C1q.  
  
• The most frequently positive IgM autoantibodies were 
against Sm/RNP, glycated albumin and collagen III 
  
• Moderate correlation was observed between the number 
of positive IgG autoantibody specificities and neutrophil 








Scatter plots (figure 3) displaying 
correlation between Microarray ratio 
and ELISA arbitrary units for XL-
CGD carriers 
• A significant weak positive 
correlation (R >0.3, p < 0.05) was 
observed between the microarray 
ratio and ELISA interpolated 
values. 
 
•  The differences may arise from 
distinct epitope presentation 
produced by the two methods of 
antigen fixation to solid surfaces 
	
Background 	
• X-linked chronic granulomatous disease (XL-CGD) is a rare primary immunodeficiency 
due to mutations in CYBB causing reduction in, or absence of, phagocyte respiratory 
oxidative burst. 
• Clinical manifestations of CGD include susceptibility to infection, granuloma formation 
and inflammatory/autoimmune disease.   
• XL-CGD carriers have two populations of leukocytes, expressing either the wild type or 
the mutant CYBB gene.  The percentage of wild-type population can be measured by 
the neutrophil oxidative burst (NOB).  
• Discoid lupus has been observed in several XL-CGD carriers, and there is evidence that 
autoimmune phenomena are also more common. However, routine autoantibody 
screening  in symptomatic carriers by indirect-immunofluorescence is usually negative. 
• Novel microarray technology exhibits greater sensitivity for autoantibody detection 
than traditional techniques and permits rapid screening of a large set of autoantibody 




• To investigate the frequency and characteristics of autoantibodies in XL-CGD carriers using a 
high-throughput microarray method 




• Serum samples from 42 XL-CGD carriers, identified via the UK CGD registry, normal 
controls and Systemic Lupus Erythematosus (SLE) positive control were probed for 
IgG and IgM antibodies against a panel of 94 auto-antigens at University of Texas 
South Western Microarray Core Facility. Normalised frequency intensity (NFI) data 
was provided.  
 
• Data were converted into an optimised data set by calculating a ratio	
	
• Positivity was defined as a ratio greater than 1 
• Data were visualised using MultiExperiment Viewer (Open Source software 
available at http://mev-tm4.sourceforge.net) 
• To validate the microarray findings, serum samples were tested for four IgG 
autoantibodies (against dsDNA, Nup62, PCNA and Scl70) using standard ELISA 
techniques. 
• Arbitrary units were interpolated from the ELISA optical density at 1:40 dilution, 
using the SLE control as a standard curve. The correlation between microarray and 
ELISA data was assessed using Spearman’s rank. 
• NOB was measured by Dihydrorhodamine Flow Cytometric Assay  at Newcastle 





AUTOANTIBODIES IN X-LINKED CARRIERS OF CHRONIC GRANULOMATOUS DISEASE 
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This research was supported by a scholarship grant from the Faculty of Medical Sciences, Newcastle University and The Bubble Foundation. 
Chronic Granulomatous Disease (CGD) is a rare primary immunodeficiency in which one of the NADPH oxidase subunits is defective. Patients suffer 
recurrent, serious infection and inflammation.   
70% of cases are X-linked (XL) due to the CYBB mutation, resulting in defective production of gp91phox.  XL-CGD carriers have a dual population of 
phagocytes, those which express gp91phox  and function normally and those which do not.  
There is increasing evidence that female carriers of XL-CGD experience a range of inflammatory symptoms [1] (Poster ESID-0185) 
Many XL-CGD carriers also report excessive fatigue[2] which may be due to inflammatory processes mediated by cytokines. 
To date, there has been no investigation of the possible mechanism of this fatigue in XL-CGD carriers. 
 
Aim 





Serum IL-8 is significantly higher in XL-CGD carriers than in healthy and Sjogren’s disease control groups. 
Higher serum IL-8 levels are significantly correlated with higher levels of fatigue in XL-CGD carriers. 
IL-8, which has been associated with fatigue,[4] may be a driver of fatigue in this group via an inflammatory process. 
It is hoped that this initial finding will stimulate further research into how IL-8 influences fatigue in XL-CGD carriers and how its effects can 
be managed to improve the quality of life for these women. 
Design 
Serum from 52 XL-CGD carriers was compared with 
inflammatory disease control groups of 10 high and 10 low 
fatigue Sjogren’s disease patients and 15 healthy controls. 
 
Data collection 
Cytometric Bead Array (CBA) immunoassay assessed levels 
of IL-1α, IL-5, IL-8, IL-10, IL-17, IFNα and IFN-γ using BD 
Biosciences LSRFortessa™ cell analyser (Figure 1). 
 
Data analysis 
FACSDiva, BD Biosciences; FCAP Array, Soft Flow Inc.; 
SPSS, IBM (Mann-Whitney U Tests). 
High serum levels of IL-8 are associated with excessive fatigue in female carriers of X-linked 
Chronic Granulomatous Disease 
A Battersby1, A.J. Martin2, J.R. Tarn1,  W.F. Ng1, C. Cale3, D. Goldblatt4, A.R. Gennery1 
1Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK 2Newcastle University, 3 Clinical Immunology, Great Ormond 
Street Hospital, London. 4 Institute of Child Health, University College London, London. 
 
Serum from 52 XL-CGD carriers was compared with inflammatory 
disease control groups of 10 high and 10 low fatigue Sjogren’s disease 



















































25/52 (48%) of XL-CGD carriers reported fatigue on a validated questionnaire.[3] 
IL-8 concentration (mean 1459u/ml) was significantly higher in XL-
CGD carriers than in healthy controls (mean 72u/ml) (p=0.015) and 
Sjogren’s disease controls (mean 203u/ml) (p=0.031) as a whole 
(high and low fatigue grouped). 
IL-8 concentration was significantly higher in the subgroup of XL-
CGD carriers who reported fatigue (mean 2405u/ml) than in those 
who did not (mean 400u/ml) (p=0.005). 
Other investigated cytokines were not significantly raised. 
Figure 2: Log box plot of IL-8 concentration in each group. Figure 3: Log box plot of IL-8 concentration in each XL-CGD sub-group. 
Figure 1: Preparation and analysis of samples 
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Appendix 7: Prizes 
Best Poster Award, ESID 2014 
ESID-0851 High Fatigue Levels in XL-CGD Carriers Associated with Raised Serum 
IL-8 
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